US20070038260A1 - Stimulation lead for stimulating the baroreceptors in the pulmonary artery - Google Patents

Stimulation lead for stimulating the baroreceptors in the pulmonary artery Download PDF

Info

Publication number
US20070038260A1
US20070038260A1 US11/482,563 US48256306A US2007038260A1 US 20070038260 A1 US20070038260 A1 US 20070038260A1 US 48256306 A US48256306 A US 48256306A US 2007038260 A1 US2007038260 A1 US 2007038260A1
Authority
US
United States
Prior art keywords
electrode
baroreceptor
pulmonary artery
baroreceptors
pulse generator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/482,563
Inventor
Robert Kieval
Martin Rossing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CVRX Inc
Original Assignee
CVRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/671,850 external-priority patent/US6522926B1/en
Application filed by CVRX Inc filed Critical CVRX Inc
Priority to US11/482,563 priority Critical patent/US20070038260A1/en
Assigned to CVRX, INC. reassignment CVRX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROSSING, MARTIN A., KIEVAL, ROBERT S.
Publication of US20070038260A1 publication Critical patent/US20070038260A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114Cardiac control, e.g. by vagal stimulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114Cardiac control, e.g. by vagal stimulation
    • A61N1/36117Cardiac control, e.g. by vagal stimulation for treating hypertension

Definitions

  • the present invention generally relates to medical devices and methods of use for the treatment and/or management of cardiovascular, renal, and neurological disorders. Specifically, the present invention relates to devices and methods for controlling the low-pressure baroreflex system for the treatment and/or management of cardiovascular, renal, and neurological disorders.
  • Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year in the United States.
  • Hypertension or high blood pressure, is a major cardiovascular disorder that is estimated to affect over 50 million people in the United Sates alone. Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure. Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures. Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith.
  • Heart failure is the final common expression of a variety of cardiovascular disorders, including ischemic heart disease. It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival. It is estimated that approximately 5,000,000 people in the United States suffer from heart failure, directly leading to 39,000 deaths per year and contributing to another 225,000 deaths per year. Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood. Many of these responses are mediated by an increase in the level of activation of the sympathetic nervous system, as well as by activation of multiple other neurohormonal responses.
  • this sympathetic nervous system activation signals the heart to increase heart rate and force of contraction to increase the cardiac output; it signals the kidneys to expand the blood volume by retaining sodium and water; and it signals the arterioles to constrict to elevate the blood pressure.
  • the cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. Accordingly, it is desirable to reduce the level of sympathetic nervous system activation in order to stop or at least minimize this vicious cycle and thereby treat or manage the heart failure.
  • a number of drug treatments have been proposed for the management of hypertension, heart failure and other cardiovascular disorders. These include vasodilators to reduce the blood pressure and ease the workload of the heart, diuretics to reduce fluid overload, inhibitors and blocking agents of the body's neurohormonal responses, and other medicaments.
  • Various surgical procedures have also been proposed for these maladies. For example, heart transplantation has been proposed for patients who suffer from severe, refractory heart failure.
  • an implantable medical device such as a ventricular assist device (VAD) may be implanted in the chest to increase the pumping action of the heart.
  • an intra-aortic balloon pump (IABP) may be used for maintaining heart function for short periods of time, but typically no longer than one month.
  • Other surgical procedures are available as well. No one drug, surgical procedure, or assist system, however, has provided a complete solution to the problems of hypertension and heart failure.
  • WO 02/026314 describes the direct activation of baroreceptors for inducing changes in a patient's baroreflex system to control blood pressure and other patient functions.
  • the prior applications are particularly directed at the activation of the baroreceptors present in the carotid sinus and the aortic arch.
  • Both the carotid sinus and aortic arch are on the high-pressure or arterial side of the patient's vasculature. They are referred to as high-pressure since pressures in the systemic arterial circulation are higher than those in the veins and pulmonary circulation.
  • Activation of the high-pressure baroreceptors can send signals to the brain that cause reflex alterations in nervous system function which result in changes in activity of target organs, including the heart, vasculature, kidneys, and the like, typically to maintain homeostasis.
  • U.S. Pat. Nos. 6,073,048 and 6,178,349 each having a common invention with the present application, describe the stimulation of nerves to regulate the heart, vasculature, and other body systems. Nerve stimulation for other purposes is described in, for example, U.S. Pat. Nos. 6,292,695 B1 and 5,700,282. Publications describing baropacing of the carotid arteries for controlling hypertension include Neufeld et al. (1965) Israel J. Med. Sci 1:630-632; Bilgutay et al., Proc. Baroreceptors and Hypertension, Dayton, Ohio, Nov. 16-17, 1965, pp 425-437; Bilgutary and Gebhei (1966) Am. J. Cariol.
  • the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors.
  • the present invention reduces excessive blood pressure, sympathetic nervous system activation and neurohormonal activation, thereby minimizing their deleterious effects on the heart, vasculature and other organs and tissues.
  • the present invention provides a system and method for treating a patient by inducing a baroreceptor signal to effect a change in the baroreflex system (e.g., reduced heart rate, reduced blood pressure, etc.).
  • the baroreceptor signal is activated or otherwise modified by selectively activating baroreceptors.
  • the system and method of the present invention utilize a baroreceptor activation device positioned near a baroreceptor in the venous or low-pressure side of a patient's vasculature.
  • the phrase “low-pressure side of the vasculature” will mean the venous and cardiopulmonary vasculature, including particularly the chambers in the heart, veins near the entrances to the atria, the pulmonary artery, the portal vein of the liver, the superior vena cava (SVC), the inferior vena cava (IVC), the jugular vein, the subclavian veins, the iliac veins, the femoral veins, and other peripheral areas of the vasculature where baroreceptor and baroreceptor-like receptors are found.
  • SVC superior vena cava
  • IVC inferior vena cava
  • jugular vein the subclavian veins
  • the iliac veins the iliac veins
  • femoral veins femoral veins
  • Particular target mechanoreceptors are described in Kostreva and Pontus (1993), cited above, the full disclosure of which is incorporated herein by reference.
  • the baroreceptors and baroreceptor-like receptors on the low-pressure side of the vasculature will function similarly to, but not necessarily identically to, baroreceptors on the high-pressure side of the vasculature.
  • cardiovascular receptors may be sensitive to pressure and/or mechanical deformation and are referred to as baroreceptors, mechanoreceptors, pressoreceptors, stretch receptors, and the like.
  • the present invention is intended to activate or otherwise interact with any or all of these types of receptors so long as such activation or interaction results in modulation of the reflex control of the patient's circulation.
  • activation may be directed at any of these receptors so long as they provide the desired effects.
  • receptors will provide afferent signals, i.e., signals to the brain, which provide the blood pressure and/or volume information to the brain which allow the brain to cause “reflex” changes in the autonomic nervous system which in turn modulate organ activity to maintain desired hemodynamics and organ perfusion.
  • afferent signals i.e., signals to the brain
  • Such activation of afferent pathways may also affect brain functions in such a way that could aid in the treatment of neurologic disease.
  • the ability to control the baroreflex response and cardiovascular, renal, and neurological function, by intervention on the low-pressure side of the vasculature is advantageous in several respects. Intervention on the venous and cardiopulmonary side of the vasculature reduces the risk of organ damage, including stroke, from systemic arterial thromboembolism. Moreover, the devices and structures used for intervening on the venous and cardiopulmonary side of the vasculature may be less complicated since the risk they pose to venous circulation is much less than to arterial circulation. Additionally, the availability of venous and cardiopulmonary baroreceptors allows placement of electrodes and other devices which reduce the risk of unwanted tissue stimulation resulting from current leakage to closely adjacent nerves, muscles, and other tissues.
  • the baroreceptor activation device may be activated, deactivated or otherwise modulated to activate one or more baroreceptors and induce a baroreceptor signal or a change in the baroreceptor signal to thereby effect a change in the baroreflex system.
  • the baroreceptor activation device may be activated, deactivated, or otherwise modulated continuously, periodically, or episodically.
  • the baroreceptor activation device may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate the baroreceptor.
  • the baroreceptor may be activated directly, or activated indirectly via the adjacent vascular tissue.
  • the baroreceptor activation device may be positioned inside the vascular lumen (i.e., intravascularly), outside the vascular wall (i.e., extravascularly) or within the vascular wall (i.e., intramurally).
  • the particular activation patterns may be selected to mimic those which naturally occur in the venous and cardiopulmonary vasculature, which conditions might vary from those characteristic of the arterial vasculature. In other cases, the activation patterns may be different from the natural patterns and selected to achieve an optimized barosystem response.
  • a control system may be used to generate a control signal which activates, deactivates or otherwise modulates the baroreceptor activation device.
  • the control system may operate in an open-loop or a closed-loop mode.
  • the open-loop mode the patient and/or physician may directly or remotely interface with the control system to prescribe the control signal.
  • the control signal may be responsive to feedback from a sensor, wherein the response is dictated by a preset or programmable algorithm.
  • the present invention provides a number of devices, systems and methods by which the blood pressure may be selectively and controllably regulated by inhibiting or dampening baroreceptor signals.
  • the present invention reduces conditions associated with low blood pressure.
  • the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors, baroreceptor-like mechanoreceptors or pressoreceptors, or the like.
  • baroreceptors By selectively and controllably activating baroreceptors, the present invention reduces excessive blood, pressure, sympathetic nervous system activation and neurohormonal activation, thereby minimizing their deleterious effects on the heart, vasculature and other organs and tissues.
  • the present invention provides a system and method for treating a patient by inducing a baroreceptor signal to effect a change in the baroreflex system (e.g., reduced heart rate, reduced blood pressure, etc.).
  • the baroreceptor signal is activated or otherwise modified by selectively activating baroreceptors.
  • the system and method of the present invention utilize a baroreceptor activation device positioned near a baroreceptor in a vein, the pulmonary vasculature, in a heart chamber, at a veno-atrial junction, or the like.
  • the baroreceptor activation device may be activated, deactivated or otherwise modulated to activate one or more baroreceptors and induce a baroreceptor signal or a change in the baroreceptor signal to thereby effect a change in the baroreflex system.
  • the baroreceptor activation device may be activated, deactivated, or otherwise modulated continuously, periodically, or episodically.
  • the baroreceptor activation device may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate the baroreceptor.
  • the baroreceptor may be activated directly, or activated indirectly via the adjacent vascular tissue.
  • the baroreceptor activation device may be positioned inside the vascular lumen (i.e., intravascularly), outside the vascular wall (i.e., extravascularly) or within the vascular wall (i.e., intramurally).
  • a control system may be used to generate a control signal which activates, deactivates or otherwise modulates the baroreceptor activation device.
  • the control system may operate in an open-loop or a closed-loop mode.
  • the open-loop mode the patient and/or physician may directly or remotely interface with the control system to prescribe the control signal.
  • the control signal may be responsive to feedback from a sensor, wherein the response is dictated by a preset or programmable algorithm.
  • the present invention provides a number of devices, systems and methods by which the blood pressure may be selectively and controllably regulated by inhibiting or dampening baroreceptor signals.
  • the present invention reduces conditions associated with low blood pressure.
  • FIG. 1 is a schematic illustration of the upper torso of a human body showing the major arteries and veins and associated anatomy.
  • FIG. 1A is a schematic illustration of the lower abdominal vasculature including the abdominal aorta and the inferior vena cava.
  • FIG. 2 is a cross-sectional schematic illustration of baroreceptors within a vascular wall.
  • FIG. 3 is a schematic illustration of a baroreceptor activation system in accordance with the present invention.
  • FIG. 4 is a schematic illustration of a baroreceptor activation device in the form of an internal inflatable balloon which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 5 is a schematic illustration of a baroreceptor activation device in the form of an external pressure cuff which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 6A is a schematic illustration of a baroreceptor activation device in the form of an internal deformable coil structure which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIGS. 6B and 6C are cross-sectional views of alternative embodiments of the coil member illustrated in FIG. 6 .
  • FIG. 7 is a schematic illustration of a baroreceptor activation device in the form of an external deformable coil structure which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 8 is a schematic illustration of a baroreceptor activation device in the form of an external flow regulator which artificially creates back pressure to induce a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 9 is a schematic illustration of a baroreceptor activation device in the form of an internal flow regulator which artificially creates back pressure to induce a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 10 is a schematic illustration of a baroreceptor activation device in the form of a magnetic device which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 11 is a schematic illustration of a baroreceptor activation device in the form of a transducer which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 12 is a schematic illustration of a baroreceptor activation device in the form of a fluid delivery device which may be used to deliver an agent which chemically or biologically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 13 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 14 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an internal inductor, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 15 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an internal inductor located in an adjacent vessel, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 16 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an external inductor, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 17 is a schematic illustration of a baroreceptor activation device in the form of an external conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 18 is a schematic illustration of a baroreceptor activation device in the form of an internal bipolar conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 19 is a schematic illustration of a baroreceptor activation device in the form of an electromagnetic field responsive device which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 20 is a schematic illustration of a baroreceptor activation device in the form of an external Peltier device which thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIGS. 21A-21C are schematic illustrations of a preferred embodiment of an inductively activated electrically conductive structure.
  • FIGS. 22A-22C are ECG charts of a dog undergoing stimulation of the abdominal IVC.
  • FIG. 1 is a schematic illustration of the upper torso of a human body 10 showing some of the major arteries and veins of the cardiovascular system.
  • the left ventricle of the heart 11 pumps oxygenated blood up into the aortic arch 12 .
  • the right subclavian artery 13 , the right common carotid artery 14 , the left common carotid artery 15 and the left subclavian artery 16 branch off the aortic arch 12 proximal of the descending thoracic aorta 17 .
  • brachiocephalic artery 22 connects the right subclavian artery 13 and the right common carotid artery 14 to the aortic arch 12 .
  • the right carotid artery 14 bifurcates into the right external carotid artery 18 and the right internal carotid artery 19 at the right carotid sinus 20 .
  • the left carotid artery 15 similarly bifurcates into the left external carotid artery and the left internal carotid artery at the left carotid sinus.
  • oxygenated blood flows into the carotid arteries 18 / 19 and the subclavian arteries 13 / 16 .
  • oxygenated blood circulates through the head and cerebral vasculature and oxygen depleted blood returns to the heart 11 by way of the jugular veins, of which only the right internal jugular vein 21 is shown for sake of clarity.
  • oxygenated blood circulates through the upper peripheral vasculature and oxygen depleted blood returns to the heart by way of the subclavian veins, of which only the right subclavian vein 23 is shown, also for sake of clarity.
  • the heart 11 pumps the oxygen-depleted blood through the pulmonary system where it is re-oxygenated.
  • the re-oxygenated blood returns to the heart 11 which pumps the re-oxygenated blood into the aortic arch as described above, and the cycle repeats.
  • oxygenated blood is delivered to the organs and lower limbs through the abdominal aorta 23 . 2 .
  • Deoxygenated blood returns to the heart through the inferior vena cava 23 . 3 .
  • Baroreceptors are a type of stretch receptor used by the body to sense blood pressure and blood volume. An increase in blood pressure or volume causes the vascular wall to stretch, and a decrease in blood pressure or volume causes the vascular wall to return to its original size. In many vessels, such a cycle is repeated with each beat of the heart. In others, in particular some of the body's veins, the pressure and volume change more slowly. Because baroreceptors are located within the vascular wall, they are able to sense deformation of the adjacent tissue, which is indicative of a change in blood pressure or volume.
  • FIG. 2 shows a schematic illustration of baroreceptors 30 disposed in a generic vascular wall 40 and a schematic flow chart of the baroreflex system 50 .
  • Baroreceptors 30 are profusely distributed within the arterial walls 40 of the blood vessels major arteries discussed previously, and are presently believed by the inventors to form an arbor 32 as is characteristic of the analogous receptors in the arterial system as described in parent application Ser. No. 09/672,850, previously incorporated herein by reference.
  • a baroreceptor arbor 32 would comprise a plurality of baroreceptors 30 , each of which transmits baroreceptor signals to the brain 52 via nerve 38 .
  • the baroreceptors 30 may be so profusely distributed and arborized within the vascular wall 40 that discrete baroreceptor arbors 32 are not readily discernable. To this end, those skilled in the art will appreciate that the baroreceptors 30 shown in FIG. 2 are primarily schematic for purposes of illustration and discussion. In other regions, the baroreceptors may be so sparsely distributed that activation over a relatively greater length of the vein would be required than would be with an artery where the receptors might be more concentrated.
  • Baroreceptor signals in the arterial vasculature are used to activate a number of body systems which collectively may be referred to as the baroreflex system 50 .
  • the baroreflex system 50 For the purposes of the present invention, it will be assumed that the “receptors” in the venous and cardiopulmonary vasculature and heart chambers function analogously to the baroreceptors in the arterial vasculature, but such assumption is not intended to limit the present invention in any way. In particular, the methods described herein will function and achieve at least some of the stated therapeutic objectives regardless of the precise and actual mechanism responsible for the result.
  • the present invention may activate baroreceptors, mechanoreceptors, pressoreceptors, or any other venous heart, or cardiopulmonary receptors which affect the blood pressure, nervous system activity, and neurohormonal activity in a manner analogous to baroreceptors in the arterial vasculation.
  • baroreceptors all such venous receptors will be referred to collectively herein as “baroreceptors.”
  • baroreceptors 30 are connected to the brain 52 via the nervous system 51 .
  • the brain 52 is able to detect changes in blood pressure which are indicative of cardiac output and/or blood volume.
  • the baroreflex system 50 activates a number of body systems, including the heart 11 , kidneys 53 , vessels 54 , and other organs/tissues. Such activation of the baroreflex system 50 generally corresponds to an increase in neurohormonal activity. Specifically, the baroreflex system 50 initiates a neurohormonal sequence that signals the heart 11 to increase heart rate and increase contraction force in order to increase cardiac output, signals the kidneys 53 to increase blood volume by retaining sodium and water, and signals the vessels 54 to constrict to elevate blood pressure. The cardiac, renal and vascular responses increase blood pressure and cardiac output 55 , and thus increase the workload of the heart 11 . In a patient with heart failure, this further accelerates myocardial damage and exacerbates the heart failure state.
  • the present invention basically provides a number of devices, systems and methods by which the baroreflex system 50 is activated to reduce excessive blood pressure, autonomic nervous system activity and neurohormonal activation.
  • the present invention provides a number of devices, systems and methods by which baroreceptors 30 may be activated, thereby indicating an increase in blood pressure and signaling the brain 52 to reduce the body's blood pressure and level of sympathetic nervous system and neurohormonal activation, and increase parasypathetic nervous system activation, thus having a beneficial effect on the cardiovascular system and other body systems.
  • the present invention generally provides a system including a control system 60 , a baroreceptor activation device 70 , and a sensor 80 (optional).
  • the baroreceptor activation device 70 is shown to be located on, in or near the inferior vena cava 23 . 3 , but it could also be located at the other baroreceptor target locations discussed elsewhere in this application.
  • the exemplary control system 60 generally operates in the following manner.
  • the sensor 80 senses and/or monitors a parameter (e.g., cardiovascular function) indicative of the need to modify the baroreflex system and generates a signal indicative of the parameter.
  • the control system 60 generates a control signal as a function of the received sensor signal.
  • the control signal activates, deactivates or otherwise modulates the baroreceptor activation device 70 .
  • activation of the device 70 results in activation of the baroreceptors 30 ( FIG. 2 ).
  • deactivation or modulation of the baroreceptor activation device 70 may cause or modify activation of the baroreceptors 30 .
  • the baroreceptor activation device 70 may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate baroreceptors 30 .
  • the control system 60 when the sensor 80 detects a parameter indicative of the need to modify the baroreflex system activity (e.g., excessive blood pressure), the control system 60 generates a control signal to modulate (e.g.
  • the control system 60 When the sensor 80 detects a parameter indicative of normal body function (e.g., normal blood pressure), the control system 60 generates a control signal to modulate (e.g., deactivate) the baroreceptor activation device 70 .
  • a parameter indicative of normal body function e.g., normal blood pressure
  • the baroreceptor activation device 70 may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological or other means to activate the baroreceptors 30 . Specific embodiments of the generic baroreceptor activation device 70 are discussed with reference to FIGS. 4-21 . In most instances, particularly the mechanical activation embodiments, the baroreceptor activation device 70 indirectly activates one or more baroreceptors 30 by stretching or otherwise deforming the vascular wall 40 surrounding the baroreceptors 30 . In some other instances, particularly the non-mechanical activation embodiments, the baroreceptor activation device 70 may directly activate one or more baroreceptors 30 by changing the electrical, thermal or chemical environment or potential across the baroreceptors 30 .
  • changing the electrical, thermal or chemical potential across the tissue surrounding the baroreceptors 30 may cause the surrounding tissue to stretch or otherwise deform, thus mechanically activating the baroreceptors 30 .
  • a change in the function or sensitivity of the baroreceptors 30 may be induced by changing the biological activity in the baroreceptors 30 and altering their intracellular makeup and function.
  • baroreceptor activation device 70 are suitable for implantation, and are preferably implanted using a minimally invasive percutaneous transluminal approach and/or a minimally invasive surgical approach, depending on whether the device 70 is disposed intravascularly, extravascularly or within the vascular wall 40 .
  • the baroreceptor activation device 70 may be positioned anywhere in or proximate the venous or cardiopulmonary vasculature, and/or the heart chambers, where baroreceptors capable of modulating the baroreflex system 50 are present.
  • the baroreceptor activation device 70 will usually be implanted such that the device 70 is positioned immediately adjacent the baroreceptors 30 .
  • the baroreceptor activation device 70 may be outside the body such that the device 70 is positioned a short distance from but proximate to the baroreceptors 30 .
  • the baroreceptor activation device 70 is implanted at a location which permits selective activation of the target baroreceptor, typically being in, around, or near the target baroreceptor.
  • the present invention is described with reference to baroreceptor activation device 70 positioned near the inferior vena cava 23 . 3 .
  • the optional sensor 80 is operably coupled to the control system 60 by electric sensor cable or lead 82 .
  • the sensor 80 may comprise any suitable device that measures or monitors a parameter indicative of the need to modify the activity of the baroreflex system.
  • the sensor 80 may comprise a physiologic transducer or gauge that measures ECG, blood pressure (systolic, diastolic, average or pulse pressure), blood volumetric flow rate, blood flow velocity, blood pH, O2 or CO2 content, mixed venous oxygen saturation (SVO2), vasoactivity, nerve activity, tissue activity or composition.
  • suitable transducers or gauges for the sensor 80 include ECG electrodes, a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, an ultrasonic volumetric flow rate transducer, a thermodilution flow velocity transducer, a capacitive pressure transducer, a membrane pH electrode, an optical detector (SVO2) or a strain gage. Although only one sensor 80 is shown, multiple sensors 80 of the same or different type at the same or different locations may be utilized.
  • the sensor 80 is preferably positioned in a chamber of the heart I 1 , or in/on a major artery such as the aortic arch 12 , a common carotid artery 14 / 15 , a subclavian artery 13 / 16 or the brachiocephalic artery 22 , or in any of the low-pressure venous or cardiopulmonary sites, such that the parameter of interest may be readily ascertained.
  • the sensor 80 may be disposed inside the body such as in or on an artery, a vein or a nerve (e.g. vagus nerve), or disposed outside the body, depending on the type of transducer or gauge utilized.
  • the sensor 80 may be separate from the baroreceptor activation device 70 or combined therewith. For purposes of illustration only, the sensor 80 is shown positioned on the right subclavian artery 13 .
  • control system 60 includes a control block 61 comprising a processor 63 and a memory 62 .
  • Control system 60 is connected to the sensor 80 by way of sensor cable 82 .
  • Control system 60 is also connected to the baroreceptor activation device 70 by way of electric control cable 72 .
  • the control system 60 receives a sensor signal from the sensor 80 by way of sensor cable 82 , and transmits a control signal to the baroreceptor activation device 70 by way of control cable 72 .
  • the memory 62 may contain data related to the sensor signal, the control signal, and/or values and commands provided by the input device 64 .
  • the memory 62 may also include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal.
  • the algorithm may dictate activation or deactivation control signals depending on the sensor signal or a mathematical derivative thereof.
  • the algorithm may dictate an activation or deactivation control signal when the sensor signal falls below a lower predetermined threshold value, rises above an upper predetermined threshold value or when the sensor signal indicates a specific physiologic event.
  • the baroreceptor activation device 70 may activate baroreceptors 30 mechanically, electrically, thermally, chemically, biologically or otherwise.
  • the control system 60 includes a driver 66 to provide the desired power mode for the baroreceptor activation device 70 .
  • the driver 66 may comprise a pressure/vacuum source and the cable 72 may comprise fluid line(s).
  • the driver 66 may comprise a power amplifier or the like and the cable 72 may comprise electrical lead(s).
  • the driver 66 may comprise a fluid reservoir and a pressure/vacuum source, and the cable 72 may comprise fluid line(s). In other instances, the driver 66 may not be necessary, particularly if the processor 63 generates a sufficiently strong electrical signal for low level electrical or thermal actuation of the baroreceptor activation device 70 .
  • the control system 60 may operate as a closed loop utilizing feedback from the sensor 80 , or as an open loop utilizing commands received by input device 64 .
  • the open loop operation of the control system 60 preferably utilizes some feedback from the transducer 80 , but may also operate without feedback.
  • Commands received by the input device 64 may directly influence the control signal or may alter the software and related algorithms contained in memory 62 .
  • the patient and/or treating physician may provide commands to input device 64 .
  • Display 65 may be used to view the sensor signal, control signal and/or the software/data contained in memory 62 .
  • the control signal generated by the control system 60 may be continuous, periodic, episodic or a combination thereof, as dictated by an algorithm contained in memory 62 .
  • Continuous control signals include a constant pulse, a constant train of pulses, a triggered pulse and a triggered train of pulses.
  • periodic control signals include each of the continuous control signals described above which have a designated start time (e.g., beginning of each minute, hour or day) and a designated duration (e.g., 1 second, 1 minute, 1 hour).
  • Examples of episodic control signals include each of the continuous control signals described above which are triggered by an episode (e.g., activation by the patient/physician, an increase in blood pressure above a certain threshold, etc.).
  • the control system 60 may be implanted in whole or in part.
  • the entire control system 60 may be carried externally by the patient utilizing transdermal connections to the sensor lead 82 and the control lead 72 .
  • the control block 61 and driver 66 may be implanted with the input device 64 and display 65 carried externally by the patient utilizing transdermal connections therebetween.
  • the transdermal connections may be replaced by cooperating transmitters/receivers to remotely communicate between components of the control system 60 and/or the sensor 80 and baroreceptor activation device 70 .
  • FIGS. 4-21 schematic illustrations of specific embodiments of the baroreceptor activation device 70 are shown.
  • the design, function and use of these specific embodiments, in addition to the control system 60 and sensor 80 (not shown), are the same as described with reference to FIG. 3 , unless otherwise noted or apparent from the description.
  • the anatomical features illustrated in FIGS. 4-20 are the same as discussed with reference to FIGS. 1, 1A , and 2 , unless otherwise noted.
  • the connections between the components 60 / 70 / 80 may be physical (e.g., wires, tubes, cables, etc.) or remote (e.g., transmitter/receiver, inductive, magnetic, etc.).
  • the connection may travel intraarterially, intravenously, subcutaneously, or through other natural tissue paths.
  • FIG. 4 shows schematic illustrations of a baroreceptor activation device 100 in the form of an intravascular inflatable balloon 100 .
  • the inflatable balloon device 100 includes a helical balloon 102 which is connected to a fluid line 104 .
  • a similar helical balloon is disclosed in U.S. Pat. No. 5,181,911 to Shturman, the entire disclosure of which is hereby incorporated by reference.
  • the balloon 102 preferably has a helical geometry or any other geometry which allows blood perfusion therethrough.
  • the fluid line 104 is connected to the driver 66 of the control system 60 ( FIG. 3 ).
  • the driver 66 comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the helical balloon 102 .
  • a pressure/vacuum source i.e., an inflation device
  • the helical balloon 102 expands, preferably increasing in outside diameter only, to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40 .
  • the helical balloon 102 Upon deflation, the helical balloon 102 returns to its relaxed geometry such that the vascular wall 40 returns to its nominal state.
  • the baroreceptors 30 adjacent thereto may be selectively activated.
  • a mechanical expansion device may be used to expand or dilate the vascular wall 40 and thereby mechanically activate the baroreceptors 30 .
  • the mechanical expansion device may comprise a tubular wire braid structure that diametrically expands when longitudinally compressed as disclosed in U.S. Pat. No. 5,222,971 to Willard et al., the entire disclosure of which is hereby incorporated by reference.
  • the tubular braid may be disposed intravascularly and permits blood perfusion through the wire mesh.
  • the driver 66 may comprise a linear actuator connected by actuation cables to opposite ends of the braid. When the opposite ends of the tubular braid are brought closer together by actuation of the cables, the diameter of the braid increases to expand the vascular wall 40 and activate the baroreceptors 30 .
  • FIG. 5 shows a baroreceptor activation device 120 in the form of an extravascular pressure cuff 120 .
  • the pressure cuff device 120 includes an inflatable cuff 122 which is connected to a fluid line 124 .
  • Examples of a similar cuffs 122 are disclosed in U.S. Pat. No. 4,256,094 to Kapp et al. and U.S. Pat. No. 4,881,939 to Newman, the entire disclosures of which are hereby incorporated by reference.
  • the fluid line 124 is connected to the driver 66 ( FIG. 3 ) of the control system 60 .
  • the driver 66 comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the cuff 122 .
  • a pressure/vacuum source i.e., an inflation device
  • the cuff 122 expands, preferably increasing in inside diameter only, to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40 .
  • the cuff 122 Upon deflation, the cuff 122 returns to its relaxed geometry such that the vascular wall 40 returns to its nominal state.
  • the baroreceptors 30 adjacent thereto may be selectively activated.
  • the driver 66 may be automatically actuated by the control system 60 as discussed above, or may be manually actuated.
  • An example of an externally manually actuated pressure/vacuum source is disclosed in U.S. Pat. No. 4,709,690 to Haber, the entire disclosure of which is hereby incorporated by reference.
  • Examples of transdermally manually actuated pressure/vacuum sources are disclosed in U.S. Pat. No. 4,586,501 to Claracq, U.S. Pat. No. 4,828,544 to Lane et al., and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which are hereby incorporated by reference.
  • a piston actuated by a solenoid may apply compression to the vascular wall.
  • An example of a solenoid actuated piston device is disclosed in U.S. Pat. No. 4,014,318 to Dokum et al, and an example of a hydraulically or pneumatically actuated piston device is disclosed in U.S. Pat. No. 4,586,501 to Claracq, the entire disclosures of which are hereby incorporated by reference.
  • Other examples include a rotary ring compression device as disclosed in U.S. Pat. No. 4,551,862 to Haber, and an electromagnetically actuated compression ring device as disclosed in U.S. Pat. No. 5 , 509 , 888 to Miller, the entire disclosures of which are hereby incorporated by reference.
  • FIG. 6 shows a baroreceptor activation device 140 in the form of an intravascular deformable structure.
  • the deformable structure device 140 includes a coil, braid or other stent-like structure 142 disposed in the vascular lumen.
  • the deformable structure 142 includes one or more individual structural members connected to an electrical lead 144 .
  • Each of the structural members forming deformable structure 142 may comprise a shape memory material 146 (e.g., nickel titanium alloy) as illustrated in FIG. 6B , or a bimetallic material 148 as illustrated in FIG. 6C .
  • the electrical lead 144 is connected to the driver 66 of the control system 60 .
  • the driver 66 comprises an electric power generator or amplifier which selectively delivers electric current to the structure 142 which resistively heats the structural members 146 / 148 .
  • the structure 142 may be unipolar as shown using the surrounding tissue as ground, or bipolar or multipolar using leads connected to either end of the structure 142 . Electrical power may also be delivered to the structure 142 inductively as described hereinafter with reference to FIGS. 14-16 .
  • the shape memory material 146 Upon application of electrical current to the shape memory material 146 , it is resistively heated causing a phase change and a corresponding change in shape.
  • the bimetallic material 148 Upon application of electrical current to the bimetallic material 148 , it is resistively heated causing a differential in thermal expansion and a corresponding change in shape.
  • the material 146 / 148 is designed such that the change in shape causes expansion of the structure 142 to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40 .
  • the material 146 / 148 cools and the structure 142 returns to its relaxed geometry such that the baroreceptors 30 and/or the vascular wall 40 return to their nominal state.
  • the baroreceptors 30 adjacent thereto may be selectively activated.
  • FIG. 7 shows a baroreceptor activation device 160 in the form of an extravascular deformable structure.
  • the extravascular deformable structure device 160 is substantially the same as the intravascular deformable structure device 140 described with reference to FIGS. 6A and 6B , except that the extravascular device 160 is disposed about the vascular wall, and therefore compresses, rather than expands, the vascular wall 40 .
  • the deformable structure device 160 includes a coil, braid or other stent-like structure 162 comprising one or more individual structural members connected to an electrical lead 164 .
  • Each of the structural members may comprise a shape memory material 166 (e.g., nickel titanium alloy) as illustrated in FIG. 7C , or a bimetallic material 168 .
  • shape memory material 166 e.g., nickel titanium alloy
  • the structure 162 may be unipolar as shown using the surrounding tissue as ground, or bipolar or multipolar using leads connected to either end of the structure 162 . Electrical power may also be delivered to the structure 162 inductively as described hereinafter with reference to FIGS. 14-16 .
  • the shape memory material 166 Upon application of electrical current to the shape memory material 166 , it is resistively heated causing a phase change and a corresponding change in shape.
  • the bimetallic material 168 Upon application of electrical current to the bimetallic material 168 , it is resistively heated causing a differential in thermal expansion and a corresponding change in shape.
  • the material 166 / 168 is designed such that the change in shape causes constriction of the structure 162 to mechanically activate baroreceptors 30 by compressing or otherwise deforming the baroreceptors 30 and/or the vascular wall 40 .
  • the material 166 / 168 cools and the structure 162 returns to its relaxed geometry such that the baroreceptors 30 and/or the vascular wall 40 return to their nominal state.
  • the baroreceptors 30 adjacent thereto may be selectively activated.
  • FIG. 8 shows a baroreceptor activation device 180 in the form of an extravascular flow regulator which artificially creates back pressure adjacent the baroreceptors 30 .
  • the flow regulator device 180 includes an external compression device 182 , which may comprise any of the external compression devices described with reference to FIG. 5 .
  • the external compression device 182 is operably connected to the driver 66 of the control system 60 by way of cable 184 , which may comprise a fluid line or electrical lead, depending on the type of external compression device 182 utilized.
  • the external compression device 182 is disposed about the vascular wall distal of the baroreceptors 30 .
  • the external compression device 182 may be located in the distal portions of the inferior vena cava 23 . 3 to create back pressure adjacent the baroreceptors 30 upstream in the inferior vena cava.
  • the vascular wall Upon actuation of the external compression device 182 , the vascular wall is constricted thereby reducing the size of the vascular lumen therein. By reducing the size of the vascular lumen, pressure proximal of the external compression device 182 is increased thereby expanding the vascular wall. Thus, by selectively activating the external compression device 182 to constrict the vascular lumen and create back pressure, the baroreceptors 30 may be selectively activated.
  • FIG. 9 shows a baroreceptor activation device 200 in the form of an intravascular flow regular which artificially creates back pressure adjacent the baroreceptors 30 .
  • the intravascular flow regulator device 200 is substantially similar in function and use as extravascular flow regulator 180 described with reference to FIG. 8 , except that the intravascular flow regulator device 200 is disposed in the vascular lumen.
  • Intravascular flow regulator 200 includes an internal valve 202 to at least partially close the vascular lumen distal of the baroreceptors 30 .
  • an internal valve 202 By at least partially closing the vascular lumen distal of the baroreceptors 30 , back pressure is created proximal of the internal valve 202 such that the vascular wall expands to activate the baroreceptors 30 .
  • the internal valve 202 may be positioned at any of the locations described with reference to the external compression device 182 , except that the internal valve 202 is placed within the vascular lumen.
  • the internal compression device 202 may be located in the distal portions of the vasculature to create back pressure adjacent to the baroreceptors 30 in the veins or cardiopulmonary system.
  • the internal valve 202 is operably coupled to the driver 66 of the control system 60 by way of electrical lead 204 .
  • the control system 60 may selectively open, close or change the flow resistance of the valve 202 as described in more detail hereinafter.
  • the internal valve 202 may include valve leaflets 206 (bi-leaflet or tri-leaflet) which rotate inside housing 208 about an axis between an open position and a closed position. The closed position may be completely closed or partially closed, depending on the desired amount of back pressure to be created.
  • the opening and closing of the internal valve 202 may be selectively controlled by altering the resistance of leaflet 206 rotation or by altering the opening force of the leaflets 206 .
  • the resistance of rotation of the leaflets 206 may be altered utilizing electromagnetically actuated metallic bearings carried by the housing 208 .
  • the opening force of the leaflets 206 may be altered by utilizing electromagnetic coils in each of the leaflets to selectively magnetize the leaflets such that they either repel or attract each other, thereby facilitating valve opening and closing, respectively.
  • intravascular flow regulators may be used in place of internal valve 202 .
  • internal inflatable balloon devices as disclosed in U.S. Pat. No. 4,682,583 to Burton et al. and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which is hereby incorporated by reference, may be adapted for use in place of valve 202 .
  • Such inflatable balloon devices may be operated in a similar manner as the inflatable cuff 122 described with reference to FIG. 5 .
  • the driver 66 would comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the internal balloon.
  • a pressure/vacuum source i.e., an inflation device
  • the balloon Upon inflation, the balloon expands to partially occlude blood flow and create back pressure to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40 .
  • the internal balloon Upon deflation, the internal balloon returns to its normal profile such that flow is not hindered and back pressure is eliminated.
  • the baroreceptors 30 proximal thereof may be selectively activated by creating back pressure.
  • the magnetic particles 222 may comprise magnetically responsive materials (i.e., ferrous based materials) and may be magnetically neutral or magnetically active.
  • the magnetic particles 222 comprise permanent magnets having an elongate cylinder shape with north and south poles to strongly respond to magnetic fields.
  • the magnetic particles 222 are actuated by an electromagnetic coil 224 which is operably coupled to the driver 66 of the control system 60 by way of an electrical cable 226 .
  • the electromagnetic coil 224 may be implanted as shown, or located outside the body, in which case the driver 66 and the remainder of the control system 60 would also be located outside the body.
  • the magnetic particles 222 may be repelled, attracted or rotated.
  • the magnetic field created by the electromagnetic coil 224 may be alternated such that the magnetic particles 222 vibrate within the vascular wall 40 .
  • the baroreceptors 30 are mechanically activated.
  • the electromagnetic coil 224 is preferably placed as close as possible to the magnetic particles 222 in the vascular wall 40 , and may be placed intravascularly, extravascularly, or in any of the alternative locations discussed with reference to inductor shown in FIGS. 14-16 .
  • the magnetic particles 222 may be implanted in the vascular wall 40 by injecting a ferro-fluid or a ferro-particle suspension into the vascular wall adjacent to the baroreceptors 30 .
  • the particles 222 may be coated with a ceramic, polymeric or other inert material. Injection of the fluid carrying the magnetic particles 222 is preferably performed percutaneously.
  • FIG. 11 shows a baroreceptor activation device 240 in the form of one or more transducers 242 .
  • the transducers 242 comprise an array surrounding the vascular wall.
  • the transducers 242 may be intravascularly or extravascularly positioned adjacent to the baroreceptors 30 .
  • the transducers 242 comprise devices which convert electrical signals into some physical phenomena, such as mechanical vibration or acoustic waves.
  • the electrical signals are provided to the transducers 242 by way of electrical cables 244 which are connected to the driver 66 of the control system 60 .
  • the baroreceptors 30 may be mechanically activated.
  • the transducers 242 may comprise an acoustic transmitter which transmits sonic or ultrasonic sound waves into the vascular wall 40 to activate the baroreceptors 30 .
  • the transducers 242 may comprise a piezoelectric material which vibrates the vascular wall to activate the baroreceptors 30 .
  • the transducers 242 may comprise an artificial muscle which deflects upon application of an electrical signal.
  • An example of an artificial muscle transducer comprises plastic impregnated with a lithium-perchlorate electrolyte disposed between sheets of polypyrrole, a conductive polymer. Such plastic muscles may be electrically activated to cause deflection in different directions depending on the polarity of the applied current.
  • FIG. 12 shows a baroreceptor activation device 260 in the form of a local fluid delivery device 262 suitable for delivering a chemical or biological fluid agent to the vascular wall adjacent the baroreceptors 30 .
  • the local fluid delivery device 262 may be located intravascularly, extravascularly, or intramurally. For purposes of illustration only, the local fluid delivery device 262 is positioned extravascularly.
  • the local fluid delivery device 262 may include proximal and distal seals 266 which retain the fluid agent disposed in the lumen or cavity 268 adjacent to vascular wall. Preferably, the local fluid delivery device 262 completely surrounds the vascular wall 40 to maintain an effective seal. Those skilled in the art will recognize that the local fluid delivery device 262 may comprise a wide variety of implantable drug delivery devices or pumps known in the art.
  • the local fluid delivery device 260 is connected to a fluid line 264 which is connected to the driver 66 of the control system 60 .
  • the driver 66 comprises a pressure/vacuum source and fluid reservoir containing the desired chemical or biological fluid agent.
  • the chemical or biological fluid agent may comprise a wide variety of stimulatory substances. Examples include veratridine, bradykinin, prostaglandins, and related substances. Such stimulatory substances activate the baroreceptors 30 directly or enhance their sensitivity to other stimuli and therefore may be used in combination with the other baroreceptor activation devices described herein.
  • Other examples include growth factors and other agents that modify the function of the baroreceptors 30 or the cells of the vascular tissue surrounding the baroreceptors 30 causing the baroreceptors 30 to be activated or causing alteration of their responsiveness or activation pattern to other stimuli. It is also contemplated that injectable stimulators that are induced remotely, as described in U.S. Pat. No. 6,061,596 which is incorporated herein by reference, may be used with the present invention.
  • the fluid delivery device 260 may be used to deliver a photochemical that is essentially inert until activated by light to have a stimulatory effect as described above.
  • the fluid delivery device 260 would include a light source such as a light emitting diode (LED), and the driver 66 of the control system 60 would include a pulse generator for the LED combined with a pressure/vacuum source and fluid reservoir described previously.
  • the photochemical would be delivered with the fluid delivery device 260 as described above, and the photochemical would be activated, deactivated or modulated by activating, deactivating or modulating the LED.
  • the fluid delivery device 260 may be used to deliver a warm or hot fluid (e.g. saline) to thermally activate the baroreceptors 30 .
  • a warm or hot fluid e.g. saline
  • the driver 66 of the control system 60 would include a heat generator for heating the fluid, combined with a pressure/vacuum source and fluid reservoir described previously.
  • the hot or warm fluid would be delivered and preferably circulated with the fluid delivery device 260 as described above, and the temperature of the fluid would be controlled by the driver 66 .
  • the electrode structure 282 may comprise a self-expanding or balloon expandable coil, braid or other stent-like structure disposed in the vascular lumen.
  • the electrode structure 282 may serve the dual purpose of maintaining lumen patency while also delivering electrical stimuli.
  • the electrode structure 282 may be implanted utilizing conventional intravascular stent and filter delivery techniques.
  • the electrode structure 282 comprises a geometry which allows blood perfusion therethrough.
  • the electrode structure 282 comprises electrically conductive material which may be selectively insulated to establish contact with the inside surface of the vascular wall 40 at desired locations, and limit extraneous electrical contact with blood flowing through the vessel and other tissues.
  • the electrode structure 282 is connected to electric lead 284 which is connected to the driver 66 of the control system 60 .
  • the driver 66 may comprise a power amplifier, pulse generator or the like to selectively deliver electrical control signals to structure 282 .
  • the electrical control signal generated by the driver 66 may be continuous, periodic, episodic or a combination thereof, as dictated by an algorithm contained in memory 62 of the control system 60 .
  • Continuous control signals include a constant pulse, a constant train of pulses, a triggered pulse and a triggered train of pulses.
  • Periodic control signals include each of the continuous control signals described above which have a designated start time and a designated duration.
  • Episodic control signals include each of the continuous control signals described above which are triggered by an episode.
  • electrical energy may be delivered to the vascular wall to activate the baroreceptors 30 .
  • activation of the baroreceptors 30 may occur directly or indirectly.
  • the electrical signal delivered to the vascular wall 40 by the electrode structure 282 may cause the vascular wall to stretch or otherwise deform thereby indirectly activating the baroreceptors 30 disposed therein.
  • the electrical signals delivered to the vascular wall by the electrode structure 282 may directly activate the baroreceptors 30 by changing the electrical potential across the baroreceptors 30 . In either case, the electrical signal is delivered to the vascular wall 40 immediately adjacent to the baroreceptors 30 .
  • the electrode structure 282 may delivery thermal energy by utilizing a semi-conductive material having a higher resistance such that the electrode structure 282 resistively generates heat upon application of electrical energy.
  • the electrode structure 282 may be unipolar as shown in FIG. 13 using the surrounding tissue as ground, or bipolar using leads connected to either end of the structure 282 as shown in Figure.
  • the electrode structure 282 includes two or more individual electrically conductive members 283 / 285 which are electrically isolated at their respective cross-over points utilizing insulative materials. Each of the members 283 / 285 is connected to a separate conductor contained within the electrical lead 284 .
  • an array of bipoles may be used as described in more detail with reference to FIG. 21 .
  • a multipolar arrangement may be used wherein three or more electrically conductive members are included in the structure 282 .
  • a tripolar arrangement may be provided by one electrically conductive member having a polarity disposed between two electrically conductive members having the opposite polarity.
  • the electrical signals may be directly delivered to the electrode structure 282 as described with reference to FIG. 13 , or indirectly delivered utilizing an inductor 286 as illustrated in FIGS. 14-16 and 21 .
  • the embodiments of FIGS. 14-16 and 21 utilize an inductor 286 which is operably connected to the driver 66 of the control system 60 by way of electrical lead 284 .
  • the inductor 286 comprises an electrical winding which creates a magnetic field 287 (as seen in FIG. 21 ) around the electrode structure 282 .
  • the magnetic field 287 may be alternated by alternating the direction of current flow through the inductor 286 .
  • the inductor 286 may be utilized to create current flow in the electrode structure 282 to thereby deliver electrical signals to the vascular wall 40 to directly or indirectly activate the baroreceptors 30 .
  • the inductor 286 may be covered with an electrically insulative material to eliminate direct electrical stimulation of tissues surrounding the inductor 286 .
  • a preferred embodiment of an inductively activated electrode structure 282 is described in more detail with reference to FIGS. 21A-21C .
  • FIGS. 13-16 may be modified to form a cathode/anode arrangement.
  • the electrical inductor 286 would be connected to the driver 66 as shown in FIGS. 14-16 and the electrode structure 282 would be connected to the driver 66 as shown in FIG. 13 .
  • the electrode structure 282 and the inductor 286 may be any suitable geometry and need not be coiled for purposes of induction.
  • the electrode structure 282 and the inductor 286 would comprise a cathode/anode or anode/cathode pair.
  • the cathode 282 when activated, may generate a primary stream of electrons which travel through the inter-electrode space (i.e., vascular tissue and baroreceptors 30 ) to the anode 286 .
  • the cathode is preferably cold, as opposed to thermionic, during electron emission.
  • the electrons may be used to electrically or thermally activate the baroreceptors 30 as discussed previously.
  • the electrical inductor 286 is preferably disposed as close as possible to the electrode structure 282 .
  • the electrical inductor 286 may be disposed adjacent the vascular wall as illustrated in FIG. 14 .
  • the inductor 286 may be disposed in an adjacent vessel 289 as illustrated in FIG. 15 .
  • the electrode structure 282 is disposed in the carotid sinus 20
  • the inductor 286 may be disposed in the internal jugular vein 21 as illustrated in FIG. 15 .
  • the electrical inductor 286 may comprise a similar structure as the electrode structure 282 .
  • the electrical inductor 286 may be disposed outside the patient's body, but as close as possible to the electrode structure 282 . If the electrode structure 282 is disposed in the carotid sinus 20 , for example, the electrical inductor 286 may be disposed on the right or left side of the neck of the patient as illustrated in FIG. 16 . In the embodiment of FIG. 16 , wherein the electrical inductor 286 is disposed outside the patient's body, the control system 60 may also be disposed outside the patient's body.
  • the electrode structure 282 may be intravascularly disposed as described with reference to FIG. 13 , or extravascularly disposed as described with reference to FIG. 17 , which show schematic illustrations of a baroreceptor activation device 300 in the form of an extravascular electrically conductive structure or electrode 302 . Except as described herein, the extravascular electrode structure 302 is the same in design, function, and use as the intravascular electrode structure 282 .
  • the electrode structure 302 may comprise a coil, braid or other structure capable of surrounding the vascular wall. Alternatively, the electrode structure 302 may comprise one or more electrode patches distributed around the outside surface of the vascular wall.
  • the extravascular electrode structure 302 may receive electrical signals directly from the driver 66 of the control system 60 by way of electrical lead 304 , or indirectly by utilizing an inductor (not shown) as described with reference to FIGS. 14-16 .
  • FIG. 19 shows a baroreceptor activation device 320 in the form of electrically conductive particles 322 disposed in the vascular wall.
  • This embodiment is substantially the same as the embodiments described with reference to FIGS. 13-18 , except that the electrically conductive particles 322 are disposed within the vascular wall, as opposed to the electrically conductive structures 282 / 302 which are disposed on either side of the vascular wall.
  • this embodiment is similar to the embodiment described with reference to FIG. 10 , except that the electrically conductive particles 322 are not necessarily magnetic as with magnetic particles 222 , and the electrically conductive particles 322 are driven by an electromagnetic filed rather than by a magnetic field.
  • the driver 66 of the control system 60 comprises an electromagnetic transmitter such as an radiofrequency or microwave transmitter. Electromagnetic radiation is created by the transmitter 66 which is operably coupled to an antenna 324 by way of electrical lead 326 . Electromagnetic waves are emitted by the antenna 324 and received by the electrically conductive particles 322 disposed in the vascular wall 40 . Electromagnetic energy creates oscillating current flow within the electrically conductive particles 322 , and depending on the intensity of the electromagnetic radiation and the resistivity of the conductive particles 322 , may cause the electrical particles 322 to generate heat. The electrical or thermal energy generated by the electrically conductive particles 322 may directly activate the baroreceptors 30 , or indirectly activate the baroreceptors 30 by way of the surrounding vascular wall tissue.
  • an electromagnetic transmitter such as an radiofrequency or microwave transmitter. Electromagnetic radiation is created by the transmitter 66 which is operably coupled to an antenna 324 by way of electrical lead 326 . Electromagnetic waves are emitted by the antenna 324 and received
  • the electromagnetic radiation transmitter 66 and antenna 324 may be disposed in the patient's body, with the antenna 324 disposed adjacent to the conductive particles in the vascular wall 40 as illustrated in FIG. 19 .
  • the antenna 324 may be disposed in any of the positions described with reference to the electrical inductor shown in FIGS. 14 - 16 .
  • the electromagnetic radiation transmitter 66 and antenna 324 may be utilized in combination with the intravascular and extravascular electrically conductive structures 282 / 302 described with reference to FIGS. 13-18 to generate thermal energy on either side of the vascular wall.
  • the electromagnetic radiation transmitter 66 and antenna 324 may be used without the electrically conductive particles 322 .
  • the electromagnetic radiation transmitter 66 and antenna 324 may be used to deliver electromagnetic radiation (e.g., RF, microwave) directly to the baroreceptors 30 or the tissue adjacent thereto to cause localized heating, thereby thermally inducing a baroreceptor 30 signal.
  • electromagnetic radiation e.g., RF, microwave
  • FIG. 20 shows a baroreceptor activation device 340 in the form of a Peltier effect device 342 .
  • the Peltier effect device 342 may be extravascularly positioned as illustrated, or may be intravascularly positioned similar to an intravascular stent or filter.
  • the Peltier effect device 342 is operably connected to the driver 66 of the control system 60 by way of electrical lead 344 .
  • the Peltier effect device 342 includes two dissimilar metals or semiconductors 343 / 345 separated by a thermal transfer junction 347 .
  • the driver 66 comprises a power source which delivers electrical energy to the dissimilar metals or semiconductors 343 / 345 to create current flow across the thermal junction 347 .
  • a cooling effect is created at the thermal junction 347 .
  • a heating effect created at the junction between the individual leads 344 connected to the dissimilar metals or semiconductors 343 / 345 .
  • This heating effect which is proportional to the cooling effect, may be utilized to activate the baroreceptors 30 by positioning the junction between the electrical leads 344 and the dissimilar metals or semiconductors 343 / 345 adjacent to the vascular wall 40 .
  • FIGS. 21A-21C show schematic illustrations of a preferred embodiment of an inductively activated electrode structure 282 for use with the embodiments described with reference to FIGS. 14-16 .
  • current flow in the electrode structure 282 is induced by a magnetic field 287 created by an inductor 286 which is operably coupled to the driver 66 of the control system 60 by way of electrical cable 284 .
  • the electrode structure 282 preferably comprises a multi-filar self-expanding braid structure including a plurality of individual members 282 a, 282 b, 282 c and 282 d.
  • the electrode structure 282 may simply comprise a single coil for purposes of this embodiment.
  • Each of the individual coil members 282 a- 282 d comprising the electrode structure 282 consists of a plurality of individual coil turns 281 connected end to end as illustrated in FIGS. 21B and 21C .
  • FIG. 21C is a detailed view of the connection between adjacent coil turns 281 as shown in FIG. 21B .
  • Each coil turn 281 comprises electrically isolated wires or receivers in which a current flow is established when a changing magnetic field 287 is created by the inductor 286 .
  • the inductor 286 is preferably covered with an electrically insulative material to eliminate direct electrical stimulation of tissues surrounding the inductor 286 .
  • Current flow through each coil turn 281 results in a potential drop 288 between each end of the coil turn 281 .
  • each coil turn 281 comprises an electrically conductive wire material 290 surrounded by an electrically insulative material 292 .
  • the ends of each coil turn 281 are connected by an electrically insulated material 294 such that each coil turn 281 remains electrically isolated.
  • the insulative material 294 mechanically joins but electrically isolates adjacent coil turns 281 such that each turn 281 responds with a similar potential drop 288 when current flow is induced by the changing magnetic field 287 of the inductor 286 .
  • An exposed portion 296 is provided at each end of each coil turn 281 to facilitate contact with the vascular wall tissue.
  • Each exposed portion 296 comprises an isolated electrode in contact with the vessel wall.
  • the changing magnetic field 287 of the inductor 286 causes a potential drop in each coil turn 281 thereby creating small current flow cells in the vessel wall corresponding to adjacent exposed regions 296 .
  • the creation of multiple small current cells along the inner wall of the blood vessel serves to create a cylindrical zone of relatively high current density such that the baroreceptors 30 are activated.
  • the cylindrical current density field quickly reduces to a negligible current density near the outer wall of the vascular wall, which serves to limit extraneous current leakage to minimize or eliminate unwanted activation of extravascular tissues and structures such as nerves or muscles.
  • some of the baroreceptor activation devices described previously may be used to selectively and controllably regulate blood pressure by inhibiting or dampening baroreceptor signals.
  • the present invention reduces conditions associated with low blood pressure as described previously. Specifically, the present invention would function to increase the blood pressure and level of sympathetic nervous system activation by inhibiting or dampening the activation of baroreceptors.
  • Mechanical means may be triggered off the pressure pulse of the heart to mechanically limit deformation of the arterial wall.
  • mechanical means may be triggered off the pressure pulse of the heart to mechanically limit deformation of the arterial wall.
  • either of the external compression devices 120 / 160 described previously may be used to limit deformation of the arterial wall.
  • the external compression device may simply limit diametrical expansion of the vascular wall adjacent the baroreceptors without the need for a trigger or control signal.
  • Thermal means may be used to cool the baroreceptors 30 and adjacent tissue to reduce the responsiveness of the baroreceptors 30 and thereby dampen baroreceptor signals.
  • the baroreceptor 30 signals may be dampened by either directly cooling the baroreceptors 30 , to reduce their sensitivity, metabolic activity and function, or by cooling the surrounding vascular wall tissue thereby causing the wall to become less responsive to increases in blood pressure.
  • An example of this approach is to use the cooling effect of the Peltier device 340 .
  • the thermal transfer junction 347 may be positioned adjacent the vascular wall to provide a cooling effect. The cooling effect may be used to dampen signals generated by the baroreceptors 30 .
  • the fluid delivery device 260 to deliver a cool or cold fluid (e.g. saline).
  • the driver 66 would include a heat exchanger to cool the fluid and the control system 60 may be used to regulate the temperature of the fluid, thereby regulating the degree of baroreceptor 30 signal dampening.
  • Electrical means may be used to inhibit baroreceptor 30 activation by, for example, hyperpolarizing cells in or adjacent to the baroreceptors 30 .
  • hyperpolarizing cells examples include U.S. Pat. No. 5,814,079 to Kieval, and U.S. Pat. No. 5,800,464 to Kieval, the entire disclosures of which are hereby incorporated by reference.
  • Such electrical means may be implemented using any of the embodiments discussed with reference to FIGS. 13-18 and 21 .
  • Chemical or biological means may be used to reduce the sensitivity of the baroreceptors 30 .
  • a substance that reduces baroreceptor sensitivity may be delivered using the fluid delivery device 260 described previously.
  • the desensitizing agent may comprise, for example, tetrodotoxin or other inhibitor of excitable tissues.
  • the baroreceptor activation devices described previously may also be used to provide antiarrhythmic effects. It is well known that the susceptibility of the myocardium to the development of conduction disturbances and malignant cardiac arrhythmias is influenced by the balance between sympathetic and parasympathetic nervous system stimulation to the heart. That is, heightened sympathetic nervous system activation, coupled with decreased parasympathetic stimulation, increases the irritability of the myocardium and likelihood of an arrhythmia. Thus, by decreasing the level of sympathetic nervous system activation and enhancing the level of parasympathetic activation, the devices, systems and methods of the current invention may be used to provide a protective effect against the development of cardiac conduction disturbances.
  • An electrode system was introduced into the inferior vena cava of an anesthetized dog.
  • the electrode system was an eight lead, 64-electrode 8F Constellation® catheter from Boston Scientific EP Technologies, Sunnyvale, Calif.
  • the electrode system was placed endovascularly in the abdominal vena cava.
  • the electrode system was activated using trains of electrical impulses of 0-6 volts, a frequency of 100 hz, and a pulse width of 0.5 ms.
  • arterial pressure, mean arterial pressure and heart rate were monitored. The results of three experiments are shown in FIGS. 22 A-C. These figures demonstrate a change in blood pressure as energy is applied to the vessel wall, with recovery to pre-activation levels when the energy is discontinued.

Abstract

The present invention is an apparatus comprising, a flexible lead body extending from a proximal end to a distal end, the lead body having an outer diameter dimensioned to abut a wall of a pulmonary artery, an electrode coupled to the flexible lead body and an implantable pulse generator electrically coupled to the electrode, wherein the implantable pulse generator is adapted to deliver a baroreceptor stimulation signal to a baroreceptor in the pulmonary artery via the electrode.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 10/284,063, (Attorney Docket No. 021433-000150US), filed on Oct. 29, 2002, which is a continuation-in-part of U.S. patent application Ser. No. 09/671,850 (Attorney Docket No. 021433-000100US), filed on Sep. 27, 2000, which is now issued as U.S. Pat. No. 6,522,926, the full disclosures of which are incorporated herein by reference. The parent application for this application has incorporated by reference the disclosures of the following U.S. patent applications: U.S. patent application Ser. No. 09/964,079 (Attorney Docket No. 021433-000110US), filed on Sep. 26, 2001, now issued as U.S. Pat. No. 6,985,774, U.S. patent application Ser. No. 09/963,777 (Attorney Docket No. 021433-000120US), filed Sep. 26, 2001, and U.S. patent application Ser. No. 09/963,991, filed on Sep. 26, 2001, now issued as U.S. Pat. No. 6,850,801, (Attorney Docket No. 021433-000130US), the disclosures of which are also effectively incorporated by reference herein.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention generally relates to medical devices and methods of use for the treatment and/or management of cardiovascular, renal, and neurological disorders. Specifically, the present invention relates to devices and methods for controlling the low-pressure baroreflex system for the treatment and/or management of cardiovascular, renal, and neurological disorders.
  • Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year in the United States. Hypertension, or high blood pressure, is a major cardiovascular disorder that is estimated to affect over 50 million people in the United Sates alone. Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure. Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures. Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith.
  • Heart failure is the final common expression of a variety of cardiovascular disorders, including ischemic heart disease. It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival. It is estimated that approximately 5,000,000 people in the United States suffer from heart failure, directly leading to 39,000 deaths per year and contributing to another 225,000 deaths per year. Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood. Many of these responses are mediated by an increase in the level of activation of the sympathetic nervous system, as well as by activation of multiple other neurohormonal responses. Generally speaking, this sympathetic nervous system activation signals the heart to increase heart rate and force of contraction to increase the cardiac output; it signals the kidneys to expand the blood volume by retaining sodium and water; and it signals the arterioles to constrict to elevate the blood pressure. The cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. Accordingly, it is desirable to reduce the level of sympathetic nervous system activation in order to stop or at least minimize this vicious cycle and thereby treat or manage the heart failure.
  • A number of drug treatments have been proposed for the management of hypertension, heart failure and other cardiovascular disorders. These include vasodilators to reduce the blood pressure and ease the workload of the heart, diuretics to reduce fluid overload, inhibitors and blocking agents of the body's neurohormonal responses, and other medicaments. Various surgical procedures have also been proposed for these maladies. For example, heart transplantation has been proposed for patients who suffer from severe, refractory heart failure. Alternatively, an implantable medical device such as a ventricular assist device (VAD) may be implanted in the chest to increase the pumping action of the heart. Alternatively, an intra-aortic balloon pump (IABP) may be used for maintaining heart function for short periods of time, but typically no longer than one month. Other surgical procedures are available as well. No one drug, surgical procedure, or assist system, however, has provided a complete solution to the problems of hypertension and heart failure.
  • For these reasons, it would be desirable to provide alternative and improved methods for treating hypertension, heart failure, and other cardiovascular, neurological, and renal disorders. Such methods and systems should allow for treatment of patients where other therapies have failed or are unavailable, such as heart transplantation. It would be further desirable if the methods could lessen or eliminate the need for chronic drug use in at least some patients. Additionally, it would be desirable if the methods and systems were mechanically simple and inherently reliable, in contrast to complex mechanical systems such as VAD's, IABP's, and the like.
  • One particularly promising approach for improving the treatment of hypertension, heart failure, and other cardiovascular and renal disorders is described in published PCT Application No. WO 02/026314, which claims the benefit of U.S. patent application Ser. No. 09/671,850, which is the parent of the present application. The full disclosures of both WO 02/026314 and U.S. Ser. No. 09/671,850, are incorporated herein by reference. WO 02/026314 describes the direct activation of baroreceptors for inducing changes in a patient's baroreflex system to control blood pressure and other patient functions. The prior applications are particularly directed at the activation of the baroreceptors present in the carotid sinus and the aortic arch. Both the carotid sinus and aortic arch are on the high-pressure or arterial side of the patient's vasculature. They are referred to as high-pressure since pressures in the systemic arterial circulation are higher than those in the veins and pulmonary circulation. Activation of the high-pressure baroreceptors can send signals to the brain that cause reflex alterations in nervous system function which result in changes in activity of target organs, including the heart, vasculature, kidneys, and the like, typically to maintain homeostasis.
  • While highly promising, the need to implant electrodes or other effectors on the arterial or high-pressure side of the vasculature may be disadvantageous in some respects. Arteries and other vessels on the high-pressure side of the vasculature are at risk of damage, and implantation of an electrode on or in the carotid sinus or aortic arch requires more care, and improper device implantation on the arterial side presents a small risk of arterial thromboembolism which in turn can cause stroke and other organ damage. Some arterial locations can also cause unwanted tissue or nerve stimulation due to current leakage.
  • Thus, it would be desirable to provide improved methods and systems for artificial and selective activation of a patient's baroreflex system in order to achieve a variety of therapeutic objectives, including the control of hypertension, renal function, heart failure, and the treatment of other cardiovascular and neurological disorders. It would be particularly desirable if such methods and systems did not require intervention on the arterial or high-pressure side of a patient's vasculature, thus lessening the risk to the patient of arterial damage and damage resulting from thromboembolism or hemorrhage. At least some of these objectives will be met by the inventions described hereinafter.
  • 2. Description of the Background Art
  • U.S. Pat. Nos. 6,073,048 and 6,178,349, each having a common invention with the present application, describe the stimulation of nerves to regulate the heart, vasculature, and other body systems. Nerve stimulation for other purposes is described in, for example, U.S. Pat. Nos. 6,292,695 B1 and 5,700,282. Publications describing baropacing of the carotid arteries for controlling hypertension include Neufeld et al. (1965) Israel J. Med. Sci 1:630-632; Bilgutay et al., Proc. Baroreceptors and Hypertension, Dayton, Ohio, Nov. 16-17, 1965, pp 425-437; Bilgutary and Lillehei (1966) Am. J. Cariol. 17:663-667; and Itoh (1972) Jap. Heart J. 13: 136-149. Publications which describe the existence of baroreceptors and/or related receptors in the venous vasculature and atria include Goldberger et al. (1999) J. Neuro. Meth. 91:109-114; Kostreva and Pontus (1993) Am. J. Physiol. 265:G15-G20; Coleridge et al. (1973) Circ. Res. 23:87-97; Mifflin and Kunze (1982) Circ. Res. 51:241-249; and Schaurte et al. (2000) J. Cardiovasc Electrophysiol. 11:64-69.
  • BRIEF SUMMARY OF THE INVENTION
  • To address hypertension, heart failure, cardia arrhythmias, and associated cardiovascular, renal, and nervous system disorders, the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors. By selectively and controllably activating baroreceptors, the present invention reduces excessive blood pressure, sympathetic nervous system activation and neurohormonal activation, thereby minimizing their deleterious effects on the heart, vasculature and other organs and tissues.
  • In an exemplary embodiment, the present invention provides a system and method for treating a patient by inducing a baroreceptor signal to effect a change in the baroreflex system (e.g., reduced heart rate, reduced blood pressure, etc.). The baroreceptor signal is activated or otherwise modified by selectively activating baroreceptors. To accomplish this, the system and method of the present invention utilize a baroreceptor activation device positioned near a baroreceptor in the venous or low-pressure side of a patient's vasculature. As used hereinafter, the phrase “low-pressure side of the vasculature” will mean the venous and cardiopulmonary vasculature, including particularly the chambers in the heart, veins near the entrances to the atria, the pulmonary artery, the portal vein of the liver, the superior vena cava (SVC), the inferior vena cava (IVC), the jugular vein, the subclavian veins, the iliac veins, the femoral veins, and other peripheral areas of the vasculature where baroreceptor and baroreceptor-like receptors are found. Particular target mechanoreceptors are described in Kostreva and Pontus (1993), cited above, the full disclosure of which is incorporated herein by reference.
  • The baroreceptors and baroreceptor-like receptors on the low-pressure side of the vasculature will function similarly to, but not necessarily identically to, baroreceptors on the high-pressure side of the vasculature. In general, cardiovascular receptors may be sensitive to pressure and/or mechanical deformation and are referred to as baroreceptors, mechanoreceptors, pressoreceptors, stretch receptors, and the like. For cardiovascular and renal therapies, the present invention is intended to activate or otherwise interact with any or all of these types of receptors so long as such activation or interaction results in modulation of the reflex control of the patient's circulation. While there may be small structural or anatomical differences among various receptors in the vasculature, for the purposes of the present invention, activation may be directed at any of these receptors so long as they provide the desired effects. In particular, such receptors will provide afferent signals, i.e., signals to the brain, which provide the blood pressure and/or volume information to the brain which allow the brain to cause “reflex” changes in the autonomic nervous system which in turn modulate organ activity to maintain desired hemodynamics and organ perfusion. Such activation of afferent pathways may also affect brain functions in such a way that could aid in the treatment of neurologic disease.
  • The ability to control the baroreflex response and cardiovascular, renal, and neurological function, by intervention on the low-pressure side of the vasculature is advantageous in several respects. Intervention on the venous and cardiopulmonary side of the vasculature reduces the risk of organ damage, including stroke, from systemic arterial thromboembolism. Moreover, the devices and structures used for intervening on the venous and cardiopulmonary side of the vasculature may be less complicated since the risk they pose to venous circulation is much less than to arterial circulation. Additionally, the availability of venous and cardiopulmonary baroreceptors allows placement of electrodes and other devices which reduce the risk of unwanted tissue stimulation resulting from current leakage to closely adjacent nerves, muscles, and other tissues.
  • Generally speaking, the baroreceptor activation device may be activated, deactivated or otherwise modulated to activate one or more baroreceptors and induce a baroreceptor signal or a change in the baroreceptor signal to thereby effect a change in the baroreflex system. The baroreceptor activation device may be activated, deactivated, or otherwise modulated continuously, periodically, or episodically. The baroreceptor activation device may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate the baroreceptor. The baroreceptor may be activated directly, or activated indirectly via the adjacent vascular tissue. The baroreceptor activation device may be positioned inside the vascular lumen (i.e., intravascularly), outside the vascular wall (i.e., extravascularly) or within the vascular wall (i.e., intramurally). The particular activation patterns may be selected to mimic those which naturally occur in the venous and cardiopulmonary vasculature, which conditions might vary from those characteristic of the arterial vasculature. In other cases, the activation patterns may be different from the natural patterns and selected to achieve an optimized barosystem response.
  • A control system may be used to generate a control signal which activates, deactivates or otherwise modulates the baroreceptor activation device. The control system may operate in an open-loop or a closed-loop mode. For example, in the open-loop mode, the patient and/or physician may directly or remotely interface with the control system to prescribe the control signal. In the closed-loop mode, the control signal may be responsive to feedback from a sensor, wherein the response is dictated by a preset or programmable algorithm.
  • To address low blood pressure and other conditions requiring blood pressure augmentation, the present invention provides a number of devices, systems and methods by which the blood pressure may be selectively and controllably regulated by inhibiting or dampening baroreceptor signals. By selectively and controllably inhibiting or dampening baroreceptor signals, the present invention reduces conditions associated with low blood pressure.
  • To address hypertension, heart failure, cardiac arrhythmias, and their associated cardiovascular and nervous system disorders, the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors, baroreceptor-like mechanoreceptors or pressoreceptors, or the like. By selectively and controllably activating baroreceptors, the present invention reduces excessive blood, pressure, sympathetic nervous system activation and neurohormonal activation, thereby minimizing their deleterious effects on the heart, vasculature and other organs and tissues.
  • In an exemplary embodiment, the present invention provides a system and method for treating a patient by inducing a baroreceptor signal to effect a change in the baroreflex system (e.g., reduced heart rate, reduced blood pressure, etc.). The baroreceptor signal is activated or otherwise modified by selectively activating baroreceptors. To accomplish this, the system and method of the present invention utilize a baroreceptor activation device positioned near a baroreceptor in a vein, the pulmonary vasculature, in a heart chamber, at a veno-atrial junction, or the like.
  • Generally speaking, the baroreceptor activation device may be activated, deactivated or otherwise modulated to activate one or more baroreceptors and induce a baroreceptor signal or a change in the baroreceptor signal to thereby effect a change in the baroreflex system. The baroreceptor activation device may be activated, deactivated, or otherwise modulated continuously, periodically, or episodically. The baroreceptor activation device may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate the baroreceptor. The baroreceptor may be activated directly, or activated indirectly via the adjacent vascular tissue. The baroreceptor activation device may be positioned inside the vascular lumen (i.e., intravascularly), outside the vascular wall (i.e., extravascularly) or within the vascular wall (i.e., intramurally).
  • A control system may be used to generate a control signal which activates, deactivates or otherwise modulates the baroreceptor activation device. The control system may operate in an open-loop or a closed-loop mode. For example, in the open-loop mode, the patient and/or physician may directly or remotely interface with the control system to prescribe the control signal. In the closed-loop mode, the control signal may be responsive to feedback from a sensor, wherein the response is dictated by a preset or programmable algorithm.
  • To address low blood pressure and other conditions requiring blood pressure augmentation, the present invention provides a number of devices, systems and methods by which the blood pressure may be selectively and controllably regulated by inhibiting or dampening baroreceptor signals. By selectively and controllably inhibiting or dampening baroreceptor signals, the present invention reduces conditions associated with low blood pressure.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic illustration of the upper torso of a human body showing the major arteries and veins and associated anatomy.
  • FIG. 1A is a schematic illustration of the lower abdominal vasculature including the abdominal aorta and the inferior vena cava.
  • FIG. 2 is a cross-sectional schematic illustration of baroreceptors within a vascular wall.
  • FIG. 3 is a schematic illustration of a baroreceptor activation system in accordance with the present invention.
  • FIG. 4 is a schematic illustration of a baroreceptor activation device in the form of an internal inflatable balloon which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 5 is a schematic illustration of a baroreceptor activation device in the form of an external pressure cuff which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 6A is a schematic illustration of a baroreceptor activation device in the form of an internal deformable coil structure which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIGS. 6B and 6C are cross-sectional views of alternative embodiments of the coil member illustrated in FIG. 6.
  • FIG. 7 is a schematic illustration of a baroreceptor activation device in the form of an external deformable coil structure which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 8 is a schematic illustration of a baroreceptor activation device in the form of an external flow regulator which artificially creates back pressure to induce a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 9 is a schematic illustration of a baroreceptor activation device in the form of an internal flow regulator which artificially creates back pressure to induce a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 10 is a schematic illustration of a baroreceptor activation device in the form of a magnetic device which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 11 is a schematic illustration of a baroreceptor activation device in the form of a transducer which mechanically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 12 is a schematic illustration of a baroreceptor activation device in the form of a fluid delivery device which may be used to deliver an agent which chemically or biologically induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 13 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 14 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an internal inductor, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 15 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an internal inductor located in an adjacent vessel, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 16 is a schematic illustration of a baroreceptor activation device in the form of an internal conductive structure, activated by an external inductor, which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 17 is a schematic illustration of a baroreceptor activation device in the form of an external conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 18 is a schematic illustration of a baroreceptor activation device in the form of an internal bipolar conductive structure which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 19 is a schematic illustration of a baroreceptor activation device in the form of an electromagnetic field responsive device which electrically or thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIG. 20 is a schematic illustration of a baroreceptor activation device in the form of an external Peltier device which thermally induces a baroreceptor signal in accordance with an embodiment of the present invention.
  • FIGS. 21A-21C are schematic illustrations of a preferred embodiment of an inductively activated electrically conductive structure.
  • FIGS. 22A-22C are ECG charts of a dog undergoing stimulation of the abdominal IVC.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
  • To better understand the present invention, it may be useful to explain some of the basic vascular anatomy associated with the cardiovascular system. Refer to FIG. 1 which is a schematic illustration of the upper torso of a human body 10 showing some of the major arteries and veins of the cardiovascular system. The left ventricle of the heart 11 pumps oxygenated blood up into the aortic arch 12. The right subclavian artery 13, the right common carotid artery 14, the left common carotid artery 15 and the left subclavian artery 16 branch off the aortic arch 12 proximal of the descending thoracic aorta 17. Although relatively short, a distinct vascular segment referred to as the brachiocephalic artery 22 connects the right subclavian artery 13 and the right common carotid artery 14 to the aortic arch 12. The right carotid artery 14 bifurcates into the right external carotid artery 18 and the right internal carotid artery 19 at the right carotid sinus 20. Although not shown for purposes of clarity only, the left carotid artery 15 similarly bifurcates into the left external carotid artery and the left internal carotid artery at the left carotid sinus.
  • From the aortic arch 12, oxygenated blood flows into the carotid arteries 18/19 and the subclavian arteries 13/16. From the carotid arteries 18/19, oxygenated blood circulates through the head and cerebral vasculature and oxygen depleted blood returns to the heart 11 by way of the jugular veins, of which only the right internal jugular vein 21 is shown for sake of clarity. From the subclavian arteries 13/16, oxygenated blood circulates through the upper peripheral vasculature and oxygen depleted blood returns to the heart by way of the subclavian veins, of which only the right subclavian vein 23 is shown, also for sake of clarity. Deoxygenated blood from the upper torso and head eventually return to the heart 11 through the superior vena cava 23.1, shown diagrammatically only. The heart 11 pumps the oxygen-depleted blood through the pulmonary system where it is re-oxygenated. The re-oxygenated blood returns to the heart 11 which pumps the re-oxygenated blood into the aortic arch as described above, and the cycle repeats. In the abdomen and lower extremities, oxygenated blood is delivered to the organs and lower limbs through the abdominal aorta 23.2. Deoxygenated blood returns to the heart through the inferior vena cava 23.3.
  • Within the walls of many veins, the pulmonary vasculature and the chambers of the heart, as in the walls of the carotid sinus, aorta and other arterial structures, there are baroreceptors. Baroreceptors are a type of stretch receptor used by the body to sense blood pressure and blood volume. An increase in blood pressure or volume causes the vascular wall to stretch, and a decrease in blood pressure or volume causes the vascular wall to return to its original size. In many vessels, such a cycle is repeated with each beat of the heart. In others, in particular some of the body's veins, the pressure and volume change more slowly. Because baroreceptors are located within the vascular wall, they are able to sense deformation of the adjacent tissue, which is indicative of a change in blood pressure or volume.
  • Refer now to FIG. 2, which shows a schematic illustration of baroreceptors 30 disposed in a generic vascular wall 40 and a schematic flow chart of the baroreflex system 50. Baroreceptors 30 are profusely distributed within the arterial walls 40 of the blood vessels major arteries discussed previously, and are presently believed by the inventors to form an arbor 32 as is characteristic of the analogous receptors in the arterial system as described in parent application Ser. No. 09/672,850, previously incorporated herein by reference. A baroreceptor arbor 32 would comprise a plurality of baroreceptors 30, each of which transmits baroreceptor signals to the brain 52 via nerve 38. The baroreceptors 30 may be so profusely distributed and arborized within the vascular wall 40 that discrete baroreceptor arbors 32 are not readily discernable. To this end, those skilled in the art will appreciate that the baroreceptors 30 shown in FIG. 2 are primarily schematic for purposes of illustration and discussion. In other regions, the baroreceptors may be so sparsely distributed that activation over a relatively greater length of the vein would be required than would be with an artery where the receptors might be more concentrated.
  • Baroreceptor signals in the arterial vasculature are used to activate a number of body systems which collectively may be referred to as the baroreflex system 50. For the purposes of the present invention, it will be assumed that the “receptors” in the venous and cardiopulmonary vasculature and heart chambers function analogously to the baroreceptors in the arterial vasculature, but such assumption is not intended to limit the present invention in any way. In particular, the methods described herein will function and achieve at least some of the stated therapeutic objectives regardless of the precise and actual mechanism responsible for the result. Moreover, the present invention may activate baroreceptors, mechanoreceptors, pressoreceptors, or any other venous heart, or cardiopulmonary receptors which affect the blood pressure, nervous system activity, and neurohormonal activity in a manner analogous to baroreceptors in the arterial vasculation. For convenience, all such venous receptors will be referred to collectively herein as “baroreceptors.” Thus for discussion purposes, it will be assumed that baroreceptors 30 are connected to the brain 52 via the nervous system 51. Thus, the brain 52 is able to detect changes in blood pressure which are indicative of cardiac output and/or blood volume. If cardiac output and/or blood volume are insufficient to meet demand (i.e., the heart 11 is unable to pump sufficient blood), the baroreflex system 50 activates a number of body systems, including the heart 11, kidneys 53, vessels 54, and other organs/tissues. Such activation of the baroreflex system 50 generally corresponds to an increase in neurohormonal activity. Specifically, the baroreflex system 50 initiates a neurohormonal sequence that signals the heart 11 to increase heart rate and increase contraction force in order to increase cardiac output, signals the kidneys 53 to increase blood volume by retaining sodium and water, and signals the vessels 54 to constrict to elevate blood pressure. The cardiac, renal and vascular responses increase blood pressure and cardiac output 55, and thus increase the workload of the heart 11. In a patient with heart failure, this further accelerates myocardial damage and exacerbates the heart failure state.
  • To address the problems of hypertension, heart failure, cardiac arrhythmias, renal dysfunction, and nervous system other cardiovascular disorders, the present invention basically provides a number of devices, systems and methods by which the baroreflex system 50 is activated to reduce excessive blood pressure, autonomic nervous system activity and neurohormonal activation. In particular, the present invention provides a number of devices, systems and methods by which baroreceptors 30 may be activated, thereby indicating an increase in blood pressure and signaling the brain 52 to reduce the body's blood pressure and level of sympathetic nervous system and neurohormonal activation, and increase parasypathetic nervous system activation, thus having a beneficial effect on the cardiovascular system and other body systems.
  • With reference to FIG. 3, the present invention generally provides a system including a control system 60, a baroreceptor activation device 70, and a sensor 80 (optional). For purposes of illustration, the baroreceptor activation device 70 is shown to be located on, in or near the inferior vena cava 23.3, but it could also be located at the other baroreceptor target locations discussed elsewhere in this application. The exemplary control system 60, generally operates in the following manner. The sensor 80 senses and/or monitors a parameter (e.g., cardiovascular function) indicative of the need to modify the baroreflex system and generates a signal indicative of the parameter. The control system 60 generates a control signal as a function of the received sensor signal. The control signal activates, deactivates or otherwise modulates the baroreceptor activation device 70. Typically, activation of the device 70 results in activation of the baroreceptors 30 (FIG. 2). Alternatively, deactivation or modulation of the baroreceptor activation device 70 may cause or modify activation of the baroreceptors 30. The baroreceptor activation device 70 may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological, or other means to activate baroreceptors 30. Thus, when the sensor 80 detects a parameter indicative of the need to modify the baroreflex system activity (e.g., excessive blood pressure), the control system 60 generates a control signal to modulate (e.g. activate) the baroreceptor activation device 70 thereby inducing a baroreceptor 30 signal that is perceived by the brain 52 to be apparent excessive blood pressure. When the sensor 80 detects a parameter indicative of normal body function (e.g., normal blood pressure), the control system 60 generates a control signal to modulate (e.g., deactivate) the baroreceptor activation device 70.
  • As mentioned previously, the baroreceptor activation device 70 may comprise a wide variety of devices which utilize mechanical, electrical, thermal, chemical, biological or other means to activate the baroreceptors 30. Specific embodiments of the generic baroreceptor activation device 70 are discussed with reference to FIGS. 4-21. In most instances, particularly the mechanical activation embodiments, the baroreceptor activation device 70 indirectly activates one or more baroreceptors 30 by stretching or otherwise deforming the vascular wall 40 surrounding the baroreceptors 30. In some other instances, particularly the non-mechanical activation embodiments, the baroreceptor activation device 70 may directly activate one or more baroreceptors 30 by changing the electrical, thermal or chemical environment or potential across the baroreceptors 30. It is also possible that changing the electrical, thermal or chemical potential across the tissue surrounding the baroreceptors 30 may cause the surrounding tissue to stretch or otherwise deform, thus mechanically activating the baroreceptors 30. In other instances, particularly the biological activation embodiments, a change in the function or sensitivity of the baroreceptors 30 may be induced by changing the biological activity in the baroreceptors 30 and altering their intracellular makeup and function.
  • All of the specific embodiments of the baroreceptor activation device 70 are suitable for implantation, and are preferably implanted using a minimally invasive percutaneous transluminal approach and/or a minimally invasive surgical approach, depending on whether the device 70 is disposed intravascularly, extravascularly or within the vascular wall 40. The baroreceptor activation device 70 may be positioned anywhere in or proximate the venous or cardiopulmonary vasculature, and/or the heart chambers, where baroreceptors capable of modulating the baroreflex system 50 are present. The baroreceptor activation device 70 will usually be implanted such that the device 70 is positioned immediately adjacent the baroreceptors 30. Alternatively, the baroreceptor activation device 70 may be outside the body such that the device 70 is positioned a short distance from but proximate to the baroreceptors 30. Preferably, the baroreceptor activation device 70 is implanted at a location which permits selective activation of the target baroreceptor, typically being in, around, or near the target baroreceptor. For purposes of illustration only, the present invention is described with reference to baroreceptor activation device 70 positioned near the inferior vena cava 23.3.
  • The optional sensor 80 is operably coupled to the control system 60 by electric sensor cable or lead 82. The sensor 80 may comprise any suitable device that measures or monitors a parameter indicative of the need to modify the activity of the baroreflex system. For example, the sensor 80 may comprise a physiologic transducer or gauge that measures ECG, blood pressure (systolic, diastolic, average or pulse pressure), blood volumetric flow rate, blood flow velocity, blood pH, O2 or CO2 content, mixed venous oxygen saturation (SVO2), vasoactivity, nerve activity, tissue activity or composition. Examples of suitable transducers or gauges for the sensor 80 include ECG electrodes, a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, an ultrasonic volumetric flow rate transducer, a thermodilution flow velocity transducer, a capacitive pressure transducer, a membrane pH electrode, an optical detector (SVO2) or a strain gage. Although only one sensor 80 is shown, multiple sensors 80 of the same or different type at the same or different locations may be utilized.
  • The sensor 80 is preferably positioned in a chamber of the heart I 1, or in/on a major artery such as the aortic arch 12, a common carotid artery 14/15, a subclavian artery 13/16 or the brachiocephalic artery 22, or in any of the low-pressure venous or cardiopulmonary sites, such that the parameter of interest may be readily ascertained. The sensor 80 may be disposed inside the body such as in or on an artery, a vein or a nerve (e.g. vagus nerve), or disposed outside the body, depending on the type of transducer or gauge utilized. The sensor 80 may be separate from the baroreceptor activation device 70 or combined therewith. For purposes of illustration only, the sensor 80 is shown positioned on the right subclavian artery 13.
  • By way of example, the control system 60 includes a control block 61 comprising a processor 63 and a memory 62. Control system 60 is connected to the sensor 80 by way of sensor cable 82. Control system 60 is also connected to the baroreceptor activation device 70 by way of electric control cable 72. Thus, the control system 60 receives a sensor signal from the sensor 80 by way of sensor cable 82, and transmits a control signal to the baroreceptor activation device 70 by way of control cable 72.
  • The memory 62 may contain data related to the sensor signal, the control signal, and/or values and commands provided by the input device 64. The memory 62 may also include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal. The algorithm may dictate activation or deactivation control signals depending on the sensor signal or a mathematical derivative thereof. The algorithm may dictate an activation or deactivation control signal when the sensor signal falls below a lower predetermined threshold value, rises above an upper predetermined threshold value or when the sensor signal indicates a specific physiologic event.
  • As mentioned previously, the baroreceptor activation device 70 may activate baroreceptors 30 mechanically, electrically, thermally, chemically, biologically or otherwise. In some instances, the control system 60 includes a driver 66 to provide the desired power mode for the baroreceptor activation device 70. For example if the baroreceptor activation device 70 utilizes pneumatic or hydraulic actuation, the driver 66 may comprise a pressure/vacuum source and the cable 72 may comprise fluid line(s). If the baroreceptor activation device 70 utilizes electrical or thermal actuation, the driver 66 may comprise a power amplifier or the like and the cable 72 may comprise electrical lead(s). If the baroreceptor activation device 70 utilizes chemical or biological actuation, the driver 66 may comprise a fluid reservoir and a pressure/vacuum source, and the cable 72 may comprise fluid line(s). In other instances, the driver 66 may not be necessary, particularly if the processor 63 generates a sufficiently strong electrical signal for low level electrical or thermal actuation of the baroreceptor activation device 70.
  • The control system 60 may operate as a closed loop utilizing feedback from the sensor 80, or as an open loop utilizing commands received by input device 64. The open loop operation of the control system 60 preferably utilizes some feedback from the transducer 80, but may also operate without feedback. Commands received by the input device 64 may directly influence the control signal or may alter the software and related algorithms contained in memory 62. The patient and/or treating physician may provide commands to input device 64. Display 65 may be used to view the sensor signal, control signal and/or the software/data contained in memory 62.
  • The control signal generated by the control system 60 may be continuous, periodic, episodic or a combination thereof, as dictated by an algorithm contained in memory 62. Continuous control signals include a constant pulse, a constant train of pulses, a triggered pulse and a triggered train of pulses. Examples of periodic control signals include each of the continuous control signals described above which have a designated start time (e.g., beginning of each minute, hour or day) and a designated duration (e.g., 1 second, 1 minute, 1 hour). Examples of episodic control signals include each of the continuous control signals described above which are triggered by an episode (e.g., activation by the patient/physician, an increase in blood pressure above a certain threshold, etc.).
  • The control system 60 may be implanted in whole or in part. For example, the entire control system 60 may be carried externally by the patient utilizing transdermal connections to the sensor lead 82 and the control lead 72. Alternatively, the control block 61 and driver 66 may be implanted with the input device 64 and display 65 carried externally by the patient utilizing transdermal connections therebetween. As a further alternative, the transdermal connections may be replaced by cooperating transmitters/receivers to remotely communicate between components of the control system 60 and/or the sensor 80 and baroreceptor activation device 70.
  • With general reference to FIGS. 4-21, schematic illustrations of specific embodiments of the baroreceptor activation device 70 are shown. The design, function and use of these specific embodiments, in addition to the control system 60 and sensor 80 (not shown), are the same as described with reference to FIG. 3, unless otherwise noted or apparent from the description. In addition, the anatomical features illustrated in FIGS. 4-20 are the same as discussed with reference to FIGS. 1, 1A, and 2, unless otherwise noted. In each embodiment, the connections between the components 60/70/80 may be physical (e.g., wires, tubes, cables, etc.) or remote (e.g., transmitter/receiver, inductive, magnetic, etc.). For physical connections, the connection may travel intraarterially, intravenously, subcutaneously, or through other natural tissue paths.
  • Refer now to FIG. 4 which shows schematic illustrations of a baroreceptor activation device 100 in the form of an intravascular inflatable balloon 100. The inflatable balloon device 100 includes a helical balloon 102 which is connected to a fluid line 104. An example of a similar helical balloon is disclosed in U.S. Pat. No. 5,181,911 to Shturman, the entire disclosure of which is hereby incorporated by reference. The balloon 102 preferably has a helical geometry or any other geometry which allows blood perfusion therethrough. The fluid line 104 is connected to the driver 66 of the control system 60 (FIG. 3). In this embodiment, the driver 66 comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the helical balloon 102. Upon inflation, the helical balloon 102 expands, preferably increasing in outside diameter only, to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40. Upon deflation, the helical balloon 102 returns to its relaxed geometry such that the vascular wall 40 returns to its nominal state. Thus, by selectively inflating the helical balloon 102, the baroreceptors 30 adjacent thereto may be selectively activated.
  • As an alternative to pneumatic or hydraulic expansion utilizing a balloon, a mechanical expansion device (not shown) may be used to expand or dilate the vascular wall 40 and thereby mechanically activate the baroreceptors 30. For example, the mechanical expansion device may comprise a tubular wire braid structure that diametrically expands when longitudinally compressed as disclosed in U.S. Pat. No. 5,222,971 to Willard et al., the entire disclosure of which is hereby incorporated by reference. The tubular braid may be disposed intravascularly and permits blood perfusion through the wire mesh. In this embodiment, the driver 66 may comprise a linear actuator connected by actuation cables to opposite ends of the braid. When the opposite ends of the tubular braid are brought closer together by actuation of the cables, the diameter of the braid increases to expand the vascular wall 40 and activate the baroreceptors 30.
  • Refer now to FIG. 5 which shows a baroreceptor activation device 120 in the form of an extravascular pressure cuff 120. The pressure cuff device 120 includes an inflatable cuff 122 which is connected to a fluid line 124. Examples of a similar cuffs 122 are disclosed in U.S. Pat. No. 4,256,094 to Kapp et al. and U.S. Pat. No. 4,881,939 to Newman, the entire disclosures of which are hereby incorporated by reference. The fluid line 124 is connected to the driver 66 (FIG. 3) of the control system 60. In this embodiment, the driver 66 comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the cuff 122. Upon inflation, the cuff 122 expands, preferably increasing in inside diameter only, to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40. Upon deflation, the cuff 122 returns to its relaxed geometry such that the vascular wall 40 returns to its nominal state. Thus, by selectively inflating the inflatable cuff 122, the baroreceptors 30 adjacent thereto may be selectively activated.
  • The driver 66 may be automatically actuated by the control system 60 as discussed above, or may be manually actuated. An example of an externally manually actuated pressure/vacuum source is disclosed in U.S. Pat. No. 4,709,690 to Haber, the entire disclosure of which is hereby incorporated by reference. Examples of transdermally manually actuated pressure/vacuum sources are disclosed in U.S. Pat. No. 4,586,501 to Claracq, U.S. Pat. No. 4,828,544 to Lane et al., and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which are hereby incorporated by reference.
  • Those skilled in the art will recognize that other external compression devices may be used in place of the inflatable cuff device 120. For example, a piston actuated by a solenoid may apply compression to the vascular wall. An example of a solenoid actuated piston device is disclosed in U.S. Pat. No. 4,014,318 to Dokum et al, and an example of a hydraulically or pneumatically actuated piston device is disclosed in U.S. Pat. No. 4,586,501 to Claracq, the entire disclosures of which are hereby incorporated by reference. Other examples include a rotary ring compression device as disclosed in U.S. Pat. No. 4,551,862 to Haber, and an electromagnetically actuated compression ring device as disclosed in U.S. Pat. No. 5,509,888 to Miller, the entire disclosures of which are hereby incorporated by reference.
  • Refer now to FIG. 6 which shows a baroreceptor activation device 140 in the form of an intravascular deformable structure. The deformable structure device 140 includes a coil, braid or other stent-like structure 142 disposed in the vascular lumen. The deformable structure 142 includes one or more individual structural members connected to an electrical lead 144. Each of the structural members forming deformable structure 142 may comprise a shape memory material 146 (e.g., nickel titanium alloy) as illustrated in FIG. 6B, or a bimetallic material 148 as illustrated in FIG. 6C. The electrical lead 144 is connected to the driver 66 of the control system 60. In this embodiment, the driver 66 comprises an electric power generator or amplifier which selectively delivers electric current to the structure 142 which resistively heats the structural members 146/148. The structure 142 may be unipolar as shown using the surrounding tissue as ground, or bipolar or multipolar using leads connected to either end of the structure 142. Electrical power may also be delivered to the structure 142 inductively as described hereinafter with reference to FIGS. 14-16.
  • Upon application of electrical current to the shape memory material 146, it is resistively heated causing a phase change and a corresponding change in shape. Upon application of electrical current to the bimetallic material 148, it is resistively heated causing a differential in thermal expansion and a corresponding change in shape. In either case, the material 146/148 is designed such that the change in shape causes expansion of the structure 142 to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40. Upon removal of the electrical current, the material 146/148 cools and the structure 142 returns to its relaxed geometry such that the baroreceptors 30 and/or the vascular wall 40 return to their nominal state. Thus, by selectively expanding the structure 142, the baroreceptors 30 adjacent thereto may be selectively activated.
  • Refer now to FIG. 7 which shows a baroreceptor activation device 160 in the form of an extravascular deformable structure. The extravascular deformable structure device 160 is substantially the same as the intravascular deformable structure device 140 described with reference to FIGS. 6A and 6B, except that the extravascular device 160 is disposed about the vascular wall, and therefore compresses, rather than expands, the vascular wall 40. The deformable structure device 160 includes a coil, braid or other stent-like structure 162 comprising one or more individual structural members connected to an electrical lead 164. Each of the structural members may comprise a shape memory material 166 (e.g., nickel titanium alloy) as illustrated in FIG. 7C, or a bimetallic material 168. The structure 162 may be unipolar as shown using the surrounding tissue as ground, or bipolar or multipolar using leads connected to either end of the structure 162. Electrical power may also be delivered to the structure 162 inductively as described hereinafter with reference to FIGS. 14-16.
  • Upon application of electrical current to the shape memory material 166, it is resistively heated causing a phase change and a corresponding change in shape. Upon application of electrical current to the bimetallic material 168, it is resistively heated causing a differential in thermal expansion and a corresponding change in shape. In either case, the material 166/168 is designed such that the change in shape causes constriction of the structure 162 to mechanically activate baroreceptors 30 by compressing or otherwise deforming the baroreceptors 30 and/or the vascular wall 40. Upon removal of the electrical current, the material 166/168 cools and the structure 162 returns to its relaxed geometry such that the baroreceptors 30 and/or the vascular wall 40 return to their nominal state. Thus, by selectively compressing the structure 162, the baroreceptors 30 adjacent thereto may be selectively activated.
  • Refer now to FIG. 8 which shows a baroreceptor activation device 180 in the form of an extravascular flow regulator which artificially creates back pressure adjacent the baroreceptors 30. The flow regulator device 180 includes an external compression device 182, which may comprise any of the external compression devices described with reference to FIG. 5. The external compression device 182 is operably connected to the driver 66 of the control system 60 by way of cable 184, which may comprise a fluid line or electrical lead, depending on the type of external compression device 182 utilized. The external compression device 182 is disposed about the vascular wall distal of the baroreceptors 30. For example, the external compression device 182 may be located in the distal portions of the inferior vena cava 23.3 to create back pressure adjacent the baroreceptors 30 upstream in the inferior vena cava.
  • Upon actuation of the external compression device 182, the vascular wall is constricted thereby reducing the size of the vascular lumen therein. By reducing the size of the vascular lumen, pressure proximal of the external compression device 182 is increased thereby expanding the vascular wall. Thus, by selectively activating the external compression device 182 to constrict the vascular lumen and create back pressure, the baroreceptors 30 may be selectively activated.
  • Refer now to FIG. 9 which shows a baroreceptor activation device 200 in the form of an intravascular flow regular which artificially creates back pressure adjacent the baroreceptors 30. The intravascular flow regulator device 200 is substantially similar in function and use as extravascular flow regulator 180 described with reference to FIG. 8, except that the intravascular flow regulator device 200 is disposed in the vascular lumen.
  • Intravascular flow regulator 200 includes an internal valve 202 to at least partially close the vascular lumen distal of the baroreceptors 30. By at least partially closing the vascular lumen distal of the baroreceptors 30, back pressure is created proximal of the internal valve 202 such that the vascular wall expands to activate the baroreceptors 30. The internal valve 202 may be positioned at any of the locations described with reference to the external compression device 182, except that the internal valve 202 is placed within the vascular lumen. Specifically, the internal compression device 202 may be located in the distal portions of the vasculature to create back pressure adjacent to the baroreceptors 30 in the veins or cardiopulmonary system.
  • The internal valve 202 is operably coupled to the driver 66 of the control system 60 by way of electrical lead 204. The control system 60 may selectively open, close or change the flow resistance of the valve 202 as described in more detail hereinafter. The internal valve 202 may include valve leaflets 206 (bi-leaflet or tri-leaflet) which rotate inside housing 208 about an axis between an open position and a closed position. The closed position may be completely closed or partially closed, depending on the desired amount of back pressure to be created. The opening and closing of the internal valve 202 may be selectively controlled by altering the resistance of leaflet 206 rotation or by altering the opening force of the leaflets 206. The resistance of rotation of the leaflets 206 may be altered utilizing electromagnetically actuated metallic bearings carried by the housing 208. The opening force of the leaflets 206 may be altered by utilizing electromagnetic coils in each of the leaflets to selectively magnetize the leaflets such that they either repel or attract each other, thereby facilitating valve opening and closing, respectively.
  • A wide variety of intravascular flow regulators may be used in place of internal valve 202. For example, internal inflatable balloon devices as disclosed in U.S. Pat. No. 4,682,583 to Burton et al. and U.S. Pat. No. 5,634,878 to Grundei et al., the entire disclosures of which is hereby incorporated by reference, may be adapted for use in place of valve 202. Such inflatable balloon devices may be operated in a similar manner as the inflatable cuff 122 described with reference to FIG. 5. Specifically, in this embodiment, the driver 66 would comprises a pressure/vacuum source (i.e., an inflation device) which selectively inflates and deflates the internal balloon. Upon inflation, the balloon expands to partially occlude blood flow and create back pressure to mechanically activate baroreceptors 30 by stretching or otherwise deforming them and/or the vascular wall 40. Upon deflation, the internal balloon returns to its normal profile such that flow is not hindered and back pressure is eliminated. Thus, by selectively inflating the internal balloon, the baroreceptors 30 proximal thereof may be selectively activated by creating back pressure.
  • Refer now to FIG. 10 which shows a baroreceptor activation device 220 in the form of magnetic particles 222 disposed in the vascular wall 40. The magnetic particles 222 may comprise magnetically responsive materials (i.e., ferrous based materials) and may be magnetically neutral or magnetically active. Preferably, the magnetic particles 222 comprise permanent magnets having an elongate cylinder shape with north and south poles to strongly respond to magnetic fields. The magnetic particles 222 are actuated by an electromagnetic coil 224 which is operably coupled to the driver 66 of the control system 60 by way of an electrical cable 226. The electromagnetic coil 224 may be implanted as shown, or located outside the body, in which case the driver 66 and the remainder of the control system 60 would also be located outside the body. By selectively activating the electromagnetic coil 224 to create a magnetic field, the magnetic particles 222 may be repelled, attracted or rotated. Alternatively, the magnetic field created by the electromagnetic coil 224 may be alternated such that the magnetic particles 222 vibrate within the vascular wall 40. When the magnetic particles are repelled, attracted, rotated, vibrated or otherwise moved by the magnetic field created by the electromagnetic coil 224, the baroreceptors 30 are mechanically activated.
  • The electromagnetic coil 224 is preferably placed as close as possible to the magnetic particles 222 in the vascular wall 40, and may be placed intravascularly, extravascularly, or in any of the alternative locations discussed with reference to inductor shown in FIGS. 14-16. The magnetic particles 222 may be implanted in the vascular wall 40 by injecting a ferro-fluid or a ferro-particle suspension into the vascular wall adjacent to the baroreceptors 30. To increase biocompatibility, the particles 222 may be coated with a ceramic, polymeric or other inert material. Injection of the fluid carrying the magnetic particles 222 is preferably performed percutaneously.
  • Refer now to FIG. 11 which shows a baroreceptor activation device 240 in the form of one or more transducers 242. Preferably, the transducers 242 comprise an array surrounding the vascular wall. The transducers 242 may be intravascularly or extravascularly positioned adjacent to the baroreceptors 30. In this embodiment, the transducers 242 comprise devices which convert electrical signals into some physical phenomena, such as mechanical vibration or acoustic waves. The electrical signals are provided to the transducers 242 by way of electrical cables 244 which are connected to the driver 66 of the control system 60. By selectively activating the transducers 242 to create a physical phenomena, the baroreceptors 30 may be mechanically activated.
  • The transducers 242 may comprise an acoustic transmitter which transmits sonic or ultrasonic sound waves into the vascular wall 40 to activate the baroreceptors 30. Alternatively, the transducers 242 may comprise a piezoelectric material which vibrates the vascular wall to activate the baroreceptors 30. As a further alternative, the transducers 242 may comprise an artificial muscle which deflects upon application of an electrical signal. An example of an artificial muscle transducer comprises plastic impregnated with a lithium-perchlorate electrolyte disposed between sheets of polypyrrole, a conductive polymer. Such plastic muscles may be electrically activated to cause deflection in different directions depending on the polarity of the applied current.
  • Refer now to FIG. 12 which shows a baroreceptor activation device 260 in the form of a local fluid delivery device 262 suitable for delivering a chemical or biological fluid agent to the vascular wall adjacent the baroreceptors 30. The local fluid delivery device 262 may be located intravascularly, extravascularly, or intramurally. For purposes of illustration only, the local fluid delivery device 262 is positioned extravascularly.
  • The local fluid delivery device 262 may include proximal and distal seals 266 which retain the fluid agent disposed in the lumen or cavity 268 adjacent to vascular wall. Preferably, the local fluid delivery device 262 completely surrounds the vascular wall 40 to maintain an effective seal. Those skilled in the art will recognize that the local fluid delivery device 262 may comprise a wide variety of implantable drug delivery devices or pumps known in the art.
  • The local fluid delivery device 260 is connected to a fluid line 264 which is connected to the driver 66 of the control system 60. In this embodiment, the driver 66 comprises a pressure/vacuum source and fluid reservoir containing the desired chemical or biological fluid agent. The chemical or biological fluid agent may comprise a wide variety of stimulatory substances. Examples include veratridine, bradykinin, prostaglandins, and related substances. Such stimulatory substances activate the baroreceptors 30 directly or enhance their sensitivity to other stimuli and therefore may be used in combination with the other baroreceptor activation devices described herein. Other examples include growth factors and other agents that modify the function of the baroreceptors 30 or the cells of the vascular tissue surrounding the baroreceptors 30 causing the baroreceptors 30 to be activated or causing alteration of their responsiveness or activation pattern to other stimuli. It is also contemplated that injectable stimulators that are induced remotely, as described in U.S. Pat. No. 6,061,596 which is incorporated herein by reference, may be used with the present invention.
  • As an alternative, the fluid delivery device 260 may be used to deliver a photochemical that is essentially inert until activated by light to have a stimulatory effect as described above. In this embodiment, the fluid delivery device 260 would include a light source such as a light emitting diode (LED), and the driver 66 of the control system 60 would include a pulse generator for the LED combined with a pressure/vacuum source and fluid reservoir described previously. The photochemical would be delivered with the fluid delivery device 260 as described above, and the photochemical would be activated, deactivated or modulated by activating, deactivating or modulating the LED.
  • As a further alternative, the fluid delivery device 260 may be used to deliver a warm or hot fluid (e.g. saline) to thermally activate the baroreceptors 30. In this embodiment, the driver 66 of the control system 60 would include a heat generator for heating the fluid, combined with a pressure/vacuum source and fluid reservoir described previously. The hot or warm fluid would be delivered and preferably circulated with the fluid delivery device 260 as described above, and the temperature of the fluid would be controlled by the driver 66.
  • Refer now to FIG. 13 which shows a baroreceptor activation device 280 in the form of an intravascular electrically conductive structure or electrode 282. The electrode structure 282 may comprise a self-expanding or balloon expandable coil, braid or other stent-like structure disposed in the vascular lumen. The electrode structure 282 may serve the dual purpose of maintaining lumen patency while also delivering electrical stimuli. To this end, the electrode structure 282 may be implanted utilizing conventional intravascular stent and filter delivery techniques. Preferably, the electrode structure 282 comprises a geometry which allows blood perfusion therethrough. The electrode structure 282 comprises electrically conductive material which may be selectively insulated to establish contact with the inside surface of the vascular wall 40 at desired locations, and limit extraneous electrical contact with blood flowing through the vessel and other tissues.
  • The electrode structure 282 is connected to electric lead 284 which is connected to the driver 66 of the control system 60. The driver 66, in this embodiment, may comprise a power amplifier, pulse generator or the like to selectively deliver electrical control signals to structure 282. As mentioned previously, the electrical control signal generated by the driver 66 may be continuous, periodic, episodic or a combination thereof, as dictated by an algorithm contained in memory 62 of the control system 60. Continuous control signals include a constant pulse, a constant train of pulses, a triggered pulse and a triggered train of pulses. Periodic control signals include each of the continuous control signals described above which have a designated start time and a designated duration. Episodic control signals include each of the continuous control signals described above which are triggered by an episode.
  • By selectively activating, deactivating or otherwise modulating the electrical control signal transmitted to the electrode structure 282, electrical energy may be delivered to the vascular wall to activate the baroreceptors 30. As discussed previously, activation of the baroreceptors 30 may occur directly or indirectly. In particular, the electrical signal delivered to the vascular wall 40 by the electrode structure 282 may cause the vascular wall to stretch or otherwise deform thereby indirectly activating the baroreceptors 30 disposed therein. Alternatively, the electrical signals delivered to the vascular wall by the electrode structure 282 may directly activate the baroreceptors 30 by changing the electrical potential across the baroreceptors 30. In either case, the electrical signal is delivered to the vascular wall 40 immediately adjacent to the baroreceptors 30. It is also contemplated that the electrode structure 282 may delivery thermal energy by utilizing a semi-conductive material having a higher resistance such that the electrode structure 282 resistively generates heat upon application of electrical energy.
  • Various alternative embodiments are contemplated for the electrode structure 282, including its design, implanted location, and method of electrical activation. For example, the electrode structure 282 may be unipolar as shown in FIG. 13 using the surrounding tissue as ground, or bipolar using leads connected to either end of the structure 282 as shown in Figure. In the embodiment of FIGS. 18A and 18B, the electrode structure 282 includes two or more individual electrically conductive members 283/285 which are electrically isolated at their respective cross-over points utilizing insulative materials. Each of the members 283/285 is connected to a separate conductor contained within the electrical lead 284. Alternatively, an array of bipoles may be used as described in more detail with reference to FIG. 21. As a further alternative, a multipolar arrangement may be used wherein three or more electrically conductive members are included in the structure 282. For example, a tripolar arrangement may be provided by one electrically conductive member having a polarity disposed between two electrically conductive members having the opposite polarity.
  • In terms of electrical activation, the electrical signals may be directly delivered to the electrode structure 282 as described with reference to FIG. 13, or indirectly delivered utilizing an inductor 286 as illustrated in FIGS. 14-16 and 21. The embodiments of FIGS. 14-16 and 21 utilize an inductor 286 which is operably connected to the driver 66 of the control system 60 by way of electrical lead 284. The inductor 286 comprises an electrical winding which creates a magnetic field 287 (as seen in FIG. 21) around the electrode structure 282. The magnetic field 287 may be alternated by alternating the direction of current flow through the inductor 286. Accordingly, the inductor 286 may be utilized to create current flow in the electrode structure 282 to thereby deliver electrical signals to the vascular wall 40 to directly or indirectly activate the baroreceptors 30. In all embodiments, the inductor 286 may be covered with an electrically insulative material to eliminate direct electrical stimulation of tissues surrounding the inductor 286. A preferred embodiment of an inductively activated electrode structure 282 is described in more detail with reference to FIGS. 21A-21C.
  • The embodiments of FIGS. 13-16 may be modified to form a cathode/anode arrangement. Specifically, the electrical inductor 286 would be connected to the driver 66 as shown in FIGS. 14-16 and the electrode structure 282 would be connected to the driver 66 as shown in FIG. 13. With this arrangement, the electrode structure 282 and the inductor 286 may be any suitable geometry and need not be coiled for purposes of induction. The electrode structure 282 and the inductor 286 would comprise a cathode/anode or anode/cathode pair. For example, when activated, the cathode 282 may generate a primary stream of electrons which travel through the inter-electrode space (i.e., vascular tissue and baroreceptors 30) to the anode 286. The cathode is preferably cold, as opposed to thermionic, during electron emission. The electrons may be used to electrically or thermally activate the baroreceptors 30 as discussed previously.
  • The electrical inductor 286 is preferably disposed as close as possible to the electrode structure 282. For example, the electrical inductor 286 may be disposed adjacent the vascular wall as illustrated in FIG. 14. Alternatively, the inductor 286 may be disposed in an adjacent vessel 289 as illustrated in FIG. 15. If the electrode structure 282 is disposed in the carotid sinus 20, for example, the inductor 286 may be disposed in the internal jugular vein 21 as illustrated in FIG. 15. In the embodiment of FIG. 15, the electrical inductor 286 may comprise a similar structure as the electrode structure 282. As a further alternative, the electrical inductor 286 may be disposed outside the patient's body, but as close as possible to the electrode structure 282. If the electrode structure 282 is disposed in the carotid sinus 20, for example, the electrical inductor 286 may be disposed on the right or left side of the neck of the patient as illustrated in FIG. 16. In the embodiment of FIG. 16, wherein the electrical inductor 286 is disposed outside the patient's body, the control system 60 may also be disposed outside the patient's body.
  • In terms of implant location, the electrode structure 282 may be intravascularly disposed as described with reference to FIG. 13, or extravascularly disposed as described with reference to FIG. 17, which show schematic illustrations of a baroreceptor activation device 300 in the form of an extravascular electrically conductive structure or electrode 302. Except as described herein, the extravascular electrode structure 302 is the same in design, function, and use as the intravascular electrode structure 282. The electrode structure 302 may comprise a coil, braid or other structure capable of surrounding the vascular wall. Alternatively, the electrode structure 302 may comprise one or more electrode patches distributed around the outside surface of the vascular wall. Because the electrode structure 302 is disposed on the outside surface of the vascular wall, intravascular delivery techniques may not be practical, but minimally invasive surgical techniques will suffice. The extravascular electrode structure 302 may receive electrical signals directly from the driver 66 of the control system 60 by way of electrical lead 304, or indirectly by utilizing an inductor (not shown) as described with reference to FIGS. 14-16.
  • Refer now to FIG. 19 which shows a baroreceptor activation device 320 in the form of electrically conductive particles 322 disposed in the vascular wall. This embodiment is substantially the same as the embodiments described with reference to FIGS. 13-18, except that the electrically conductive particles 322 are disposed within the vascular wall, as opposed to the electrically conductive structures 282/302 which are disposed on either side of the vascular wall. In addition, this embodiment is similar to the embodiment described with reference to FIG. 10, except that the electrically conductive particles 322 are not necessarily magnetic as with magnetic particles 222, and the electrically conductive particles 322 are driven by an electromagnetic filed rather than by a magnetic field.
  • In this embodiment, the driver 66 of the control system 60 comprises an electromagnetic transmitter such as an radiofrequency or microwave transmitter. Electromagnetic radiation is created by the transmitter 66 which is operably coupled to an antenna 324 by way of electrical lead 326. Electromagnetic waves are emitted by the antenna 324 and received by the electrically conductive particles 322 disposed in the vascular wall 40. Electromagnetic energy creates oscillating current flow within the electrically conductive particles 322, and depending on the intensity of the electromagnetic radiation and the resistivity of the conductive particles 322, may cause the electrical particles 322 to generate heat. The electrical or thermal energy generated by the electrically conductive particles 322 may directly activate the baroreceptors 30, or indirectly activate the baroreceptors 30 by way of the surrounding vascular wall tissue.
  • The electromagnetic radiation transmitter 66 and antenna 324 may be disposed in the patient's body, with the antenna 324 disposed adjacent to the conductive particles in the vascular wall 40 as illustrated in FIG. 19. Alternatively, the antenna 324 may be disposed in any of the positions described with reference to the electrical inductor shown in FIGS. 14-16. It is also contemplated that the electromagnetic radiation transmitter 66 and antenna 324 may be utilized in combination with the intravascular and extravascular electrically conductive structures 282/302 described with reference to FIGS. 13-18 to generate thermal energy on either side of the vascular wall.
  • As an alternative, the electromagnetic radiation transmitter 66 and antenna 324 may be used without the electrically conductive particles 322. Specifically, the electromagnetic radiation transmitter 66 and antenna 324 may be used to deliver electromagnetic radiation (e.g., RF, microwave) directly to the baroreceptors 30 or the tissue adjacent thereto to cause localized heating, thereby thermally inducing a baroreceptor 30 signal.
  • Refer now to FIG. 20 which shows a baroreceptor activation device 340 in the form of a Peltier effect device 342. The Peltier effect device 342 may be extravascularly positioned as illustrated, or may be intravascularly positioned similar to an intravascular stent or filter. The Peltier effect device 342 is operably connected to the driver 66 of the control system 60 by way of electrical lead 344. The Peltier effect device 342 includes two dissimilar metals or semiconductors 343/345 separated by a thermal transfer junction 347. In this particular embodiment, the driver 66 comprises a power source which delivers electrical energy to the dissimilar metals or semiconductors 343/345 to create current flow across the thermal junction 347.
  • When current is delivered in an appropriate direction, a cooling effect is created at the thermal junction 347. There is also a heating effect created at the junction between the individual leads 344 connected to the dissimilar metals or semiconductors 343/345. This heating effect, which is proportional to the cooling effect, may be utilized to activate the baroreceptors 30 by positioning the junction between the electrical leads 344 and the dissimilar metals or semiconductors 343/345 adjacent to the vascular wall 40.
  • Refer now to FIGS. 21A-21C which show schematic illustrations of a preferred embodiment of an inductively activated electrode structure 282 for use with the embodiments described with reference to FIGS. 14-16. In this embodiment, current flow in the electrode structure 282 is induced by a magnetic field 287 created by an inductor 286 which is operably coupled to the driver 66 of the control system 60 by way of electrical cable 284. The electrode structure 282 preferably comprises a multi-filar self-expanding braid structure including a plurality of individual members 282a, 282b, 282c and 282d. However, the electrode structure 282 may simply comprise a single coil for purposes of this embodiment.
  • Each of the individual coil members 282a-282d comprising the electrode structure 282 consists of a plurality of individual coil turns 281 connected end to end as illustrated in FIGS. 21B and 21C. FIG. 21C is a detailed view of the connection between adjacent coil turns 281 as shown in FIG. 21B. Each coil turn 281 comprises electrically isolated wires or receivers in which a current flow is established when a changing magnetic field 287 is created by the inductor 286. The inductor 286 is preferably covered with an electrically insulative material to eliminate direct electrical stimulation of tissues surrounding the inductor 286. Current flow through each coil turn 281 results in a potential drop 288 between each end of the coil turn 281. With a potential drop defined at each junction between adjacent coil turns 281, a localized current flow cell is created in the vessel wall adjacent each junction. Thus an array or plurality of bipoles are created by the electrode structure 282 and uniformly distributed around the vessel wall. Each coil turn 281 comprises an electrically conductive wire material 290 surrounded by an electrically insulative material 292. The ends of each coil turn 281 are connected by an electrically insulated material 294 such that each coil turn 281 remains electrically isolated. The insulative material 294 mechanically joins but electrically isolates adjacent coil turns 281 such that each turn 281 responds with a similar potential drop 288 when current flow is induced by the changing magnetic field 287 of the inductor 286. An exposed portion 296 is provided at each end of each coil turn 281 to facilitate contact with the vascular wall tissue. Each exposed portion 296 comprises an isolated electrode in contact with the vessel wall. The changing magnetic field 287 of the inductor 286 causes a potential drop in each coil turn 281 thereby creating small current flow cells in the vessel wall corresponding to adjacent exposed regions 296. The creation of multiple small current cells along the inner wall of the blood vessel serves to create a cylindrical zone of relatively high current density such that the baroreceptors 30 are activated. However, the cylindrical current density field quickly reduces to a negligible current density near the outer wall of the vascular wall, which serves to limit extraneous current leakage to minimize or eliminate unwanted activation of extravascular tissues and structures such as nerves or muscles.
  • To address low blood pressure and other conditions requiring blood pressure augmentation, some of the baroreceptor activation devices described previously may be used to selectively and controllably regulate blood pressure by inhibiting or dampening baroreceptor signals. By selectively and controllably inhibiting or dampening baroreceptor signals, the present invention reduces conditions associated with low blood pressure as described previously. Specifically, the present invention would function to increase the blood pressure and level of sympathetic nervous system activation by inhibiting or dampening the activation of baroreceptors.
  • This may be accomplished by utilizing mechanical, thermal, electrical and chemical or biological means. Mechanical means may be triggered off the pressure pulse of the heart to mechanically limit deformation of the arterial wall. For example, either of the external compression devices 120/160 described previously may be used to limit deformation of the arterial wall. Alternatively, the external compression device may simply limit diametrical expansion of the vascular wall adjacent the baroreceptors without the need for a trigger or control signal.
  • Thermal means may be used to cool the baroreceptors 30 and adjacent tissue to reduce the responsiveness of the baroreceptors 30 and thereby dampen baroreceptor signals. Specifically, the baroreceptor 30 signals may be dampened by either directly cooling the baroreceptors 30, to reduce their sensitivity, metabolic activity and function, or by cooling the surrounding vascular wall tissue thereby causing the wall to become less responsive to increases in blood pressure. An example of this approach is to use the cooling effect of the Peltier device 340. Specifically, the thermal transfer junction 347 may be positioned adjacent the vascular wall to provide a cooling effect. The cooling effect may be used to dampen signals generated by the baroreceptors 30. Another example of this approach is to use the fluid delivery device 260 to deliver a cool or cold fluid (e.g. saline). In this embodiment, the driver 66 would include a heat exchanger to cool the fluid and the control system 60 may be used to regulate the temperature of the fluid, thereby regulating the degree of baroreceptor 30 signal dampening.
  • Electrical means may be used to inhibit baroreceptor 30 activation by, for example, hyperpolarizing cells in or adjacent to the baroreceptors 30. Examples of devices and method of hyperpolarizing cells are disclosed in U.S. Pat. No. 5,814,079 to Kieval, and U.S. Pat. No. 5,800,464 to Kieval, the entire disclosures of which are hereby incorporated by reference. Such electrical means may be implemented using any of the embodiments discussed with reference to FIGS. 13-18 and 21.
  • Chemical or biological means may be used to reduce the sensitivity of the baroreceptors 30. For example, a substance that reduces baroreceptor sensitivity may be delivered using the fluid delivery device 260 described previously. The desensitizing agent may comprise, for example, tetrodotoxin or other inhibitor of excitable tissues. From the foregoing, it should be apparent to those skilled in the art that the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors or by inhibiting/dampening baroreceptor signals. Thus, the present invention may be used to increase or decrease blood pressure, sympathetic nervous system activity and neurohormonal activity, as needed to minimize deleterious effects on the heart, vasculature and other organs and tissues.
  • The baroreceptor activation devices described previously may also be used to provide antiarrhythmic effects. It is well known that the susceptibility of the myocardium to the development of conduction disturbances and malignant cardiac arrhythmias is influenced by the balance between sympathetic and parasympathetic nervous system stimulation to the heart. That is, heightened sympathetic nervous system activation, coupled with decreased parasympathetic stimulation, increases the irritability of the myocardium and likelihood of an arrhythmia. Thus, by decreasing the level of sympathetic nervous system activation and enhancing the level of parasympathetic activation, the devices, systems and methods of the current invention may be used to provide a protective effect against the development of cardiac conduction disturbances.
  • Experimental
  • An electrode system was introduced into the inferior vena cava of an anesthetized dog. The electrode system was an eight lead, 64-electrode 8F Constellation® catheter from Boston Scientific EP Technologies, Sunnyvale, Calif. The electrode system was placed endovascularly in the abdominal vena cava. The electrode system was activated using trains of electrical impulses of 0-6 volts, a frequency of 100 hz, and a pulse width of 0.5 ms. During various activation experiments, arterial pressure, mean arterial pressure and heart rate were monitored. The results of three experiments are shown in FIGS. 22A-C. These figures demonstrate a change in blood pressure as energy is applied to the vessel wall, with recovery to pre-activation levels when the energy is discontinued.
  • Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departures in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.

Claims (23)

1. An apparatus comprising:
a flexible lead body extending from a proximal end to a distal end, the distal end having a biased portion having an outer diameter dimensioned to abut a wall of a pulmonary artery;
an electrode coupled proximate the distal end; and
an implantable pulse generator electrically coupled to the electrode, wherein the implantable pulse generator is adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode.
2. The apparatus of claim 1, wherein the electrode includes a porous surface.
3. The apparatus of claim 1, wherein the lead includes a second electrode located proximally from the distal end.
4. The apparatus of claim 1, wherein the pulse generator delivers at least a 10 hertz pulse train via the electrode.
5. The apparatus of claim 1, wherein the electrode is adapted to be chronically implanted in the pulmonary artery.
6. The apparatus of claim 1, wherein the lead further includes a sensor to monitor blood pressure.
7. The apparatus of claim i, wherein the electrode is adapted to be located near the ligamentum arteriosum of the left pulmonary artery.
8. The apparatus of claim 1, further including a sensor to sense a physiological parameter regarding an efficacy of the baroreflex therapy and to provide a signal indicative of the efficacy of the baroreflex therapy.
9. The apparatus of claim 8, further including a controller connected to the pulse generator to control the baroreflex stimulation signal and to the sensor to receive the signal indicative of the efficacy of the baroreflex therapy.
10. The apparatus of claim 1, wherein the lead is adapted to be fed through a right ventricle and a pulmonary valve into the pulmonary artery to position the electrode in the pulmonary artery.
11. The apparatus of claim 1, wherein the pulse generator is further adapted to generate a cardiac pacing signal, the lead further including a second electrode to be positioned to deliver the cardiac pacing signal to capture the heart.
12. An apparatus comprising:
a flexible lead body extending from a proximal end to a distal end;
an electrode coupled to the distal end of the lead body; and
an implantable pulse generator electrically coupled to the electrode, the implantable pulse generator being adapted to deliver a baroreflex stimulation signal to a baroreceptor in the pulmonary artery via the electrode, wherein a biased portion of the distal end is adapted to passively fixate the electrode within the pulmonary artery.
13. The apparatus of claim 12, wherein the pulse generator delivers at least a 10 hertz waveform via the electrode.
14. A method comprising:
positioning an electrode on a distal end of a lead within a pulmonary artery, such that the electrode is adjacent a baroreceptor site; and
delivering a baroreflex stimulation pulse train to a baroreceptor in the pulmonary artery via the electrode.
15. The method of claim 14, wherein positioning the electrode includes providing the distal end with a positive fixation mechanism to implant the electrode against a wall of the pulmonary artery.
16. The method of claim 14, wherein the electrode is adapted to be chronically implanted in the pulmonary artery.
17. The method of claim 14, further including monitoring a blood pressure to sense an efficacy of the baroreflex stimulation pulse train and to provide a signal indicative of the efficacy of the baroreflex stimulation pulse train.
18. The method of claim 14, wherein positioning includes positioning the electrode proximate the ligamentum arteriosum of the left pulmonary artery.
19. The method of claim 14, wherein positioning includes feeding the electrode through a right ventricle and a pulmonary valve into the pulmonary artery to position the electrode in the pulmonary artery.
20. The method of claim 14, wherein delivering the baroreflex stimulation pulse train includes an at least 10 hertz pulse train via the electrode.
21. An apparatus comprising:
a flexible lead body extending from a proximal end to a distal end, the lead body having an outer diameter dimensioned to abut a wall of a pulmonary artery;
an electrode coupled to the flexible lead body; and
an implantable pulse generator electrically coupled to the electrode, wherein the implantable pulse generator is adapted to deliver a baroreceptor stimulation signal to a baroreceptor in the pulmonary artery via the electrode.
22. An apparatus comprising:
a flexible lead body;
an electrode coupled to the lead body; and
an implantable pulse generator electrically coupled to the electrode, the implantable pulse generator being adapted to deliver a baroreceptor stimulation signal to a baroreceptor in the pulmonary artery via the electrode, wherein the electrode is expandable to passively fixate the electrode within the pulmonary artery.
23. A method comprising:
positioning an electrode on a lead within a pulmonary artery, such that the electrode is adjacent a baroreceptor site; and
delivering a baroreceptor stimulation pulse train to the baroreceptor site in the pulmonary artery via the electrode.
US11/482,563 2000-09-27 2006-07-07 Stimulation lead for stimulating the baroreceptors in the pulmonary artery Abandoned US20070038260A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/482,563 US20070038260A1 (en) 2000-09-27 2006-07-07 Stimulation lead for stimulating the baroreceptors in the pulmonary artery

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/671,850 US6522926B1 (en) 2000-09-27 2000-09-27 Devices and methods for cardiovascular reflex control
US10/284,063 US8086314B1 (en) 2000-09-27 2002-10-29 Devices and methods for cardiovascular reflex control
US11/482,563 US20070038260A1 (en) 2000-09-27 2006-07-07 Stimulation lead for stimulating the baroreceptors in the pulmonary artery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/284,063 Continuation US8086314B1 (en) 2000-09-27 2002-10-29 Devices and methods for cardiovascular reflex control

Publications (1)

Publication Number Publication Date
US20070038260A1 true US20070038260A1 (en) 2007-02-15

Family

ID=37743521

Family Applications (9)

Application Number Title Priority Date Filing Date
US10/284,063 Expired - Fee Related US8086314B1 (en) 2000-09-27 2002-10-29 Devices and methods for cardiovascular reflex control
US11/482,264 Expired - Lifetime US8290595B2 (en) 2000-09-27 2006-07-07 Method and apparatus for stimulation of baroreceptors in pulmonary artery
US11/482,634 Abandoned US20070038261A1 (en) 2000-09-27 2006-07-07 Lead for stimulating the baroreceptors in the pulmonary artery
US11/482,563 Abandoned US20070038260A1 (en) 2000-09-27 2006-07-07 Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US11/482,505 Abandoned US20070167984A1 (en) 2000-09-27 2006-07-07 Method and apparatus for stimulation of baroreceptors
US11/535,817 Expired - Fee Related US8838246B2 (en) 2000-09-27 2006-09-27 Devices and methods for cardiovascular reflex treatments
US11/933,218 Abandoned US20080215111A1 (en) 2000-09-27 2007-10-31 Devices and Methods for Cardiovascular Reflex Control
US11/933,252 Abandoned US20080177350A1 (en) 2000-09-27 2007-10-31 Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related Thereto
US11/933,244 Abandoned US20080177349A1 (en) 2000-09-27 2007-10-31 Apparatus and method for modulating the baroreflex system

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/284,063 Expired - Fee Related US8086314B1 (en) 2000-09-27 2002-10-29 Devices and methods for cardiovascular reflex control
US11/482,264 Expired - Lifetime US8290595B2 (en) 2000-09-27 2006-07-07 Method and apparatus for stimulation of baroreceptors in pulmonary artery
US11/482,634 Abandoned US20070038261A1 (en) 2000-09-27 2006-07-07 Lead for stimulating the baroreceptors in the pulmonary artery

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11/482,505 Abandoned US20070167984A1 (en) 2000-09-27 2006-07-07 Method and apparatus for stimulation of baroreceptors
US11/535,817 Expired - Fee Related US8838246B2 (en) 2000-09-27 2006-09-27 Devices and methods for cardiovascular reflex treatments
US11/933,218 Abandoned US20080215111A1 (en) 2000-09-27 2007-10-31 Devices and Methods for Cardiovascular Reflex Control
US11/933,252 Abandoned US20080177350A1 (en) 2000-09-27 2007-10-31 Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related Thereto
US11/933,244 Abandoned US20080177349A1 (en) 2000-09-27 2007-10-31 Apparatus and method for modulating the baroreflex system

Country Status (1)

Country Link
US (9) US8086314B1 (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US20050149128A1 (en) * 2003-12-24 2005-07-07 Heil Ronald W.Jr. Barorflex stimulation system to reduce hypertension
US20050149133A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Sensing with compensation for neural stimulator
US20050149130A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulation synchronized to circadian rhythm
US20050149131A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex modulation to gradually decrease blood pressure
US20050149132A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US20050149156A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Lead for stimulating the baroreceptors in the pulmonary artery
US20050149155A1 (en) * 2003-12-24 2005-07-07 Avram Scheiner Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US20050149143A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US20050149126A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulation to treat acute myocardial infarction
US20050251212A1 (en) * 2000-09-27 2005-11-10 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20070021794A1 (en) * 2000-09-27 2007-01-25 Cvrx, Inc. Baroreflex Therapy for Disordered Breathing
US20070038259A1 (en) * 2000-09-27 2007-02-15 Cvrx, Inc. Method and apparatus for stimulation of baroreceptors in pulmonary artery
US20070142864A1 (en) * 2003-12-24 2007-06-21 Imad Libbus Automatic neural stimulation modulation based on activity
US20070185543A1 (en) * 2000-09-27 2007-08-09 Cvrx, Inc. System and method for sustained baroreflex stimulation
US20080015659A1 (en) * 2003-12-24 2008-01-17 Yi Zhang Neurostimulation systems and methods for cardiac conditions
US20080033501A1 (en) * 2005-07-25 2008-02-07 Yossi Gross Elliptical element for blood pressure reduction
US20080172101A1 (en) * 2000-09-27 2008-07-17 Cvrx, Inc. Non-linear electrode array
US20080215117A1 (en) * 2005-07-25 2008-09-04 Yossi Gross Electrical Stimulation of Blood Vessels
US20080288030A1 (en) * 2007-05-14 2008-11-20 Cardiac Pacemakers, Inc. Method and apparatus for regulating blood volume using volume receptor stimulation
US20080289920A1 (en) * 2007-05-24 2008-11-27 Hoerbiger-Origa Holding Ag Pneumatic cylinder with a self-adjusting end position damping arrangement, and method for self-adjusting end position damping
US20090234418A1 (en) * 2000-09-27 2009-09-17 Kieval Robert S Devices and methods for cardiovascular reflex control via coupled electrodes
US20090234416A1 (en) * 2008-03-11 2009-09-17 Zielinski John R Intermittent pacing therapy delivery statistics
US20090306734A1 (en) * 2005-03-11 2009-12-10 Julia Moffitt Combined neural stimulation and cardiac resynchronization therapy
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7668594B2 (en) 2005-08-19 2010-02-23 Cardiac Pacemakers, Inc. Method and apparatus for delivering chronic and post-ischemia cardiac therapies
US20100249874A1 (en) * 2000-09-27 2010-09-30 Bolea Stephen L Baroreflex therapy for disordered breathing
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US20100274321A1 (en) * 2003-12-24 2010-10-28 Imad Libbus Baroreflex activation therapy with conditional shut off
US20100305648A1 (en) * 2009-05-28 2010-12-02 Shantha Arcot-Krishnamurthy Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing
US20110009692A1 (en) * 2007-12-26 2011-01-13 Yossi Gross Nitric oxide generation to treat female sexual dysfunction
US20110071584A1 (en) * 2009-09-23 2011-03-24 Mokelke Eric A Method and apparatus for automated control of pacing post-conditioning
US20110077729A1 (en) * 2009-09-29 2011-03-31 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US20110118773A1 (en) * 2005-07-25 2011-05-19 Rainbow Medical Ltd. Elliptical device for treating afterload
US20110137370A1 (en) * 2008-01-31 2011-06-09 Enopace Biomedical Ltd. Thoracic aorta and vagus nerve stimulation
US20110178416A1 (en) * 2005-07-25 2011-07-21 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US20110213408A1 (en) * 2005-07-25 2011-09-01 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US8538535B2 (en) 2010-08-05 2013-09-17 Rainbow Medical Ltd. Enhancing perfusion by contraction
US8626290B2 (en) 2008-01-31 2014-01-07 Enopace Biomedical Ltd. Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta
US8649863B2 (en) 2010-12-20 2014-02-11 Rainbow Medical Ltd. Pacemaker with no production
US8855783B2 (en) 2011-09-09 2014-10-07 Enopace Biomedical Ltd. Detector-based arterial stimulation
US9314635B2 (en) 2003-12-24 2016-04-19 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US9386991B2 (en) 2012-02-02 2016-07-12 Rainbow Medical Ltd. Pressure-enhanced blood flow treatment
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US9592136B2 (en) 2005-07-25 2017-03-14 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9642726B2 (en) 2005-07-25 2017-05-09 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US10779965B2 (en) 2013-11-06 2020-09-22 Enopace Biomedical Ltd. Posts with compliant junctions
EP3826531A4 (en) * 2018-07-23 2022-03-30 Integrated Sensing Systems, Inc. Wireless medical implants and methods of use
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US6616624B1 (en) * 2000-10-30 2003-09-09 Cvrx, Inc. Systems and method for controlling renovascular perfusion
US7480532B2 (en) 2003-10-22 2009-01-20 Cvrx, Inc. Baroreflex activation for pain control, sedation and sleep
US20050149129A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baropacing and cardiac pacing to control output
EP1804902A4 (en) * 2004-09-10 2008-04-16 Cleveland Clinic Foundation Intraluminal electrode assembly
US7295874B2 (en) * 2005-01-06 2007-11-13 Cardiac Pacemakers, Inc. Intermittent stress augmentation pacing for cardioprotective effect
US7660628B2 (en) 2005-03-23 2010-02-09 Cardiac Pacemakers, Inc. System to provide myocardial and neural stimulation
US7493161B2 (en) 2005-05-10 2009-02-17 Cardiac Pacemakers, Inc. System and method to deliver therapy in presence of another therapy
US7499748B2 (en) * 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
US7881782B2 (en) * 2005-04-20 2011-02-01 Cardiac Pacemakers, Inc. Neural stimulation system to prevent simultaneous energy discharges
US7734348B2 (en) * 2005-05-10 2010-06-08 Cardiac Pacemakers, Inc. System with left/right pulmonary artery electrodes
US7765000B2 (en) 2005-05-10 2010-07-27 Cardiac Pacemakers, Inc. Neural stimulation system with pulmonary artery lead
US20110238133A1 (en) * 2005-07-25 2011-09-29 Rainbow Medical Ltd. Electrical stimulation of the eye
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US10406366B2 (en) * 2006-11-17 2019-09-10 Respicardia, Inc. Transvenous phrenic nerve stimulation system
EP2371416B1 (en) 2005-11-18 2018-08-22 Respicardia, Inc. System to modulate phrenic nerve to prevent sleep apnea
US7570999B2 (en) * 2005-12-20 2009-08-04 Cardiac Pacemakers, Inc. Implantable device for treating epilepsy and cardiac rhythm disorders
EP1981584B1 (en) * 2006-02-03 2015-05-13 Interventional Autonomics Corporation Intravascular device for neuromodulation
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
WO2007139799A2 (en) * 2006-05-24 2007-12-06 Mayo Foundation For Medical Education And Research Devices and methods for crossing chronic total occlusions
US8968204B2 (en) * 2006-06-12 2015-03-03 Transonic Systems, Inc. System and method of perivascular pressure and flow measurement
US8170668B2 (en) * 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
EP2094352A4 (en) 2006-12-06 2010-05-19 Cleveland Clinic Foundation Method and system for treating acute heart failure by neuromodulation
WO2008128070A2 (en) 2007-04-11 2008-10-23 The Cleveland Clinic Foundation Method and apparatus for renal neuromodulation
AU2015200960A1 (en) * 2007-10-11 2015-03-19 Milux Holding Sa System and method for thermal treatment of hypertension, hypotension or aneurysm
HUE057333T2 (en) * 2007-10-11 2022-05-28 Implantica Patent Ltd System for thermal treatment of hypertension, hypotension or aneurysm
US8160695B2 (en) 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8180446B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
JP5189654B2 (en) 2007-12-12 2013-04-24 カーディアック ペースメイカーズ, インコーポレイテッド A stimulation system that transmits neural stimulation from the pulmonary artery
US8548586B2 (en) * 2008-01-29 2013-10-01 Cardiac Pacemakers, Inc. Configurable intermittent pacing therapy
US9005106B2 (en) 2008-01-31 2015-04-14 Enopace Biomedical Ltd Intra-aortic electrical counterpulsation
WO2009117086A2 (en) * 2008-03-17 2009-09-24 Cardiac Pacemakers, Inc. Deactivation of intermittent pacing therapy
US7925352B2 (en) * 2008-03-27 2011-04-12 Synecor Llc System and method for transvascularly stimulating contents of the carotid sheath
US20100211131A1 (en) * 2008-04-07 2010-08-19 Williams Michael S Intravascular system and method for blood pressure control
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US10603489B2 (en) * 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US20100125288A1 (en) * 2008-11-17 2010-05-20 G&L Consulting, Llc Method and apparatus for reducing renal blood pressure
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US9227079B2 (en) * 2009-03-19 2016-01-05 Kyushu University, National University Corporation Stimulation device and method for treating cardiovascular disease
US20100305663A1 (en) * 2009-06-02 2010-12-02 Boston Scientific Neuromodulation Corporation Implantable medical device system having short range communication link between an external controller and an external charger
US8784310B2 (en) * 2009-07-02 2014-07-22 Cardiac Pacemakers, Inc. Vascular pressure sensor with electrocardiogram electrodes
US8397578B2 (en) 2010-06-03 2013-03-19 Medtronic, Inc. Capacitive pressure sensor assembly
US9737657B2 (en) 2010-06-03 2017-08-22 Medtronic, Inc. Implantable medical pump with pressure sensor
KR101843337B1 (en) 2010-10-28 2018-03-30 삼성전자주식회사 Display module and display system
US9744349B2 (en) 2011-02-10 2017-08-29 Respicardia, Inc. Medical lead and implantation
US9446240B2 (en) * 2011-07-11 2016-09-20 Interventional Autonomics Corporation System and method for neuromodulation
US9199082B1 (en) 2011-07-27 2015-12-01 Cvrx, Inc. Devices and methods for improved placement of implantable medical devices
EP2771062B1 (en) 2011-10-24 2017-02-01 Purdue Research Foundation Apparatus for closed-loop control of nerve activation
US8923973B2 (en) 2011-11-10 2014-12-30 Rainbow Medical Ltd. Blood flow control element
WO2013096548A1 (en) * 2011-12-23 2013-06-27 Volcano Corporation Methods and apparatus for regulating blood pressure
US9403007B2 (en) 2012-06-14 2016-08-02 Cardiac Pacemakers, Inc. Systems and methods to reduce syncope risk during neural stimulation therapy
CN104902836B (en) 2012-11-05 2017-08-08 毕达哥拉斯医疗有限公司 Controlled tissue melts
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014204980A1 (en) 2013-06-18 2014-12-24 Cardiac Pacemakers, Inc. System and method for mapping baroreceptors
US9345877B2 (en) 2013-08-05 2016-05-24 Cvrx, Inc. Adapter for connection to pulse generator
US11759186B2 (en) * 2018-06-08 2023-09-19 David S. Goldsmith Ductus side-entry and prosthetic disorder response systems
US20160051806A1 (en) * 2013-08-27 2016-02-25 David S. Goldsmith Ductus side-entry jackets and prosthetic disorder response systems
WO2015088972A1 (en) * 2013-12-09 2015-06-18 Ryan Kendall Pierce Devices and methods for treating cardiovascular and metabolic disease
US10478249B2 (en) 2014-05-07 2019-11-19 Pythagoras Medical Ltd. Controlled tissue ablation techniques
CA2946791C (en) 2014-05-22 2023-09-19 CARDIONOMIC, Inc. Catheter and catheter system for electrical neuromodulation
IL250181B1 (en) * 2014-07-20 2023-12-01 Bruckheimer Elchanan Pulmonary artery implant apparatus
EP3194017A1 (en) 2014-09-08 2017-07-26 Cardionomic, Inc. Methods for electrical neuromodulation of the heart
AU2015315658B2 (en) 2014-09-08 2019-05-23 CARDIONOMIC, Inc. Catheter and electrode systems for electrical neuromodulation
EP3610917A1 (en) 2015-01-05 2020-02-19 Cardionomic, Inc. Cardiac modulation facilitation methods and systems
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11229548B2 (en) * 2015-09-10 2022-01-25 Board Of Regents, The University Of Texas System Thermoregulatory manipulation of systemic blood pressure
KR102399724B1 (en) 2015-09-24 2022-05-20 삼성전자주식회사 Display apparatus, Door and Refrigerator having the same
US10207110B1 (en) 2015-10-13 2019-02-19 Axon Therapies, Inc. Devices and methods for treatment of heart failure via electrical modulation of a splanchnic nerve
CN109310863A (en) 2016-03-09 2019-02-05 卡迪诺米克公司 Cardiac contractility neural stimulation system and method
US11167141B2 (en) 2016-03-15 2021-11-09 Leonhardt Ventures Llc Bioelectric blood pressure management
US11185691B2 (en) 2016-03-15 2021-11-30 Leonhardt Ventures Llc Tumor therapy
US11052247B2 (en) 2016-03-15 2021-07-06 Leonhardt Ventures Llc Skin treatment system
US11110274B2 (en) 2016-03-15 2021-09-07 Leonhardt Ventures Llc System and method for treating inflammation
US11849910B2 (en) 2016-03-15 2023-12-26 Valvublator Inc. Methods, systems, and devices for heart valve decalcification, regeneration, and repair
US10960206B2 (en) 2016-03-15 2021-03-30 Leonhardt Ventures Llc Bioelectric stimulator
US11691007B2 (en) 2016-03-15 2023-07-04 Leonhardt Ventures Llc Bioelectric OPG treatment of cancer
WO2017173014A1 (en) 2016-04-01 2017-10-05 Cardiac Pacemakers, Inc. Systems and methods for detecting worsening heart failure
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
US11154354B2 (en) 2016-07-29 2021-10-26 Axon Therapies, Inc. Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation
US11771434B2 (en) 2016-09-28 2023-10-03 Restore Medical Ltd. Artery medical apparatus and methods of use thereof
US10376159B2 (en) 2016-12-20 2019-08-13 Medtronic, Inc. Exercise triggered cardiovascular pressure measurement
US10835133B2 (en) 2016-12-20 2020-11-17 Medtronic, Inc. Hydrostatic offset adjustment for measured cardiovascular pressure values
EP3624704A4 (en) 2017-06-05 2021-03-10 Restore Medical Ltd Double walled fixed length stent like apparatus and methods of use thereof
WO2019055434A1 (en) 2017-09-13 2019-03-21 CARDIONOMIC, Inc. Neurostimulation systems and methods for affecting cardiac contractility
US10561461B2 (en) 2017-12-17 2020-02-18 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
US11751939B2 (en) 2018-01-26 2023-09-12 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
WO2019222619A1 (en) 2018-05-17 2019-11-21 Boston Scientific Scimed, Inc. System for controlling blood pressure
CA3107959A1 (en) 2018-08-13 2020-02-20 CARDIONOMIC, Inc. Systems and methods for affecting cardiac contractility and/or relaxation
WO2020061538A1 (en) * 2018-09-20 2020-03-26 Cal-X Stars Business Accelerator, Inc. Bioelectric blood pressure management
US11471686B2 (en) 2019-03-13 2022-10-18 Leonhardt Ventures Llc Klotho modulation
US11446488B2 (en) 2019-03-13 2022-09-20 Leonhardt Ventures Llc Kidney treatment
US11338143B2 (en) * 2019-03-20 2022-05-24 Neuroceuticals, Inc. Control apparatus for treating myocardial infarction and control method for treating myocardial infarction
JP2022531658A (en) 2019-05-06 2022-07-08 カーディオノミック,インク. Systems and methods for noise reduction of physiological signals during electrical neural regulation
EP4241836A3 (en) 2019-06-20 2023-11-29 Axon Therapies, Inc. Devices for endovascular ablation of a splanchnic nerve
USD957646S1 (en) 2019-08-29 2022-07-12 OrthodontiCell, Inc. Dental mouthpiece
US11413090B2 (en) 2020-01-17 2022-08-16 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
IL299585A (en) 2021-12-29 2023-07-01 Cvrx Inc Devices and methods for baroreflex activation
US20230355170A1 (en) 2022-05-03 2023-11-09 Cvrx, Inc. External baroreflex activation for assessment and treatment
CN115440119B (en) * 2022-11-09 2023-03-24 德阳市人民医院 Model and demonstration method for dynamically demonstrating cerebral infarction pathology

Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645267A (en) * 1969-10-29 1972-02-29 Medtronic Inc Medical-electronic stimulator, particularly a carotid sinus nerve stimulator with controlled turn-on amplitude rate
US3650277A (en) * 1969-02-24 1972-03-21 Lkb Medical Ab Apparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US3670051A (en) * 1969-01-31 1972-06-13 Bayer Ag Carbonate containing copolymerisation products and process for their production
US3943936A (en) * 1970-09-21 1976-03-16 Rasor Associates, Inc. Self powered pacers and stimulators
US4014318A (en) * 1973-08-20 1977-03-29 Dockum James M Circulatory assist device and system
US4256094A (en) * 1979-06-18 1981-03-17 Kapp John P Arterial pressure control system
US4323073A (en) * 1978-09-11 1982-04-06 Cos Electronics Corporation Apparatus and method for controlling the application of therapeutic direct current to living tissue
US4331157A (en) * 1980-07-09 1982-05-25 Stimtech, Inc. Mutually noninterfering transcutaneous nerve stimulation and patient monitoring
US4525074A (en) * 1983-08-19 1985-06-25 Citizen Watch Co., Ltd. Apparatus for measuring the quantity of physical exercise
US4573481A (en) * 1984-06-25 1986-03-04 Huntington Institute Of Applied Research Implantable electrode array
US4586501A (en) * 1982-10-21 1986-05-06 Michel Claracq Device for partly occluding a vessel in particular the inferior vena cava and inherent component of this device
US4590946A (en) * 1984-06-14 1986-05-27 Biomed Concepts, Inc. Surgically implantable electrode for nerve bundles
US4640286A (en) * 1984-11-02 1987-02-03 Staodynamics, Inc. Optimized nerve fiber stimulation
US4641664A (en) * 1984-04-13 1987-02-10 Siemens Aktiengesellschaft Endocardial electrode arrangement
US4664120A (en) * 1986-01-22 1987-05-12 Cordis Corporation Adjustable isodiametric atrial-ventricular pervenous lead
US4719921A (en) * 1985-08-28 1988-01-19 Raul Chirife Cardiac pacemaker adaptive to physiological requirements
US4739762A (en) * 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4813418A (en) * 1987-02-02 1989-03-21 Staodynamics, Inc. Nerve fiber stimulation using symmetrical biphasic waveform applied through plural equally active electrodes
US4825871A (en) * 1984-03-27 1989-05-02 Societe Anonyme Dite: Atesys Defibrillating or cardioverting electric shock system including electrodes
US4828544A (en) * 1984-09-05 1989-05-09 Quotidian No. 100 Pty Limited Control of blood flow
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US4917092A (en) * 1988-07-13 1990-04-17 Medical Designs, Inc. Transcutaneous nerve stimulator for treatment of sympathetic nerve dysfunction
US4987897A (en) * 1989-09-18 1991-01-29 Medtronic, Inc. Body bus medical device communication system
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US5078736A (en) * 1990-05-04 1992-01-07 Interventional Thermodynamics, Inc. Method and apparatus for maintaining patency in the body passages
US5086787A (en) * 1989-12-06 1992-02-11 Medtronic, Inc. Steroid eluting intramuscular lead
US5092332A (en) * 1990-02-22 1992-03-03 Medtronic, Inc. Steroid eluting cuff electrode for peripheral nerve stimulation
US5113869A (en) * 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
US5113859A (en) * 1988-09-19 1992-05-19 Medtronic, Inc. Acoustic body bus medical device communication system
US5117826A (en) * 1987-02-02 1992-06-02 Staodyn, Inc. Combined nerve fiber and body tissue stimulation apparatus and method
US5181911A (en) * 1991-04-22 1993-01-26 Shturman Technologies, Inc. Helical balloon perfusion angioplasty catheter
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5215089A (en) * 1991-10-21 1993-06-01 Cyberonics, Inc. Electrode assembly for nerve stimulation
US5222971A (en) * 1990-10-09 1993-06-29 Scimed Life Systems, Inc. Temporary stent and methods for use and manufacture
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5295959A (en) * 1992-03-13 1994-03-22 Medtronic, Inc. Autoperfusion dilatation catheter having a bonded channel
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5304206A (en) * 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5314453A (en) * 1991-12-06 1994-05-24 Spinal Cord Society Position sensitive power transfer antenna
US5318592A (en) * 1991-09-12 1994-06-07 BIOTRONIK, Mess- und Therapiegerate GmbH & Co., Ingenieurburo Berlin Cardiac therapy system
US5324325A (en) * 1991-06-27 1994-06-28 Siemens Pacesetter, Inc. Myocardial steroid releasing lead
US5324310A (en) * 1992-07-01 1994-06-28 Medtronic, Inc. Cardiac pacemaker with auto-capture function
US5387234A (en) * 1992-05-21 1995-02-07 Siemens-Elema Ab Medical electrode device
US5408744A (en) * 1993-04-30 1995-04-25 Medtronic, Inc. Substrate for a sintered electrode
US5411540A (en) * 1993-06-03 1995-05-02 Massachusetts Institute Of Technology Method and apparatus for preferential neuron stimulation
US5509888A (en) * 1994-07-26 1996-04-23 Conceptek Corporation Controller valve device and method
US5522854A (en) * 1994-05-19 1996-06-04 Duke University Method and apparatus for the prevention of arrhythmia by nerve stimulation
US5522874A (en) * 1994-07-28 1996-06-04 Gates; James T. Medical lead having segmented electrode
US5529067A (en) * 1994-08-19 1996-06-25 Novoste Corporation Methods for procedures related to the electrophysiology of the heart
US5634878A (en) * 1993-09-17 1997-06-03 Eska Medical Gmbh & Co. Implantable device for selectively opening and closing a tubular organ of the body
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US5715837A (en) * 1996-08-29 1998-02-10 Light Sciences Limited Partnership Transcutaneous electromagnetic energy transfer
US5725563A (en) * 1993-04-21 1998-03-10 Klotz; Antoine Electronic device and method for adrenergically stimulating the sympathetic system with respect to the venous media
US5725471A (en) * 1994-11-28 1998-03-10 Neotonus, Inc. Magnetic nerve stimulator for exciting peripheral nerves
US5727558A (en) * 1996-02-14 1998-03-17 Hakki; A-Hamid Noninvasive blood pressure monitor and control device
US5741316A (en) * 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US5766236A (en) * 1996-04-19 1998-06-16 Detty; Gerald D. Electrical stimulation support braces
US5766527A (en) * 1993-10-29 1998-06-16 Medtronic, Inc. Method of manufacturing medical electrical lead
US5861015A (en) * 1997-05-05 1999-01-19 Benja-Athon; Anuthep Modulation of the nervous system for treatment of pain and related disorders
US5861012A (en) * 1994-08-16 1999-01-19 Medtronic, Inc. Atrial and ventricular capture detection and threshold-seeking pacemaker
US5878422A (en) * 1996-04-09 1999-03-02 Viasoft, Inc. System for virtually converting data in a field between first and second format by using hook routines
US5897181A (en) * 1997-06-04 1999-04-27 Maytag Corporation Method of assembling a refrigerator cabinet
US5904708A (en) * 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US5913878A (en) * 1998-02-10 1999-06-22 Angeion Corporation Tiered therapy cardiac detection system having a global counter
US5916239A (en) * 1996-03-29 1999-06-29 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6023642A (en) * 1997-05-08 2000-02-08 Biogenics Ii, Llc Compact transcutaneous electrical nerve stimulator
US6052623A (en) * 1998-11-30 2000-04-18 Medtronic, Inc. Feedthrough assembly for implantable medical devices and methods for providing same
US6058331A (en) * 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US6061598A (en) * 1997-04-21 2000-05-09 Medtronic, Inc. Fracture resistant medical electrical lead
US6073048A (en) * 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
US6077298A (en) * 1999-02-20 2000-06-20 Tu; Lily Chen Expandable/retractable stent and methods thereof
US6077227A (en) * 1998-12-28 2000-06-20 Medtronic, Inc. Method for manufacture and implant of an implantable blood vessel cuff
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6231516B1 (en) * 1997-10-14 2001-05-15 Vacusense, Inc. Endoluminal implant with therapeutic and diagnostic capability
US6253110B1 (en) * 1999-04-27 2001-06-26 Medtronic Inc Method for tissue stimulation and fabrication of low polarization implantable stimulation electrode
US20020005982A1 (en) * 2000-07-17 2002-01-17 Rolf Borlinghaus Arrangement for spectrally sensitive reflected-light and transmitted-light microscopy
US6522926B1 (en) * 2000-09-27 2003-02-18 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US20030040785A1 (en) * 2001-08-21 2003-02-27 Maschino Steve E. Circumneural electrode assembly
US20030060858A1 (en) * 2000-09-27 2003-03-27 Kieval Robert S. Stimulus regimens for cardiovascular reflex control
US20030060848A1 (en) * 2001-09-26 2003-03-27 Kieval Robert S. Mapping methods for cardiovascular reflex control devices
US20030060857A1 (en) * 2000-09-27 2003-03-27 Perrson Bruce J. Electrode designs and methods of use for cardiovascular reflex control devices
US6564101B1 (en) * 1998-02-02 2003-05-13 The Trustees Of Columbia University In The City Of New York Electrical system for weight loss and laparoscopic implanation thereof
US20040010303A1 (en) * 2001-09-26 2004-01-15 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US20040019364A1 (en) * 2000-09-27 2004-01-29 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US6701186B2 (en) * 2001-09-13 2004-03-02 Cardiac Pacemakers, Inc. Atrial pacing and sensing in cardiac resynchronization therapy
US6704598B2 (en) * 2001-05-23 2004-03-09 Cardiac Pacemakers, Inc. Cardiac rhythm management system selecting between multiple same-chamber electrodes for delivering cardiac therapy
US20040062852A1 (en) * 2002-09-30 2004-04-01 Medtronic, Inc. Method for applying a drug coating to a medical device
US20040102818A1 (en) * 2002-11-26 2004-05-27 Hakky Said I. Method and system for controlling blood pressure
US6748272B2 (en) * 2001-03-08 2004-06-08 Cardiac Pacemakers, Inc. Atrial interval based heart rate variability diagnostic for cardiac rhythm management system
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3309924A (en) 1964-06-22 1967-03-21 Universtity Of California Electromagnetic flow meter
US3421511A (en) 1965-12-10 1969-01-14 Medtronic Inc Implantable electrode for nerve stimulation
US3593718A (en) 1967-07-13 1971-07-20 Biocybernetics Inc Physiologically controlled cardiac pacer
US3522811A (en) 1969-02-13 1970-08-04 Medtronic Inc Implantable nerve stimulator and method of use
US3835864A (en) * 1970-09-21 1974-09-17 Rasor Ass Inc Intra-cardiac stimulator
USRE30366E (en) 1970-09-21 1980-08-12 Rasor Associates, Inc. Organ stimulator
GB1434524A (en) * 1972-04-27 1976-05-05 Nat Res Dev Urinary control apparatus
EP0047013B1 (en) 1980-09-02 1986-01-22 Medtronic, Inc. Subcutaneously implantable lead with drug dispenser means
US4364922A (en) 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4481953A (en) 1981-11-12 1984-11-13 Cordis Corporation Endocardial lead having helically wound ribbon electrode
US4551862A (en) 1982-12-15 1985-11-12 Haber Terry M Prosthetic sphincter
DE3313855C1 (en) * 1983-04-16 1984-03-15 Drägerwerk AG, 2400 Lübeck Respiratory system
US4531943A (en) 1983-08-08 1985-07-30 Angiomedics Corporation Catheter with soft deformable tip
US4867164A (en) 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US4702254A (en) 1983-09-14 1987-10-27 Jacob Zabara Neurocybernetic prosthesis
US4887608A (en) 1986-01-31 1989-12-19 Boston Scientific Corporation Method and apparatus for estimating tissue damage
US4682583A (en) 1984-04-13 1987-07-28 Burton John H Inflatable artificial sphincter
US4628942A (en) 1984-10-11 1986-12-16 Case Western Reserve University Asymmetric shielded two electrode cuff
US4860751A (en) 1985-02-04 1989-08-29 Cordis Corporation Activity sensor for pacemaker control
US4881939A (en) 1985-02-19 1989-11-21 The Johns Hopkins University Implantable helical cuff
US4862361A (en) 1985-06-05 1989-08-29 Massachusetts Institute Of Technology Methods and apparatus for monitoring cardiovascular regulation using heart rate power spectral analysis
US4832038A (en) 1985-06-05 1989-05-23 The Board Of Trustees Of University Of Illinois Apparatus for monitoring cardiovascular regulation using heart rate power spectral analysis
US4770177A (en) 1986-02-18 1988-09-13 Telectronics N.V. Apparatus and method for adjusting heart/pacer relative to changes in venous diameter during exercise to obtain a required cardiac output.
US4762820A (en) 1986-03-03 1988-08-09 Trustees Of Boston University Therapeutic treatment for congestive heart failure
US4709690A (en) 1986-04-21 1987-12-01 Habley Medical Technology Corporation Implantable blood flow and occlusion pressure sensing sphincteric system
US5010893A (en) 1987-01-15 1991-04-30 Siemens-Pacesetter, Inc. Motion sensor for implanted medical device
US4762130A (en) 1987-01-15 1988-08-09 Thomas J. Fogarty Catheter with corkscrew-like balloon
US4969458A (en) 1987-07-06 1990-11-13 Medtronic, Inc. Intracoronary stent and method of simultaneous angioplasty and stent implant
US4791931A (en) 1987-08-13 1988-12-20 Pacesetter Infusion, Ltd. Demand pacemaker using an artificial baroreceptor reflex
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4819662A (en) 1987-10-26 1989-04-11 Cardiac Pacemakers, Inc. Cardiac electrode with drug delivery capabilities
US4934368A (en) 1988-01-21 1990-06-19 Myo/Kinetics Systems, Inc. Multi-electrode neurological stimulation apparatus
US4926875A (en) 1988-01-25 1990-05-22 Baylor College Of Medicine Implantable and extractable biological sensor probe
CA1327838C (en) 1988-06-13 1994-03-15 Fred Zacouto Implantable device to prevent blood clotting disorders
US4960133A (en) 1988-11-21 1990-10-02 Brunswick Manufacturing Co., Inc. Esophageal electrode
US4960129A (en) 1988-12-05 1990-10-02 Trustees Of The University Of Pennsylvania Methods of observing autonomic neural stimulation and diagnosing cardiac dynamical dysfunction using heartbeat interval data to analyze cardioventilatory interactions
US4915113A (en) 1988-12-16 1990-04-10 Bio-Vascular, Inc. Method and apparatus for monitoring the patency of vascular grafts
US4940065A (en) 1989-01-23 1990-07-10 Regents Of The University Of California Surgically implantable peripheral nerve electrode
US4967159A (en) 1989-02-23 1990-10-30 Abbott Laboratories Self-balancing reflectometer
US4930517A (en) 1989-04-25 1990-06-05 Massachusetts Institute Of Technology Method and apparatus for physiologic system identification
US5114423A (en) 1989-05-15 1992-05-19 Advanced Cardiovascular Systems, Inc. Dilatation catheter assembly with heated balloon
US4972848A (en) 1989-08-23 1990-11-27 Medtronic, Inc. Medical electrical lead with polymeric monolithic controlled release device and method of manufacture
US5031621A (en) 1989-12-06 1991-07-16 Grandjean Pierre A Nerve electrode with biological substrate
US5040533A (en) 1989-12-29 1991-08-20 Medical Engineering And Development Institute Incorporated Implantable cardiovascular treatment device container for sensing a physiological parameter
US5265608A (en) 1990-02-22 1993-11-30 Medtronic, Inc. Steroid eluting electrode for peripheral nerve stimulation
US5203348A (en) 1990-06-06 1993-04-20 Cardiac Pacemakers, Inc. Subcutaneous defibrillation electrodes
DE4019002A1 (en) 1990-06-13 1992-01-02 Siemens Ag ELECTRODE ARRANGEMENT FOR A DEFIBRILLATOR
US5282844A (en) 1990-06-15 1994-02-01 Medtronic, Inc. High impedance, low polarization, low threshold miniature steriod eluting pacing lead electrodes
US5158078A (en) 1990-08-14 1992-10-27 Medtronic, Inc. Rate responsive pacemaker and methods for optimizing its operation
US5134997A (en) 1990-08-14 1992-08-04 Medtronic, Inc. Rate responsive pacemaker and pacing method
US5154170A (en) 1990-08-14 1992-10-13 Medtronic, Inc. Optimization for rate responsive cardiac pacemaker
US5680590A (en) 1990-09-21 1997-10-21 Parti; Michael Simulation system and method of using same
US5111815A (en) 1990-10-15 1992-05-12 Cardiac Pacemakers, Inc. Method and apparatus for cardioverter/pacer utilizing neurosensing
FR2671010B1 (en) 1990-12-27 1993-07-09 Ela Medical Sa ENDOCARDIAC PROBE PROVIDED WITH AN ACTIVE FIXING MEMBER
US5224491A (en) 1991-01-07 1993-07-06 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5170802A (en) 1991-01-07 1992-12-15 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5154182A (en) 1991-02-15 1992-10-13 Siemens Pacesetter, Inc. Drug or steroid releasing patch electrode for an implantable arrhythmia treatment system
US5437285A (en) 1991-02-20 1995-08-01 Georgetown University Method and apparatus for prediction of sudden cardiac death by simultaneous assessment of autonomic function and cardiac electrical stability
US5269303A (en) 1991-02-22 1993-12-14 Cyberonics, Inc. Treatment of dementia by nerve stimulation
US5144960A (en) * 1991-03-20 1992-09-08 Medtronic, Inc. Transvenous defibrillation lead and method of use
AU654552B2 (en) 1991-04-05 1994-11-10 Medtronic, Inc. Subcutaneous multi-electrode sensing system
US5251634A (en) 1991-05-03 1993-10-12 Cyberonics, Inc. Helical nerve electrode
US5335657A (en) 1991-05-03 1994-08-09 Cyberonics, Inc. Therapeutic treatment of sleep disorder by nerve stimulation
AU2399892A (en) 1991-08-09 1993-03-02 Cyberonics, Inc. Treatment of anxiety disorders by nerve stimulation
US5358514A (en) 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
JPH05245215A (en) 1992-03-03 1993-09-24 Terumo Corp Heart pace maker
IT1259358B (en) 1992-03-26 1996-03-12 Sorin Biomedica Spa IMPLANTABLE DEVICE FOR DETECTION AND CONTROL OF THE SYMPATHIC-VAGAL TONE
US5330507A (en) 1992-04-24 1994-07-19 Medtronic, Inc. Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
AU663948B2 (en) 1992-06-12 1995-10-26 Kabushiki Kaisha Advance Electrical stimulator
US5330515A (en) 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5243980A (en) 1992-06-30 1993-09-14 Medtronic, Inc. Method and apparatus for discrimination of ventricular and supraventricular tachycardia
WO1994007564A2 (en) 1992-10-01 1994-04-14 Cardiac Pacemakers, Inc. Stent-type defibrillation electrode structures
US5325870A (en) 1992-12-16 1994-07-05 Angeion Corporation Multiplexed defibrillation electrode apparatus
US5431171A (en) 1993-06-25 1995-07-11 The Regents Of The University Of California Monitoring fetal characteristics by radiotelemetric transmission
US5411531A (en) 1993-09-23 1995-05-02 Medtronic, Inc. Method and apparatus for control of A-V interval
US5527159A (en) 1993-11-10 1996-06-18 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Rotary blood pump
US5545132A (en) 1993-12-21 1996-08-13 C. R. Bard, Inc. Helically grooved balloon for dilatation catheter and method of using
US5458626A (en) 1993-12-27 1995-10-17 Krause; Horst E. Method of electrical nerve stimulation for acceleration of tissue healing
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
US5501703A (en) 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5782891A (en) 1994-06-16 1998-07-21 Medtronic, Inc. Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body
EP0688579B1 (en) 1994-06-24 2001-08-22 St. Jude Medical AB Device for heart therapy
US5695468A (en) 1994-09-16 1997-12-09 Scimed Life Systems, Inc. Balloon catheter with improved pressure source
DE4433111A1 (en) 1994-09-16 1996-03-21 Fraunhofer Ges Forschung Cuff electrode
US5531778A (en) 1994-09-20 1996-07-02 Cyberonics, Inc. Circumneural electrode assembly
US5540734A (en) 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
US5551953A (en) 1994-10-31 1996-09-03 Alza Corporation Electrotransport system with remote telemetry link
US5540735A (en) 1994-12-12 1996-07-30 Rehabilicare, Inc. Apparatus for electro-stimulation of flexing body portions
US5571150A (en) 1994-12-19 1996-11-05 Cyberonics, Inc. Treatment of patients in coma by nerve stimulation
US5531766A (en) 1995-01-23 1996-07-02 Angeion Corporation Implantable cardioverter defibrillator pulse generator kite-tail electrode system
US5741319A (en) 1995-01-27 1998-04-21 Medtronic, Inc. Biocompatible medical lead
EP0814699B1 (en) 1995-02-27 2001-09-05 Medtronic, Inc. External patient reference sensor
US5535752A (en) 1995-02-27 1996-07-16 Medtronic, Inc. Implantable capacitive absolute pressure and temperature monitor system
US5593431A (en) 1995-03-30 1997-01-14 Medtronic, Inc. Medical service employing multiple DC accelerometers for patient activity and posture sensing and method
US5775331A (en) 1995-06-07 1998-07-07 Uromed Corporation Apparatus and method for locating a nerve
US6350242B1 (en) 1995-09-28 2002-02-26 Data Sciences International, Inc. Respiration monitoring system based on sensed physiological parameters
US5694939A (en) 1995-10-03 1997-12-09 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Autogenic-feedback training exercise (AFTE) method and system
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
US5683430A (en) 1995-11-16 1997-11-04 Ael Industries, Inc. Status monitor for anomaly detection in implanted devices and method
EP0855927A1 (en) 1995-11-24 1998-08-05 Advanced Bionics Corporation System and method for conditioning pelvic musculature using an implanted microstimulator
CN2291164Y (en) 1996-12-23 1998-09-16 祝强 Instrument for bringing high blood pressure down
US5989230A (en) 1996-01-11 1999-11-23 Essex Technology, Inc. Rotate to advance catheterization system
US5913876A (en) 1996-02-20 1999-06-22 Cardiothoracic Systems, Inc. Method and apparatus for using vagus nerve stimulation in surgery
US5651378A (en) 1996-02-20 1997-07-29 Cardiothoracic Systems, Inc. Method of using vagal nerve stimulation in surgery
US5987746A (en) 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
US5776178A (en) 1996-02-21 1998-07-07 Medtronic, Inc. Medical electrical lead with surface treatment for enhanced fixation
US5824021A (en) 1996-04-25 1998-10-20 Medtronic Inc. Method and apparatus for providing feedback to spinal cord stimulation for angina
US6006134A (en) 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6449507B1 (en) 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
WO1997045160A1 (en) 1996-05-31 1997-12-04 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
JP2000514682A (en) 1996-07-11 2000-11-07 メドトロニック・インコーポレーテッド Minimal invasive implantable device for monitoring physiological events
US5800464A (en) 1996-10-03 1998-09-01 Medtronic, Inc. System for providing hyperpolarization of cardiac to enhance cardiac function
US5814079A (en) 1996-10-04 1998-09-29 Medtronic, Inc. Cardiac arrhythmia management by application of adnodal stimulation for hyperpolarization of myocardial cells
US6110098A (en) 1996-12-18 2000-08-29 Medtronic, Inc. System and method of mechanical treatment of cardiac fibrillation
US5814089A (en) 1996-12-18 1998-09-29 Medtronic, Inc. Leadless multisite implantable stimulus and diagnostic system
US5895416A (en) 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5938596A (en) 1997-03-17 1999-08-17 Medtronic, Inc. Medical electrical lead
US5954761A (en) 1997-03-25 1999-09-21 Intermedics Inc. Implantable endocardial lead assembly having a stent
US6123725A (en) 1997-07-11 2000-09-26 A-Med Systems, Inc. Single port cardiac support apparatus
US6141590A (en) 1997-09-25 2000-10-31 Medtronic, Inc. System and method for respiration-modulated pacing
US5807258A (en) 1997-10-14 1998-09-15 Cimochowski; George E. Ultrasonic sensors for monitoring the condition of a vascular graft
US6585763B1 (en) 1997-10-14 2003-07-01 Vascusense, Inc. Implantable therapeutic device and method
US5967986A (en) 1997-11-25 1999-10-19 Vascusense, Inc. Endoluminal implant with fluid flow sensing capability
US6409674B1 (en) 1998-09-24 2002-06-25 Data Sciences International, Inc. Implantable sensor with wireless communication
US6178379B1 (en) 1997-10-31 2001-01-23 Honeywell International Inc. Method and apparatus of monitoring a navigation system using deviation signals from navigation sensors
SE511823C2 (en) 1997-11-07 1999-12-06 Ericsson Telefon Ab L M Data communication networks and method related thereto
US5991667A (en) 1997-11-10 1999-11-23 Vitatron Medical, B.V. Pacing lead with porous electrode for stable low threshold high impedance pacing
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
US6161047A (en) 1998-04-30 2000-12-12 Medtronic Inc. Apparatus and method for expanding a stimulation lead body in situ
US5928272A (en) 1998-05-02 1999-07-27 Cyberonics, Inc. Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity
WO1999065561A1 (en) * 1998-06-19 1999-12-23 Cordis Webster, Inc. Method and apparatus for transvascular treatment of tachycardia and fibrillation
US5876422A (en) 1998-07-07 1999-03-02 Vitatron Medical B.V. Pacemaker system with peltier cooling of A-V node for treating atrial fibrillation
US6141588A (en) 1998-07-24 2000-10-31 Intermedics Inc. Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy
DE19847446B4 (en) 1998-10-08 2010-04-22 Biotronik Gmbh & Co. Kg Nerve electrode assembly
US6564102B1 (en) 1998-10-26 2003-05-13 Birinder R. Boveja Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator
US20030212440A1 (en) 2002-05-09 2003-11-13 Boveja Birinder R. Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system
US6356788B2 (en) 1998-10-26 2002-03-12 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6205359B1 (en) 1998-10-26 2001-03-20 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6668191B1 (en) 1998-10-26 2003-12-23 Birinder R. Boveja Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator
US9061139B2 (en) 1998-11-04 2015-06-23 Greatbatch Ltd. Implantable lead with a band stop filter having a capacitor in parallel with an inductor embedded in a dielectric body
US6701176B1 (en) 1998-11-04 2004-03-02 Johns Hopkins University School Of Medicine Magnetic-resonance-guided imaging, electrophysiology, and ablation
IT1305062B1 (en) 1998-12-23 2001-04-10 Leonardo Cammilli SINGLE INTRODUCTION CATHETER FOR MULTISITE STIMULATION OF THE FOUR CARDIAC CHAMBERS FOR TREATMENT OF PATHOLOGIES SUCH AS
US6106477A (en) 1998-12-28 2000-08-22 Medtronic, Inc. Chronically implantable blood vessel cuff with sensor
US6909917B2 (en) 1999-01-07 2005-06-21 Advanced Bionics Corporation Implantable generator having current steering means
US6210339B1 (en) 1999-03-03 2001-04-03 Endosonics Corporation Flexible elongate member having one or more electrical contacts
US6161029A (en) 1999-03-08 2000-12-12 Medtronic, Inc. Apparatus and method for fixing electrodes in a blood vessel
US6438409B1 (en) 1999-03-25 2002-08-20 Medtronic, Inc. Methods of characterizing ventricular operations and applications thereof
US6115628A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals
US6115630A (en) 1999-03-29 2000-09-05 Medtronic, Inc. Determination of orientation of electrocardiogram signal in implantable medical devices
US6128526A (en) 1999-03-29 2000-10-03 Medtronic, Inc. Method for ischemia detection and apparatus for using same
US6324421B1 (en) 1999-03-29 2001-11-27 Medtronic, Inc. Axis shift analysis of electrocardiogram signal parameters especially applicable for multivector analysis by implantable medical devices, and use of same
US6341236B1 (en) 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US6178352B1 (en) 1999-05-07 2001-01-23 Woodside Biomedical, Inc. Method of blood pressure moderation
WO2001000273A1 (en) 1999-06-25 2001-01-04 Emory University Devices and methods for vagus nerve stimulation
US6473644B1 (en) 1999-10-13 2002-10-29 Cyberonics, Inc. Method to enhance cardiac capillary growth in heart failure patients
US6438428B1 (en) 1999-10-27 2002-08-20 Axelgaard Manufacturing Co., Ltd. Electrical stimulation compress
US6942622B1 (en) 1999-11-10 2005-09-13 Pacesetter, Inc. Method for monitoring autonomic tone
US6611713B2 (en) 1999-11-30 2003-08-26 Patrick Schauerte Implantable device for diagnosing and distinguishing supraventricular and ventricular tachycardias
EP1106202A3 (en) 1999-11-30 2004-03-31 BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin Electrode for intravascular stimulation, cardioversion and /or defibrillation
US6415183B1 (en) 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
US6371922B1 (en) 2000-04-07 2002-04-16 Cardiac Pacemakers, Inc. Method for measuring baroreflex sensitivity and therapy optimization in heart failure patients
US6826428B1 (en) 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US6584362B1 (en) 2000-08-30 2003-06-24 Cardiac Pacemakers, Inc. Leads for pacing and/or sensing the heart from within the coronary veins
US20020103516A1 (en) 2000-09-20 2002-08-01 Patwardhan Ravish Vinay Carotid sinus nerve stimulation for epilepsy control
US20070185542A1 (en) 2002-03-27 2007-08-09 Cvrx, Inc. Baroreflex therapy for disordered breathing
US8086314B1 (en) 2000-09-27 2011-12-27 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US7840271B2 (en) 2000-09-27 2010-11-23 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US7623926B2 (en) 2000-09-27 2009-11-24 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20080177348A1 (en) 2000-09-27 2008-07-24 Cvrx, Inc. Electrode contact configurations for an implantable stimulator
US20080167699A1 (en) 2000-09-27 2008-07-10 Cvrx, Inc. Method and Apparatus for Providing Complex Tissue Stimulation Parameters
WO2002034327A2 (en) 2000-10-26 2002-05-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US8417334B2 (en) 2000-10-26 2013-04-09 Medtronic, Inc. Method and apparatus for electrically stimulating the nervous system to improve ventricular dysfunction, heart failure, and other cardiac conditions
EP1330178A1 (en) 2000-11-01 2003-07-30 3M Innovative Properties Company Electrical sensing and/or signal application device
US7785323B2 (en) 2000-12-04 2010-08-31 Boston Scientific Scimed, Inc. Loop structure including inflatable therapeutic device
US6445953B1 (en) 2001-01-16 2002-09-03 Kenergy, Inc. Wireless cardiac pacing system with vascular electrode-stents
AU2002250250A1 (en) 2001-03-01 2002-09-19 Three Arch Partners Intravascular device for treatment of hypertension
WO2002072192A2 (en) 2001-03-08 2002-09-19 Medtronic, Inc. Lead with adjustable angular and spatial relationships between electrodes
US6597951B2 (en) 2001-03-16 2003-07-22 Cardiac Pacemakers, Inc. Automatic selection from multiple cardiac optimization protocols
US20020151051A1 (en) 2001-03-27 2002-10-17 Sheng Feng Li Compositions and methods for isolating genes comprising subcellular localization sequences
US6766189B2 (en) 2001-03-30 2004-07-20 Cardiac Pacemakers, Inc. Method and apparatus for predicting acute response to cardiac resynchronization therapy
WO2002085448A2 (en) 2001-04-20 2002-10-31 The Board Of Regents Of The University Of Oklahoma Cardiac neuromodulation and methods of using same
US20070191895A1 (en) 2001-04-20 2007-08-16 Foreman Robert D Activation of cardiac alpha receptors by spinal cord stimulation produces cardioprotection against ischemia, arrhythmias, and heart failure
US6894204B2 (en) 2001-05-02 2005-05-17 3M Innovative Properties Company Tapered stretch removable adhesive articles and methods
WO2002096512A1 (en) 2001-05-29 2002-12-05 Medtronic, Inc. Closed-loop neuromodulation for prevention and treatment of cardiac conditions
DE50202789D1 (en) 2001-07-27 2005-05-19 Impella Cardiotech Ag NEUROSTIMULATION UNIT FOR THE IMMOBILIZATION OF THE HEART DURING CARDIOSURGICAL OPERATIONS
EP1460935A2 (en) 2001-08-17 2004-09-29 Ted W. Russell Methods, apparatus and sensor for hemodynamic monitoring
US6622041B2 (en) 2001-08-21 2003-09-16 Cyberonics, Inc. Treatment of congestive heart failure and autonomic cardiovascular drive disorders
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US7885709B2 (en) 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US6718212B2 (en) 2001-10-12 2004-04-06 Medtronic, Inc. Implantable medical electrical lead with light-activated adhesive fixation
US6934583B2 (en) 2001-10-22 2005-08-23 Pacesetter, Inc. Implantable lead and method for stimulating the vagus nerve
US6859667B2 (en) 2001-11-07 2005-02-22 Cardiac Pacemakers, Inc. Multiplexed medical device lead with standard header
US7286878B2 (en) 2001-11-09 2007-10-23 Medtronic, Inc. Multiplexed electrode array extension
US6768923B2 (en) 2001-12-05 2004-07-27 Cardiac Pacemakers, Inc. Apparatus and method for ventricular pacing triggered by detection of early ventricular excitation
US6909916B2 (en) 2001-12-20 2005-06-21 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia classification and electrode selection
US6666826B2 (en) 2002-01-04 2003-12-23 Cardiac Pacemakers, Inc. Method and apparatus for measuring left ventricular pressure
US7155284B1 (en) 2002-01-24 2006-12-26 Advanced Bionics Corporation Treatment of hypertension
US20030149450A1 (en) 2002-02-01 2003-08-07 Mayberg Marc R. Brainstem and cerebellar modulation of cardiovascular response and disease
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
JP3643564B2 (en) 2002-02-19 2005-04-27 コーリンメディカルテクノロジー株式会社 Autonomic nerve function evaluation device
US6937896B1 (en) 2002-02-26 2005-08-30 Pacesetter, Inc. Sympathetic nerve stimulator and/or pacemaker
JP2005519680A (en) 2002-03-14 2005-07-07 ブレインズゲート リミティド Blood pressure control technology
TW524670B (en) 2002-04-01 2003-03-21 Ind Tech Res Inst Non-invasive apparatus system for monitoring autonomic nervous system and uses thereof
US6922585B2 (en) 2002-04-05 2005-07-26 Medtronic, Inc. Method and apparatus for predicting recurring ventricular arrhythmias
US8204591B2 (en) 2002-05-23 2012-06-19 Bio Control Medical (B.C.M.) Ltd. Techniques for prevention of atrial fibrillation
US7321793B2 (en) 2003-06-13 2008-01-22 Biocontrol Medical Ltd. Vagal stimulation for atrial fibrillation therapy
US8036745B2 (en) 2004-06-10 2011-10-11 Bio Control Medical (B.C.M.) Ltd. Parasympathetic pacing therapy during and following a medical procedure, clinical trauma or pathology
US7139607B1 (en) 2002-06-12 2006-11-21 Pacesetter, Inc. Arrhythmia discrimination
US7277761B2 (en) 2002-06-12 2007-10-02 Pacesetter, Inc. Vagal stimulation for improving cardiac function in heart failure or CHF patients
US7123961B1 (en) 2002-06-13 2006-10-17 Pacesetter, Inc. Stimulation of autonomic nerves
US7228179B2 (en) 2002-07-26 2007-06-05 Advanced Neuromodulation Systems, Inc. Method and apparatus for providing complex tissue stimulation patterns
US6876881B2 (en) 2002-08-16 2005-04-05 Cardiac Pacemakers, Inc. Cardiac rhythm management system with respiration synchronous optimization of cardiac performance using atrial cycle length
US7313445B2 (en) 2002-09-26 2007-12-25 Medtronic, Inc. Medical lead with flexible distal guidewire extension
US7010337B2 (en) 2002-10-24 2006-03-07 Furnary Anthony P Method and apparatus for monitoring blood condition and cardiopulmonary function
US20030229380A1 (en) 2002-10-31 2003-12-11 Adams John M. Heart failure therapy device and method
US6942686B1 (en) 2002-11-01 2005-09-13 Coaxia, Inc. Regulation of cerebral blood flow by temperature change-induced vasodilatation
DE10251344B4 (en) * 2002-11-05 2006-07-13 Metrax Gmbh defibrillator
US7092755B2 (en) 2003-03-18 2006-08-15 Pacesetter, Inc. System and method of cardiac pacing during sleep apnea
US20060111626A1 (en) 2003-03-27 2006-05-25 Cvrx, Inc. Electrode structures having anti-inflammatory properties and methods of use
US7647106B2 (en) 2003-04-23 2010-01-12 Medtronic, Inc. Detection of vasovagal syncope
US7082336B2 (en) 2003-06-04 2006-07-25 Synecor, Llc Implantable intravascular device for defibrillation and/or pacing
WO2004110549A2 (en) 2003-06-13 2004-12-23 Biocontrol Medical Ltd. Applications of vagal stimulation
US7480532B2 (en) 2003-10-22 2009-01-20 Cvrx, Inc. Baroreflex activation for pain control, sedation and sleep
US7155295B2 (en) 2003-11-07 2006-12-26 Paracor Medical, Inc. Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
CA2536188A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US7706884B2 (en) 2003-12-24 2010-04-27 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US7509166B2 (en) 2003-12-24 2009-03-24 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US7460906B2 (en) 2003-12-24 2008-12-02 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US7643875B2 (en) 2003-12-24 2010-01-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US7486991B2 (en) 2003-12-24 2009-02-03 Cardiac Pacemakers, Inc. Baroreflex modulation to gradually decrease blood pressure
US20050149129A1 (en) 2003-12-24 2005-07-07 Imad Libbus Baropacing and cardiac pacing to control output
US20050149132A1 (en) 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US20050149133A1 (en) 2003-12-24 2005-07-07 Imad Libbus Sensing with compensation for neural stimulator
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
JP4479316B2 (en) 2004-04-08 2010-06-09 株式会社日立製作所 Production planning apparatus and method
US20060004417A1 (en) 2004-06-30 2006-01-05 Cvrx, Inc. Baroreflex activation for arrhythmia treatment
US8175705B2 (en) 2004-10-12 2012-05-08 Cardiac Pacemakers, Inc. System and method for sustained baroreflex stimulation
US7236861B2 (en) 2005-02-16 2007-06-26 Lockheed Martin Corporation Mission planning system with asynchronous request capability
US8401665B2 (en) 2005-04-01 2013-03-19 Boston Scientific Neuromodulation Corporation Apparatus and methods for detecting position and migration of neurostimulation leads
US7930038B2 (en) 2005-05-27 2011-04-19 Cardiac Pacemakers, Inc. Tubular lead electrodes and methods
US8109879B2 (en) 2006-01-10 2012-02-07 Cardiac Pacemakers, Inc. Assessing autonomic activity using baroreflex analysis
US20070191904A1 (en) 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670051A (en) * 1969-01-31 1972-06-13 Bayer Ag Carbonate containing copolymerisation products and process for their production
US3650277A (en) * 1969-02-24 1972-03-21 Lkb Medical Ab Apparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US3645267A (en) * 1969-10-29 1972-02-29 Medtronic Inc Medical-electronic stimulator, particularly a carotid sinus nerve stimulator with controlled turn-on amplitude rate
US3943936A (en) * 1970-09-21 1976-03-16 Rasor Associates, Inc. Self powered pacers and stimulators
US4014318A (en) * 1973-08-20 1977-03-29 Dockum James M Circulatory assist device and system
US4323073A (en) * 1978-09-11 1982-04-06 Cos Electronics Corporation Apparatus and method for controlling the application of therapeutic direct current to living tissue
US4256094A (en) * 1979-06-18 1981-03-17 Kapp John P Arterial pressure control system
US4331157A (en) * 1980-07-09 1982-05-25 Stimtech, Inc. Mutually noninterfering transcutaneous nerve stimulation and patient monitoring
US4586501A (en) * 1982-10-21 1986-05-06 Michel Claracq Device for partly occluding a vessel in particular the inferior vena cava and inherent component of this device
US4525074A (en) * 1983-08-19 1985-06-25 Citizen Watch Co., Ltd. Apparatus for measuring the quantity of physical exercise
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US4825871A (en) * 1984-03-27 1989-05-02 Societe Anonyme Dite: Atesys Defibrillating or cardioverting electric shock system including electrodes
US4641664A (en) * 1984-04-13 1987-02-10 Siemens Aktiengesellschaft Endocardial electrode arrangement
US4590946A (en) * 1984-06-14 1986-05-27 Biomed Concepts, Inc. Surgically implantable electrode for nerve bundles
US4573481A (en) * 1984-06-25 1986-03-04 Huntington Institute Of Applied Research Implantable electrode array
US4828544A (en) * 1984-09-05 1989-05-09 Quotidian No. 100 Pty Limited Control of blood flow
US4640286A (en) * 1984-11-02 1987-02-03 Staodynamics, Inc. Optimized nerve fiber stimulation
US4803988A (en) * 1984-11-02 1989-02-14 Staodynamics, Inc. Nerve fiber stimulation using plural equally active electrodes
US4719921A (en) * 1985-08-28 1988-01-19 Raul Chirife Cardiac pacemaker adaptive to physiological requirements
US4739762A (en) * 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) * 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4664120A (en) * 1986-01-22 1987-05-12 Cordis Corporation Adjustable isodiametric atrial-ventricular pervenous lead
US4813418A (en) * 1987-02-02 1989-03-21 Staodynamics, Inc. Nerve fiber stimulation using symmetrical biphasic waveform applied through plural equally active electrodes
US5117826A (en) * 1987-02-02 1992-06-02 Staodyn, Inc. Combined nerve fiber and body tissue stimulation apparatus and method
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US4917092A (en) * 1988-07-13 1990-04-17 Medical Designs, Inc. Transcutaneous nerve stimulator for treatment of sympathetic nerve dysfunction
US5113859A (en) * 1988-09-19 1992-05-19 Medtronic, Inc. Acoustic body bus medical device communication system
US4987897A (en) * 1989-09-18 1991-01-29 Medtronic, Inc. Body bus medical device communication system
US5086787A (en) * 1989-12-06 1992-02-11 Medtronic, Inc. Steroid eluting intramuscular lead
US5092332A (en) * 1990-02-22 1992-03-03 Medtronic, Inc. Steroid eluting cuff electrode for peripheral nerve stimulation
US5078736A (en) * 1990-05-04 1992-01-07 Interventional Thermodynamics, Inc. Method and apparatus for maintaining patency in the body passages
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5113869A (en) * 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
US5222971A (en) * 1990-10-09 1993-06-29 Scimed Life Systems, Inc. Temporary stent and methods for use and manufacture
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5181911A (en) * 1991-04-22 1993-01-26 Shturman Technologies, Inc. Helical balloon perfusion angioplasty catheter
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5324325A (en) * 1991-06-27 1994-06-28 Siemens Pacesetter, Inc. Myocardial steroid releasing lead
US5318592A (en) * 1991-09-12 1994-06-07 BIOTRONIK, Mess- und Therapiegerate GmbH & Co., Ingenieurburo Berlin Cardiac therapy system
US5215089A (en) * 1991-10-21 1993-06-01 Cyberonics, Inc. Electrode assembly for nerve stimulation
US5304206A (en) * 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5314453A (en) * 1991-12-06 1994-05-24 Spinal Cord Society Position sensitive power transfer antenna
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5295959A (en) * 1992-03-13 1994-03-22 Medtronic, Inc. Autoperfusion dilatation catheter having a bonded channel
US5387234A (en) * 1992-05-21 1995-02-07 Siemens-Elema Ab Medical electrode device
US5324310A (en) * 1992-07-01 1994-06-28 Medtronic, Inc. Cardiac pacemaker with auto-capture function
US5725563A (en) * 1993-04-21 1998-03-10 Klotz; Antoine Electronic device and method for adrenergically stimulating the sympathetic system with respect to the venous media
US5408744A (en) * 1993-04-30 1995-04-25 Medtronic, Inc. Substrate for a sintered electrode
US5411540A (en) * 1993-06-03 1995-05-02 Massachusetts Institute Of Technology Method and apparatus for preferential neuron stimulation
US5634878A (en) * 1993-09-17 1997-06-03 Eska Medical Gmbh & Co. Implantable device for selectively opening and closing a tubular organ of the body
US5766527A (en) * 1993-10-29 1998-06-16 Medtronic, Inc. Method of manufacturing medical electrical lead
US5522854A (en) * 1994-05-19 1996-06-04 Duke University Method and apparatus for the prevention of arrhythmia by nerve stimulation
US5509888A (en) * 1994-07-26 1996-04-23 Conceptek Corporation Controller valve device and method
US5522874A (en) * 1994-07-28 1996-06-04 Gates; James T. Medical lead having segmented electrode
US5861012A (en) * 1994-08-16 1999-01-19 Medtronic, Inc. Atrial and ventricular capture detection and threshold-seeking pacemaker
US5529067A (en) * 1994-08-19 1996-06-25 Novoste Corporation Methods for procedures related to the electrophysiology of the heart
US5725471A (en) * 1994-11-28 1998-03-10 Neotonus, Inc. Magnetic nerve stimulator for exciting peripheral nerves
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US6073048A (en) * 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
US5727558A (en) * 1996-02-14 1998-03-17 Hakki; A-Hamid Noninvasive blood pressure monitor and control device
US6050952A (en) * 1996-02-14 2000-04-18 Hakki; A-Hamid Method for noninvasive monitoring and control of blood pressure
US5916239A (en) * 1996-03-29 1999-06-29 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US5878422A (en) * 1996-04-09 1999-03-02 Viasoft, Inc. System for virtually converting data in a field between first and second format by using hook routines
US5766236A (en) * 1996-04-19 1998-06-16 Detty; Gerald D. Electrical stimulation support braces
US5715837A (en) * 1996-08-29 1998-02-10 Light Sciences Limited Partnership Transcutaneous electromagnetic energy transfer
US5741316A (en) * 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6061598A (en) * 1997-04-21 2000-05-09 Medtronic, Inc. Fracture resistant medical electrical lead
US5861015A (en) * 1997-05-05 1999-01-19 Benja-Athon; Anuthep Modulation of the nervous system for treatment of pain and related disorders
US6023642A (en) * 1997-05-08 2000-02-08 Biogenics Ii, Llc Compact transcutaneous electrical nerve stimulator
US5897181A (en) * 1997-06-04 1999-04-27 Maytag Corporation Method of assembling a refrigerator cabinet
US6231516B1 (en) * 1997-10-14 2001-05-15 Vacusense, Inc. Endoluminal implant with therapeutic and diagnostic capability
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6564101B1 (en) * 1998-02-02 2003-05-13 The Trustees Of Columbia University In The City Of New York Electrical system for weight loss and laparoscopic implanation thereof
US5913878A (en) * 1998-02-10 1999-06-22 Angeion Corporation Tiered therapy cardiac detection system having a global counter
US5904708A (en) * 1998-03-19 1999-05-18 Medtronic, Inc. System and method for deriving relative physiologic signals
US6058331A (en) * 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6052623A (en) * 1998-11-30 2000-04-18 Medtronic, Inc. Feedthrough assembly for implantable medical devices and methods for providing same
US6077227A (en) * 1998-12-28 2000-06-20 Medtronic, Inc. Method for manufacture and implant of an implantable blood vessel cuff
US6077298A (en) * 1999-02-20 2000-06-20 Tu; Lily Chen Expandable/retractable stent and methods thereof
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6253110B1 (en) * 1999-04-27 2001-06-26 Medtronic Inc Method for tissue stimulation and fabrication of low polarization implantable stimulation electrode
US20020005982A1 (en) * 2000-07-17 2002-01-17 Rolf Borlinghaus Arrangement for spectrally sensitive reflected-light and transmitted-light microscopy
US20040019364A1 (en) * 2000-09-27 2004-01-29 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US6522926B1 (en) * 2000-09-27 2003-02-18 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US6985774B2 (en) * 2000-09-27 2006-01-10 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20030060858A1 (en) * 2000-09-27 2003-03-27 Kieval Robert S. Stimulus regimens for cardiovascular reflex control
US20030060857A1 (en) * 2000-09-27 2003-03-27 Perrson Bruce J. Electrode designs and methods of use for cardiovascular reflex control devices
US6748272B2 (en) * 2001-03-08 2004-06-08 Cardiac Pacemakers, Inc. Atrial interval based heart rate variability diagnostic for cardiac rhythm management system
US6704598B2 (en) * 2001-05-23 2004-03-09 Cardiac Pacemakers, Inc. Cardiac rhythm management system selecting between multiple same-chamber electrodes for delivering cardiac therapy
US20030040785A1 (en) * 2001-08-21 2003-02-27 Maschino Steve E. Circumneural electrode assembly
US6701186B2 (en) * 2001-09-13 2004-03-02 Cardiac Pacemakers, Inc. Atrial pacing and sensing in cardiac resynchronization therapy
US20040010303A1 (en) * 2001-09-26 2004-01-15 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US20030060848A1 (en) * 2001-09-26 2003-03-27 Kieval Robert S. Mapping methods for cardiovascular reflex control devices
US6850801B2 (en) * 2001-09-26 2005-02-01 Cvrx, Inc. Mapping methods for cardiovascular reflex control devices
US20040062852A1 (en) * 2002-09-30 2004-04-01 Medtronic, Inc. Method for applying a drug coating to a medical device
US20040102818A1 (en) * 2002-11-26 2004-05-27 Hakky Said I. Method and system for controlling blood pressure
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system

Cited By (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8290595B2 (en) 2000-09-27 2012-10-16 Cvrx, Inc. Method and apparatus for stimulation of baroreceptors in pulmonary artery
US8880190B2 (en) 2000-09-27 2014-11-04 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US20100174347A1 (en) * 2000-09-27 2010-07-08 Kieval Robert S Devices and methods for cardiovascular reflex control via coupled electrodes
US20070185543A1 (en) * 2000-09-27 2007-08-09 Cvrx, Inc. System and method for sustained baroreflex stimulation
US20100179614A1 (en) * 2000-09-27 2010-07-15 Kieval Robert S Devices and methods for cardiovascular reflex control
US8838246B2 (en) 2000-09-27 2014-09-16 Cvrx, Inc. Devices and methods for cardiovascular reflex treatments
US8718789B2 (en) 2000-09-27 2014-05-06 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US8712531B2 (en) 2000-09-27 2014-04-29 Cvrx, Inc. Automatic baroreflex modulation responsive to adverse event
US8606359B2 (en) 2000-09-27 2013-12-10 Cvrx, Inc. System and method for sustained baroreflex stimulation
US8583236B2 (en) 2000-09-27 2013-11-12 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US20050251212A1 (en) * 2000-09-27 2005-11-10 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20070021794A1 (en) * 2000-09-27 2007-01-25 Cvrx, Inc. Baroreflex Therapy for Disordered Breathing
US20070021792A1 (en) * 2000-09-27 2007-01-25 Cvrx, Inc. Baroreflex Modulation Based On Monitored Cardiovascular Parameter
US20070038255A1 (en) * 2000-09-27 2007-02-15 Cvrx, Inc. Baroreflex stimulator with integrated pressure sensor
US20070038259A1 (en) * 2000-09-27 2007-02-15 Cvrx, Inc. Method and apparatus for stimulation of baroreceptors in pulmonary artery
US20070060972A1 (en) * 2000-09-27 2007-03-15 Cvrx, Inc. Devices and methods for cardiovascular reflex treatments
US9044609B2 (en) 2000-09-27 2015-06-02 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US20090234418A1 (en) * 2000-09-27 2009-09-17 Kieval Robert S Devices and methods for cardiovascular reflex control via coupled electrodes
US9427583B2 (en) 2000-09-27 2016-08-30 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US8086314B1 (en) 2000-09-27 2011-12-27 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US8060206B2 (en) 2000-09-27 2011-11-15 Cvrx, Inc. Baroreflex modulation to gradually decrease blood pressure
US20100191303A1 (en) * 2000-09-27 2010-07-29 Cvrx, Inc. Automatic baroreflex modulation responsive to adverse event
US20080172101A1 (en) * 2000-09-27 2008-07-17 Cvrx, Inc. Non-linear electrode array
US20080171923A1 (en) * 2000-09-27 2008-07-17 Cvrx, Inc. Assessing autonomic activity using baroreflex analysis
US20080177350A1 (en) * 2000-09-27 2008-07-24 Cvrx, Inc. Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related Thereto
US20080215111A1 (en) * 2000-09-27 2008-09-04 Cvrx, Inc. Devices and Methods for Cardiovascular Reflex Control
US7949400B2 (en) 2000-09-27 2011-05-24 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US20100249874A1 (en) * 2000-09-27 2010-09-30 Bolea Stephen L Baroreflex therapy for disordered breathing
US7840271B2 (en) 2000-09-27 2010-11-23 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US7813812B2 (en) 2000-09-27 2010-10-12 Cvrx, Inc. Baroreflex stimulator with integrated pressure sensor
US20080097540A1 (en) * 2001-09-26 2008-04-24 Cvrx, Inc. Ecg input to implantable pulse generator using carotid sinus leads
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US8571655B2 (en) 2003-11-03 2013-10-29 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US20100125307A1 (en) * 2003-11-03 2010-05-20 Pastore Joseph M Multi-site ventricular pacing therapy with parasympathetic stimulation
US20110082514A1 (en) * 2003-12-23 2011-04-07 Imad Libbus Hypertension therapy based on activity and circadian rhythm
US8874211B2 (en) 2003-12-23 2014-10-28 Cardiac Pacemakers, Inc. Hypertension therapy based on activity and circadian rhythm
US20090143838A1 (en) * 2003-12-24 2009-06-04 Imad Libbus Baroreflex modulation to gradually decrease blood pressure
US8000793B2 (en) 2003-12-24 2011-08-16 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US7706884B2 (en) 2003-12-24 2010-04-27 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US8626301B2 (en) 2003-12-24 2014-01-07 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US11154716B2 (en) 2003-12-24 2021-10-26 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US20100185255A1 (en) * 2003-12-24 2010-07-22 Imad Libbus Baroreflex stimulation synchronized to circadian rhythm
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US20090048641A1 (en) * 2003-12-24 2009-02-19 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US10369367B2 (en) 2003-12-24 2019-08-06 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US10342978B2 (en) 2003-12-24 2019-07-09 Cardiac Pacemakers, Inc. Vagus nerve stimulation responsive to a tachycardia precursor
US20100274321A1 (en) * 2003-12-24 2010-10-28 Imad Libbus Baroreflex activation therapy with conditional shut off
US9950170B2 (en) 2003-12-24 2018-04-24 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US9561373B2 (en) 2003-12-24 2017-02-07 Cardiac Pacemakers, Inc. System to stimulate a neural target and a heart
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US9440078B2 (en) 2003-12-24 2016-09-13 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US20050149128A1 (en) * 2003-12-24 2005-07-07 Heil Ronald W.Jr. Barorflex stimulation system to reduce hypertension
US9314635B2 (en) 2003-12-24 2016-04-19 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US20080228238A1 (en) * 2003-12-24 2008-09-18 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US20110106216A1 (en) * 2003-12-24 2011-05-05 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US9265948B2 (en) 2003-12-24 2016-02-23 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity
US20050149133A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Sensing with compensation for neural stimulator
US9020595B2 (en) 2003-12-24 2015-04-28 Cardiac Pacemakers, Inc. Baroreflex activation therapy with conditional shut off
US20050149130A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulation synchronized to circadian rhythm
US8639322B2 (en) 2003-12-24 2014-01-28 Cardiac Pacemakers, Inc. System and method for delivering myocardial and autonomic neural stimulation
US20050149131A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex modulation to gradually decrease blood pressure
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20050149132A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US20080021507A1 (en) * 2003-12-24 2008-01-24 Cardiac Pacemakers, Inc. Sensing with compensation for neural stimulator
US8121693B2 (en) 2003-12-24 2012-02-21 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US8131373B2 (en) 2003-12-24 2012-03-06 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US8626282B2 (en) 2003-12-24 2014-01-07 Cardiac Pacemakers, Inc. Baroreflex modulation to gradually change a physiological parameter
US8818513B2 (en) 2003-12-24 2014-08-26 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US8195289B2 (en) 2003-12-24 2012-06-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
US8805501B2 (en) 2003-12-24 2014-08-12 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US8285389B2 (en) 2003-12-24 2012-10-09 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on motion and physiological activity
US20080015659A1 (en) * 2003-12-24 2008-01-17 Yi Zhang Neurostimulation systems and methods for cardiac conditions
US8805513B2 (en) 2003-12-24 2014-08-12 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US8321023B2 (en) 2003-12-24 2012-11-27 Cardiac Pacemakers, Inc. Baroreflex modulation to gradually decrease blood pressure
US8442640B2 (en) 2003-12-24 2013-05-14 Cardiac Pacemakers, Inc. Neural stimulation modulation based on monitored cardiovascular parameter
US8457746B2 (en) 2003-12-24 2013-06-04 Cardiac Pacemakers, Inc. Implantable systems and devices for providing cardiac defibrillation and apnea therapy
US8473076B2 (en) 2003-12-24 2013-06-25 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20050149156A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Lead for stimulating the baroreceptors in the pulmonary artery
US20070142864A1 (en) * 2003-12-24 2007-06-21 Imad Libbus Automatic neural stimulation modulation based on activity
US20050149126A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulation to treat acute myocardial infarction
US20050149143A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baroreflex stimulator with integrated pressure sensor
US20050149155A1 (en) * 2003-12-24 2005-07-07 Avram Scheiner Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US8131362B2 (en) 2005-03-11 2012-03-06 Cardiac Pacemakers, Inc. Combined neural stimulation and cardiac resynchronization therapy
US20090306734A1 (en) * 2005-03-11 2009-12-10 Julia Moffitt Combined neural stimulation and cardiac resynchronization therapy
US20110178416A1 (en) * 2005-07-25 2011-07-21 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US9125567B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US11197992B2 (en) 2005-07-25 2021-12-14 Enopace Biomedical Ltd. Electrical stimulation of blood vessels
US20110118773A1 (en) * 2005-07-25 2011-05-19 Rainbow Medical Ltd. Elliptical device for treating afterload
US9642726B2 (en) 2005-07-25 2017-05-09 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9457174B2 (en) 2005-07-25 2016-10-04 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US9125732B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9592136B2 (en) 2005-07-25 2017-03-14 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US20080215117A1 (en) * 2005-07-25 2008-09-04 Yossi Gross Electrical Stimulation of Blood Vessels
US20080033501A1 (en) * 2005-07-25 2008-02-07 Yossi Gross Elliptical element for blood pressure reduction
US10384043B2 (en) 2005-07-25 2019-08-20 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US8862243B2 (en) 2005-07-25 2014-10-14 Rainbow Medical Ltd. Electrical stimulation of blood vessels
US20110213408A1 (en) * 2005-07-25 2011-09-01 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US9550048B2 (en) 2005-07-25 2017-01-24 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US8923972B2 (en) 2005-07-25 2014-12-30 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7668594B2 (en) 2005-08-19 2010-02-23 Cardiac Pacemakers, Inc. Method and apparatus for delivering chronic and post-ischemia cardiac therapies
US8306615B2 (en) 2005-08-19 2012-11-06 Cardiac Pacemakers, Inc. Method and apparatus for delivering chronic and post-ischemia cardiac therapies
US20080288030A1 (en) * 2007-05-14 2008-11-20 Cardiac Pacemakers, Inc. Method and apparatus for regulating blood volume using volume receptor stimulation
US8209033B2 (en) 2007-05-14 2012-06-26 Cardiac Pacemakers, Inc. Method and apparatus for regulating blood volume using volume receptor stimulation
US20080289920A1 (en) * 2007-05-24 2008-11-27 Hoerbiger-Origa Holding Ag Pneumatic cylinder with a self-adjusting end position damping arrangement, and method for self-adjusting end position damping
US20110009692A1 (en) * 2007-12-26 2011-01-13 Yossi Gross Nitric oxide generation to treat female sexual dysfunction
US20110137370A1 (en) * 2008-01-31 2011-06-09 Enopace Biomedical Ltd. Thoracic aorta and vagus nerve stimulation
US8626299B2 (en) 2008-01-31 2014-01-07 Enopace Biomedical Ltd. Thoracic aorta and vagus nerve stimulation
US8626290B2 (en) 2008-01-31 2014-01-07 Enopace Biomedical Ltd. Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta
US8140155B2 (en) 2008-03-11 2012-03-20 Cardiac Pacemakers, Inc. Intermittent pacing therapy delivery statistics
US20090234416A1 (en) * 2008-03-11 2009-09-17 Zielinski John R Intermittent pacing therapy delivery statistics
US8958873B2 (en) 2009-05-28 2015-02-17 Cardiac Pacemakers, Inc. Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing
US20100305648A1 (en) * 2009-05-28 2010-12-02 Shantha Arcot-Krishnamurthy Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing
US20110071584A1 (en) * 2009-09-23 2011-03-24 Mokelke Eric A Method and apparatus for automated control of pacing post-conditioning
US8812104B2 (en) 2009-09-23 2014-08-19 Cardiac Pacemakers, Inc. Method and apparatus for automated control of pacing post-conditioning
US20110077729A1 (en) * 2009-09-29 2011-03-31 Vascular Dynamics Inc. Devices and methods for control of blood pressure
US9649487B2 (en) 2010-08-05 2017-05-16 Enopace Biomedical Ltd. Enhancing perfusion by contraction
US8538535B2 (en) 2010-08-05 2013-09-17 Rainbow Medical Ltd. Enhancing perfusion by contraction
US8649863B2 (en) 2010-12-20 2014-02-11 Rainbow Medical Ltd. Pacemaker with no production
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US8855783B2 (en) 2011-09-09 2014-10-07 Enopace Biomedical Ltd. Detector-based arterial stimulation
US10828181B2 (en) 2011-09-09 2020-11-10 Enopace Biomedical Ltd. Annular antenna
US9386991B2 (en) 2012-02-02 2016-07-12 Rainbow Medical Ltd. Pressure-enhanced blood flow treatment
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US10779965B2 (en) 2013-11-06 2020-09-22 Enopace Biomedical Ltd. Posts with compliant junctions
US11432949B2 (en) 2013-11-06 2022-09-06 Enopace Biomedical Ltd. Antenna posts
EP3826531A4 (en) * 2018-07-23 2022-03-30 Integrated Sensing Systems, Inc. Wireless medical implants and methods of use
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Also Published As

Publication number Publication date
US20070060972A1 (en) 2007-03-15
US20070038261A1 (en) 2007-02-15
US20080177349A1 (en) 2008-07-24
US20070038259A1 (en) 2007-02-15
US8086314B1 (en) 2011-12-27
US20080215111A1 (en) 2008-09-04
US8838246B2 (en) 2014-09-16
US20080177350A1 (en) 2008-07-24
US8290595B2 (en) 2012-10-16
US20070167984A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
US8838246B2 (en) Devices and methods for cardiovascular reflex treatments
US6522926B1 (en) Devices and methods for cardiovascular reflex control
US7840271B2 (en) Stimulus regimens for cardiovascular reflex control
US6985774B2 (en) Stimulus regimens for cardiovascular reflex control
US6850801B2 (en) Mapping methods for cardiovascular reflex control devices
US7158832B2 (en) Electrode designs and methods of use for cardiovascular reflex control devices
US8880190B2 (en) Electrode structures and methods for their use in cardiovascular reflex control
US7502650B2 (en) Baroreceptor activation for epilepsy control
US7949400B2 (en) Devices and methods for cardiovascular reflex control via coupled electrodes
JP4413626B2 (en) Device and method for controlling circulatory system reflection by connecting electrodes
US20070156198A1 (en) Coordinated therapy for disordered breathing including baroreflex modulation
US20080167699A1 (en) Method and Apparatus for Providing Complex Tissue Stimulation Parameters

Legal Events

Date Code Title Description
AS Assignment

Owner name: CVRX, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIEVAL, ROBERT S.;ROSSING, MARTIN A.;REEL/FRAME:018566/0638;SIGNING DATES FROM 20061004 TO 20061005

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION